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Abstract
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The Netherlands
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Background: Early diagnosis of acute myocardial infarction (AMI) can ensure quick and effective treatment
but only 20% of adults with emergency admissions for chest pain have an AMI. High-sensitivity cardiac
troponin (hs-cTn) assays may allow rapid rule-out of AMI and avoidance of unnecessary hospital admissions
and anxiety.
Objective: To assess the clinical effectiveness and cost-effectiveness of hs-cTn assays for the early (within
4 hours of presentation) rule-out of AMI in adults with acute chest pain.
Methods: Sixteen databases, including MEDLINE and EMBASE, research registers and conference
proceedings, were searched to October 2013. Study quality was assessed using QUADAS-2. The bivariate
model was used to estimate summary sensitivity and specificity for meta-analyses involving four or more
studies, otherwise random-effects logistic regression was used. The health-economic analysis considered
the long-term costs and quality-adjusted life-years (QALYs) associated with different troponin (Tn) testing
methods. The de novo model consisted of a decision tree and Markov model. A lifetime time horizon
(60 years) was used.
Results: Eighteen studies were included in the clinical effectiveness review. The optimum strategy, based
on the Roche assay, used a limit of blank (LoB) threshold in a presentation sample to rule out AMI
[negative likelihood ratio (LR–) 0.10, 95% confidence interval (CI) 0.05 to 0.18]. Patients testing positive
could then have a further test at 2 hours; a result above the 99th centile on either sample and a delta (Δ)
of ≥ 20% has some potential for ruling in an AMI [positive likelihood ratio (LR+) 8.42, 95% CI 6.11 to
11.60], whereas a result below the 99th centile on both samples and a Δ of < 20% can be used to rule
out an AMI (LR– 0.04, 95% CI 0.02 to 0.10). The optimum strategy, based on the Abbott assay, used a
limit of detection (LoD) threshold in a presentation sample to rule out AMI (LR– 0.01, 95% CI 0.00 to
0.08). Patients testing positive could then have a further test at 3 hours; a result above the 99th centile on
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this sample has some potential for ruling in an AMI (LR+ 10.16, 95% CI 8.38 to 12.31), whereas a result
below the 99th centile can be used to rule out an AMI (LR– 0.02, 95% CI 0.01 to 0.05). In the base-case
analysis, standard Tn testing was both most effective and most costly. Strategies considered cost-effective
depending upon incremental cost-effectiveness ratio thresholds were Abbott 99th centile (thresholds
of < £6597), Beckman 99th centile (thresholds between £6597 and £30,042), Abbott optimal strategy
(LoD threshold at presentation, followed by 99th centile threshold at 3 hours) (thresholds between
£30,042 and £103,194) and the standard Tn test (thresholds over £103,194). The Roche 99th centile and
the Roche optimal strategy [LoB threshold at presentation followed by 99th centile threshold and/or Δ20%
(compared with presentation test) at 1–3 hours] were extendedly dominated in this analysis.
Conclusions: There is some evidence to suggest that hs-CTn testing may provide an effective and
cost-effective approach to early rule-out of AMI. Further research is needed to clarify optimal diagnostic
thresholds and testing strategies.
Study registration: This study is registered as PROSPERO CRD42013005939.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Cost-effectiveness analysis An economic analysis that converts effects into health terms and describes
the costs for additional health gain.
Decision modelling A mathematical construct that allows the comparison of the relationship between
costs and outcomes of alternative health-care interventions.
False-negative Incorrect negative test result – number of diseased persons with a negative test result.
False-positive Incorrect positive test result – number of non-diseased persons with a positive test result.
Incremental cost-effectiveness ratio The difference in the mean costs of two interventions in the
population of interest divided by the difference in the mean outcomes in the population of interest.
Index test The test whose performance is being evaluated.
Likelihood ratio Likelihood ratios describe how many times more likely it is that a person with the target
condition will receive a particular test result than a person without the target condition.
Markov model An analytic method particularly suited to modelling repeated events, or the progression of
a chronic disease over time.
Meta-analysis Statistical techniques used to combine the results of two or more studies and obtain a
combined estimate of effect.
Meta-regression Statistical technique used to explore the relationship between study characteristics and
study results.
Opportunity costs The cost of forgone outcomes that could have been achieved through
alternative investments.
Publication bias Bias arising from the preferential publication of studies with statistically
significant results.
Quality-adjusted life-year A measure of health gain, used in economic evaluations, in which survival
duration is weighted or adjusted by the patient’s quality of life during the survival period.
Quality of life An individual’s emotional, social and physical well-being and their ability to perform the
ordinary tasks of living.
Receiver operating characteristic curve A graph that illustrates the trade-offs between sensitivity and
specificity which result from varying the diagnostic threshold.
Reference standard The best currently available method for diagnosing the target condition. The index
test is compared against this to allow calculation of estimates of accuracy.
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Sensitivity Proportion of people with the target disorder who have a positive test result.
Specificity Proportion of people without the target disorder who have a negative test result.
True-negative Correct negative test result – number of non-diseased persons with a negative test result.
True-positive Correct positive test result – number of diseased persons with a positive test result.
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Plain English summary
Heart disease is a leading cause of death in the UK, with myocardial infarction (MI) (heart attack)accounting for approximately 5% of all deaths recorded in 2011. Many people attend hospital with
chest pain and suspected MI; chest pain has been reported as the most common cause of hospital
admissions in the UK, and 2011–12 statistics showed that it accounted for approximately 5% of all
emergency admissions. It is important to diagnose people who are suspected of having a MI as early as
possible in order to ensure quick and effective treatment. However, only around 20% of emergency
admissions for chest pain will actually have a MI and there are many other possible causes of chest pain
(e.g. gastro-oesophageal disorders, muscle pain, anxiety or stable ischaemic heart disease). Tests that can
quickly tell which patients do not have MI could therefore avoid unnecessary hospital admissions and
anxiety for many people.
This assessment aimed to determine the clinical effectiveness and cost-effectiveness of high-sensitivity
troponin (Tn) tests, used as single tests or repeated over a short time, for diagnosing or ruling out MI in
people who present to hospital with chest pain. We found that high-sensitivity Tn tests may be able to rule
out MI within the 4-hour UK NHS emergency department target. Health-economic analyses indicated that
high-sensitivity tests may be cost-effective compared with standard Tn tests, which require repeat testing
at 10–12 hours.
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Scientific summary
Background
The primary indication for this assessment is the early rule-out of acute myocardial infarction (AMI) in
people presenting with acute chest pain and suspected, but not confirmed, non-ST segment elevation
myocardial infarction (NSTEMI).
Cardiac troponins (cTns) I and T are used as markers of AMI. They are intended for use in conjunction
with clinical history-taking and electrocardiography monitoring. Elevated troponin (Tn) levels are associated
with an increased risk of adverse cardiac outcomes. However, the optimal sensitivity of standard Tn assays
for AMI occurs several (10–12) hours after the onset of symptoms. Two high-sensitivity cardiac troponin
(hs-cTn) assays are currently available for use in the NHS in England and Wales: ARCHITECT high-sensitivity
troponin I assay (Abbott Diagnostics, Chicago, IL, USA) and the Elecsys troponin T high-sensitive assay
(Roche Diagnostics GmbH, Mannheim, Germany). One additional assay, AccuTnI+3 troponin I assay
(Beckman Coulter, Brea, CA, USA), was included in the scope for this assessment pending CE marking;
CE marking has now been confirmed. These assays are able to detect lower levels of Tn in the blood with
analytical sensitivities up to 100 times greater than conventional Tn assays. Use of high-sensitivity assays
enables the detection of small changes in Tn levels and may enable AMI to be ruled out at an earlier time
after the onset of acute chest pain.
This assessment considers hs-cTn assays used singly or in series, up to 4 hours after the onset of chest pain
or up to 4 hours after presentation; for serial Tn measurements, both data on change in Tn levels and
peak Tn are considered.
Objective
To assess the clinical effectiveness and cost-effectiveness of high-sensitivity Tn assays for the management
of adults presenting with acute chest pain, in particular for the early (within 4 hours of presentation)
rule-out of AMI.
Methods
Assessment of clinical effectiveness
Sixteen databases, including MEDLINE and EMBASE, research registers and conference proceedings, were
searched to October 2013. Search results were screened for relevance independently by two reviewers.
Full-text inclusion assessment, data extraction and quality assessment were conducted by one reviewer and
checked by a second. Study quality was assessed using QUADAS-2. The bivariate/hierarchical summary
receiver operating characteristic (HSROC) model was used to estimate summary sensitivity and specificity
with 95% confidence intervals (CIs) and prediction regions around the summary points, and to derive
HSROC curves for meta-analyses involving four or more studies. For meta-analyses with fewer than
four studies we estimated separate pooled estimates of sensitivity and specificity, using random-effects
logistic regression. Summary positive likelihood ratios (LR+) and negative likelihood ratios (LR–) were
derived from the summary estimates of sensitivity and specificity. Analyses were conducted separately for
each of the three hs-cTn assays and were stratified according to whether or not the study evaluated the
prediction of AMI or major adverse cardiac event (MACE), test timing, and the threshold used to define a
positive hs-cTn result. Stratified analyses were used to investigate heterogeneity and the influence of risk of
bias on summary estimates.
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Assessment of cost-effectiveness
We considered the long-term costs and quality-adjusted life-years (QALYs) associated with different Tn
testing methods, to diagnose or rule out NSTEMI, for patients presenting at the emergency department
(ED) with suspected non-ST segment elevation acute coronary syndrome (NSTE-ACS). The de novo model
consisted of a decision tree and a Markov model. The decision tree was used to model the 30-day outcomes
after presentation, based on test results and the accompanying treatment decision. The long-term
consequences in terms of costs and QALYs were estimated using a Markov cohort model with a lifetime time
horizon (60 years). The following strategies were included in the main economic analysis:
l standard Tn at presentation and at 10–12 hours (reference standard)
l Roche Elecsys hs-cTnT at presentation: 99th centile threshold
l Roche Elecsys hs-cTnT (optimal strategy): limit of blank (LoB) threshold at presentation followed by
99th centile threshold peak within 3 hours and/or Δ20% (compared with presentation test) at 1–3 hours
l Abbott ARCHITECT hs-cTnI at presentation: 99th centile threshold
l Abbott ARCHITECT hs-cTnI (optimal strategy): limit of detection (LoD) threshold at presentation,
followed by 99th centile threshold at 3 hours
l Beckman Coulter hs-cTnI at presentation: 99th centile threshold.
In the base case, it was assumed that standard Tn testing had perfect sensitivity and specificity (reference
case) for diagnosing AMI and that only patients testing positive on the reference standard (standard Tn)
were at increased risk for adverse events and would benefit from immediate treatment. In a secondary
analysis, a proportion of patients testing positive on a hs-cTn test were treated accordingly. These patients
were assumed to be treated for the hs-cTn assays and left untreated for the standard Tn test and at
increased risk for adverse events. In addition, a number of sensitivity and subgroup analyses
were performed.
Results
Assessment of clinical effectiveness
Eighteen studies (38 publications) were included in the review. The main potential sources of bias in
the included studies related to patient spectrum and patient flow. There were also concerns regarding the
applicability of the patient population and the reference standard in some of the included studies.
Diagnostic accuracy of the Roche Elecsys high-sensitivity cardiac troponin T
assay (15 studies)
The most commonly evaluated testing strategy was the 99th centile threshold in a blood sample taken
on presentation. Studies (n= 6) that excluded patients with ST segment elevation myocardial infarction
(STEMI) gave a summary LR+ of 5.41 (95% CI 3.40 to 8.63) and summary LR– of 0.15 (95% CI 0.08 to
0.26) for this strategy. Estimates were similar when derived from all studies (n= 13) that evaluated this
strategy. The optimum strategy based on this assay appeared to be one based on the combination of
a LoB threshold in a presentation sample, which could be used to rule out AMI (LR– 0.10, 95% CI 0.05
to 0.18) but has limited potential to rule in an AMI (LR+ 1.83, 95% CI 1.70 to 1.97). Patients testing
positive could then have a further sample taken at 2 hours; a result above the 99th centile on either
the presentation or 2-hour sample and a Δ of at least 20% has some potential for ruling in an AMI
(LR+ 8.42, 95% CI 6.11 to 11.60), whereas a result below the 99th centile on both samples and a Δ of
< 20% can be used to rule out an AMI (LR– 0.04, 95% CI 0.02 to 0.10).
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Diagnostic accuracy of the Abbott ARCHITECT high-sensitivity cardiac
troponin I assay (four studies)
Three studies, all conducted in populations that included patients with STEMI, evaluated this assay at the
99th centile threshold in a blood sample taken on presentation. The summary LR+ was 11.47 (95% CI
9.04 to 16.19) and the summary LR– was 0.22 (95% CI 0.16 to 0.27). The optimum strategy appeared to
be one based on the combination of a LoD threshold in a presentation sample, which could be used
to rule out AMI (LR– 0.01, 95% CI 0.00 to 0.08) but has limited potential to rule in an AMI (LR+ 1.54,
95% CI 1.47 to 1.62). Patients testing positive could then have a further sample taken at 3 hours,
a result above the 99th centile on this sample has some potential for ruling in an AMI (LR+ 10.16,
95% CI 8.38 to 12.31), whereas a result below the 99th centile can be used to rule out an AMI
(LR– 0.02, 95% CI 0.01 to 0.05).
Diagnostic accuracy of the Beckman Coulter Access high-sensitivity cardiac
troponin I (two studies)
One study, conducted in a population that included patients with STEMI, evaluated this assay at the
99th centile threshold in a blood sample taken on presentation. The summary LR+ was 3.67 (95% CI 3.26
to 4.13) and the summary LR– was 0.11 (95% CI 0.07 to 0.17). Data were not reported for the LoB/LoD
threshold. There were insufficient data to determine the optimum testing strategy for this assay.
Assessment of cost-effectiveness
Base-case analysis
In the base-case analysis, standard Tn testing was both most effective and most costly. Strategies
considered cost-effective depending upon incremental cost-effectiveness ratio (ICER) thresholds were
Abbott ARCHITECT hs-cTnI 99th centile (thresholds of < £6597), Beckman Coulter hs-cTnI 99th centile
(thresholds between £6597 and £30,042), Abbott ARCHITECT hs-cTnI optimal strategy (LoD threshold at
presentation, followed by 99th centile threshold at 3 hours) (thresholds between £30,042 and £103,194),
and the standard Tn test (thresholds of > £103,194). The Roche Elecsys hs-cTnT 99th centile and the
Roche Elecsys hs-cTnT optimal strategy [LoB threshold at presentation followed by 99th centile threshold
and/or Δ20% (compared with presentation test) at 1–3 hours] were extendedly dominated in this analysis
(one of the more effective strategies was better value, in that the ICER was lower).
Secondary analysis
In the secondary analysis, which assumed that a proportion of false-positives (FPs) in the hs-cTn testing
strategies had an increased risk of adverse events, standard Tn was least effective and most costly, and
therefore a dominated strategy. The most effective strategy here was the Abbott ARCHITECT hs-cTnI
optimal strategy. The Roche Elecsys hs-cTnT optimal strategy was extendedly dominated (one of the more
effective strategies was better value in that the ICER was lower), as was the Beckman Coulter hs-cTnI
99th centile in this analysis. Strategies considered cost-effective were Abbott ARCHITECT hs-cTnI 99th
centile (thresholds below £12,217), Roche Elecsys hs-cTnT 99th centile (thresholds between £12,217 and
£14,992) and Abbott ARCHITECT hs-cTnI optimal strategy (thresholds over £14,992).
Sensitivity and subgroup analyses
Sensitivity analyses showed that assumptions regarding the difference between treated and untreated
patients (e.g. mortality rate, risk of re-infarction) had the largest impact on relative cost-effectiveness, as
well as whether or not patients testing FP were assigned treatment costs. In general, the base-case analysis
was affected more by varying these assumptions than the secondary analysis. Results from the subgroup
analyses led to the conclusion that hs-cTn testing is likely to be more cost-effective in younger populations,
in populations with pre-existing coronary artery disease (CAD), and for patients whose symptom onset was
< 3 hours ago. A no-testing strategy can be considered cost-effective only in populations with a prevalence
as low as 1%.
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Conclusions
Implications for service provision
There is evidence to suggest that undetectable levels of Tns (below the LoB/LoD of the assay) on
presentation, measured using the Roche Elecsys hs-cTnT assay or the Abbott ARCHITECT hs-cTnI assay,
may be sufficient to rule out NSTEMI in people presenting with symptoms suggestive of acute coronary
syndrome (ACS). There is also evidence to suggest that, for the Roche Elecsys hs-cTnT assay and the
Abbott ARCHITECT hs-cTnI assay, a further rule-out step may be possible within the 4-hour NHS ED target.
There is insufficient evidence to determine an optimum testing strategy for the Beckman Coulter hs-cTnI
assay. There is some limited evidence to suggest that a Tn level below the 99th centile on presentation,
measured using the Roche Elecsys hs-cTnT assay, may be sufficient to rule out NSTEMI in some groups
(people > 70 years old, people without pre-existing CAD and people with a clinically determined high
pre-test probability).
The economic model does not provide strong evidence to prefer one hs-cTn testing strategy over another.
Results do, however, indicate that hs-cTn testing in general may be cost-effective compared with standard
Tn testing given that hs-cTn testing leads to cost-saving at a QALY loss. This becomes more likely if one
assumes that hs-cTn testing detects some patients who require treatment despite their testing negative
with standard Tn, as shown in the secondary analysis hs-cTn testing. In particular, the Abbott ARCHITECT
hs-cTnI optimal strategy, which involves multiple testing and varying cut-off levels, may be promising. The
main issue, with regard to service provision, if implementation of a hs-cTn testing strategy is considered,
is the balance between the likely reduction in cost and the risk of a reduction in effectiveness, albeit
possibly small.
Suggested research priorities
New studies are needed to evaluate fully the performance of our proposed optimal testing strategies in a
clinical setting. Further research (diagnostic cohort studies or multivariable prediction modelling studies) is
needed to explore fully possible variation in the performance of hs-cTn assays and the optimal testing
strategies for these assays in relevant demographic and clinical subgroups (sex, age, ethnicity, renal
function, previous CAD, previous AMI) and to investigate the effects of clinical judgement (assessment
of pre-test probability) on test performance. As most of the uncertainties in the economic model were
caused by assumptions relating to clinical effectiveness, this type of research would also facilitate economic
analyses of hs-cTn testing.
Study registration
The study is registered as PROSPERO CRD42013005939.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Objective
The overall objective of this project is to assess the clinical effectiveness and cost-effectiveness ofhigh-sensitivity troponin (Tn) assays for the management of adults presenting with acute chest pain,
in particular for the early (within 4 hours of presentation) rule-out of acute myocardial infarction (AMI).
The following research questions were defined to address the review objectives:
l What is the clinical effectiveness of new, high-sensitivity troponin [high-sensitivity cardiac troponin
(hs-cTn)] assays (used singly or in series) compared with conventional diagnostic assessment, for
achieving early discharge within 4 hours of presentation, when AMI is excluded without increase in
adverse outcomes?
l What is the accuracy of new, hs-cTn assays (used singly or in series, such that results are available
within 3 hours of presentation) for the diagnosis of AMI in adults with acute chest pain?
l What is the accuracy of new, hs-cTn assays (used singly or in series, such that results are available
within 3 hours of presentation) for the prediction of major adverse cardiac events (MACEs) (cardiac
death, non-fatal AMI, revascularisation or hospitalisation for myocardial ischaemia) during 30-day
follow-up in adults with acute chest pain?
l What is the cost-effectiveness of using new, hs-cTn assays (used singly or in series, such that results are
available within 3 hours of presentation) compared with the current standard of serial Tn T and/or
I testing on admission and at 10–12 hours post admission?
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Chapter 2 Background and definition of the
decision problem(s)
Population
The primary indication for this assessment is the early rule-out of AMI and consequent early discharge in
people presenting with acute chest pain and suspected, but not confirmed, non-ST segment elevation
myocardial infarction (NSTEMI). The assessment will also consider the potential effects of early diagnosis of
AMI and of reduced specificity of testing.
Acute coronary syndrome (ACS) is the term used to describe a spectrum of conditions caused by coronary
artery disease (CAD) [also known as coronary heart disease (CHD) or ischaemic heart disease]. ACS arises
when atheromatous plaque ruptures or erodes, leading to vasospasm, thrombus formation and distal
embolisation, obstructing blood flow through the coronary arteries. It incorporates three distinct
conditions: unstable angina (UA), ST segment elevation myocardial infarction (STEMI) and NSTEMI.
CAD and AMI are a significant health burden in the UK, with Office for National Statistics (ONS) mortality
data for 2011 showing 23,705 deaths from AMI and 64,435 deaths from ischaemic heart disease; AMI
accounted for approximately 5% of all deaths recorded in 2011, and ischaemic heart disease accounted
for approximately 13%.1
People with ACS usually present with chest pain, and chest pain has been reported as the most common
cause of hospital admissions in the UK;2 Hospital Episode Statistics (HES) for 2011–12 show 243,197
emergency admissions for chest pain, accounting for approximately 5% of all emergency admissions.3
However, many people presenting with acute chest pain will have non-cardiac underlying causes, such as
gastro-oesophageal disorders, muscle pain, anxiety or stable ischaemic heart disease. A 2003 study4 on
the impact of cardiology guidelines on the diagnostic classification of people with ACS in the UK reported
that the majority of people admitted to hospital with chest pain have either no ischaemic heart disease or
stable ischaemic heart disease. HES for 2011–12 are consistent with this observation, showing diagnoses
of AMI in 47,783 emergency admissions and UA in 32,369 admissions; this represents approximately 20%
and 13% of emergency admissions with chest pain, respectively.3 Accurate and prompt differentiation of
ACS (in particular AMI), stable CAD and other causes of chest pain is therefore vital to ensure appropriate
and timely intervention when required and to avoid unnecessary hospital admissions.
ST segment elevation myocardial infarction can usually be diagnosed on presentation by electrocardiogram
(ECG), hence the main diagnostic challenge in the investigation of suspected ACS is the detection or
rule-out of NSTEMI. Investigation of ACS can also involve identification of people with UA (CAD with
worsening symptoms, but no evidence of myocardial necrosis).
Since the development of protein biomarkers of myocardial damage in the 1980s, the number of
biomarker assays available has proliferated, cardiac specificity has increased, and the role of biomarkers in
the diagnostic work-up of acute chest pain has expanded. Cardiac biomarkers are becoming increasingly
sensitive and recent European Society of Cardiology (ESC) and American College of Cardiology (ACC)
guidelines5,6 enable AMI to be diagnosed with any rise and/or fall of Tn to above the laboratory reference
range. This has resulted in fewer people being classified as having UA with no myocardial damage, and
more people being classified as having NSTEMI.7 The most recent 2 years of HES show that the number of
emergency department (ED) attendances where the first recorded investigation was a cardiac biomarker
rose from 13,743 in 2010–11 to 28,379 in 2011–12.3 Cardiac troponins I and T (cTnI and cTnT), together
with cardiac troponin C (cTnC), form the troponin–tropomyosin complex, which is responsible for
regulating cardiac muscle contraction. cTnI and cTnT are used clinically as markers of cardiomyocyte
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necrosis, indicative of AMI. Tn assays are intended for use in conjunction with clinical history-taking and
ECG monitoring as, although specificity is high, Tns may also be elevated in many other conditions,
including myocarditis, congestive heart failure (HF), severe infections, renal disease and chronic
inflammatory conditions of the muscle or skin. Standard biochemical diagnosis of NSTEMI is based on
elevation of the cardiac biomarker Tn above the 99th percentile of the reference range for the normal
population.8 Elevated Tn levels have been shown to be associated with an increased risk of adverse cardiac
outcomes.9 However, the optimal sensitivity of standard Tn assays for AMI occurs several hours after the
onset of symptoms;10 this is reflected in current clinical guidelines,11,12 which recommend cTnI or cTnT
testing at initial hospital assessment and again at 10–12 hours after the onset of symptoms. As the
majority of people presenting with chest pain do not have NSTEMI, for which presentation is within a
few hours of symptom onset, delayed biomarker measurement may result in unnecessary periods of
extended observation or hospitalisation and associated costs. The development of cardiac biomarkers
that can be used at an earlier stage without reduction in sensitivity is, therefore, desirable.
Intervention technologies
The development of hs-cTn assays means that it is possible to detect lower levels of Tn in the blood.
Current generations of commercially available assays have analytical sensitivities up to 100 times greater
than was the case for early Tn assays (1 ng/l vs. 100 ng/l).13 Use of these high-sensitivity assays enable the
detection of small changes in cTn levels, and may enable AMI to be ruled out at an earlier time after the
onset of acute chest pain. Use of the hs-cTn assays has the potential to facilitate earlier discharge for
people with normal cTn levels and earlier intervention for those with elevated levels of cTn. The
recommended definition of a hs-cTn assay uses two criteria:13,14
l The total imprecision, coefficient of variation (CV), of the assay should be ≤ 10% at the 99th percentile
value of a healthy reference population.
l The limit of detection (LoD) of the assay should be such as to allow measurable concentrations to be
attainable for at least 50% (ideally > 95%) of healthy individuals.
A number of high-sensitivity cardiac troponin I and cardiac troponin T (hs-cTnI and hs-cTnT) assays are
currently available for use in the NHS in England and Wales; all are designed for use in clinical
laboratory settings.
Abbott ARCHITECT high-sensitivity troponin I assay
The Abbott ARCHITECT® hs-cTnI STAT assay (Abbott Laboratories, Chicago, IL, USA) can be used with the
Abbott ARCHITECT® i2000SR and i1000SR analysers (Abbott Laboratories). The assay is a quantitative,
chemiluminescent microparticle immunoassay (CMIA) for serum or plasma samples. Results are available
within 16 minutes. The ARCHITECT hs-cTnI STAT assay can detect cTnI in 96% of the reference
population, and has a recommended 99th percentile cut-off of 26.2 ng/l, with a CV of 4%.15 The assay
is CE marked and available to the NHS.
AccuTnI+3 troponin I assay (Beckman Coulter)
The AccuTnI+3 hs-cTnI assay is approved for use on both the Beckman Coulter Access 2 and DxI analysers
(Brea, CA, USA) and has recently received CE mark approval. The assay is a quantitative, two-site
paramagnetic particle chemiluminescent sandwich immunoassay for serum or plasma samples. The
AccuTnI+3 assay has a recommended 99th percentile cut-off of 40 ng/l, with a CV of < 10%.16 A recent
conference abstract reported data suggesting that the assay can detect cTnI in 88% of the reference
population when used on the Access II analyser and in 58% of the reference population when used on the
DxI analyser.17 The same study17 reported a difference in the 99th centile upper reference limit between
the two analysers (41 ng/l for the Access II and 34 ng/l for the DxI).
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Roche Elecsys high-sensitivity troponin T assay
The Roche Elecsys® cTnT-hs (high-sensitive troponin T assay) and Roche Elecsys® cTnT-hs STAT assays
(Roche Diagnostics GmbH, Mannheim, Germany) can be used on the Roche Elecsys® 2010 analyser
(Roche Diagnostics GmbH) and the cobas Modular Analytics e series immunoassay analysers, e411
platform. The assay is a quantitative, sandwich electrochemiluminescence immunoassay (ECLIA) for serum
and plasma samples. Results are available within 18 minutes with the standard assay and within 9 minutes
if the STAT assay is used. Both versions of the assay can detect cTnT in 61% of the reference population
and have a recommended 99th percentile cut-off of 14 ng/l, with a CV of < 10%.18 Both versions of the
assay are CE marked and available to the NHS.
A summary of the product properties of hs-cTnI and hs-cTnT assays available to the NHS in England and
Wales is provided in Table 1.
The hs-cTn assays can be used as single diagnostic tests, or in combination with other cardiac biomarkers,
for example heart fatty acid binding protein (H-FABP) and copeptin. The use of combinations of cardiac
biomarkers may increase sensitivity, when a positive result on either test is considered to be indicative of
AMI, although this increase may be achieved at the expense of decreased specificity. Conversely, if a
positive result on both tests is required before AMI is diagnosed, increased specificity and reduced
sensitivity are likely. It is currently unclear which, if any, of the available cardiac biomarkers could add
clinical benefit if used in combination with hs-cTnI and hs-cTnT, compared with hs-cTnI and hs-cTnT alone.
A recent systematic review reported some data for combination testing, but none of the identified studies
of Tns combined with other biomarkers used high-sensitivity methods.7 Retrospective analysis of data
from one arm of a randomised controlled trial (RCT) by the same authors provided some indication that
the use of H-FABP in combination with hs-cTn, on admission, may increase sensitivity for AMI without
decreasing specificity.19 This increase was equivalent to the sensitivity achieved by serial hs-cTn testing on
admission and at 90 minutes.19 However, these tests are not readily available for analytical platforms in
routine use in the NHS and discussions at the scoping stage of this assessment concluded that practical
applications of H-FABP and copeptin assays and evidence for their effectiveness are not yet sufficiently
developed to justify their inclusion.
This assessment will consider hs-cTn assays used singly or in series, up to 4 hours after the onset of chest
pain or up to 4 hours after presentation (as reported); for serial Tn measurements, both data on change in
Tn levels and peak Tn will be considered (as reported).
TABLE 1 Overview of cardiac biomarkers
Manufacturer System Assay
LoD
(ng/l)
LoB
(ng/l)
99th
percentile
(ng/l)a
CV at 99th
percentilea
Turnaround
time
(minutes)a
CE
marked
Abbott
Diagnostics
ARCHITECT STAT hs-cTnI 1.1 to 1.9 0.7 to 1.3 26.2 4% 16 ✓
Beckman
Coulter
Access and
UniCel DxI
AccuTnI+3 10 < 10 40.0 < 10% 13 ✓
Roche Elecsys cTnT-hs 5 3 14 < 10% 18 ✓
Roche Elecsys cTnT-hs
STAT
5 3 14 < 10% 9 ✓
LoB, limit of blank.
a Information supplied to the National Institute for Health and Care Excellence (NICE) by the manufacturer.
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Comparator
The comparator for this technology appraisal is the current UK standard of serial TnT and/or I testing (using
any method not defined as a hs-cTn test) on admission and at 10–12 hours after the onset of symptoms.11
Care pathway
Diagnostic assessment
The assessment of patients with suspected ACS is described in the National Institute for Health and Care
Excellence (NICE) clinical guideline 95 (CG95)11 ‘Chest pain of recent onset: Assessment and diagnosis of
recent onset chest pain or discomfort of suspected cardiac origin’. The guideline11 specifies that initial
assessment should include a resting 12-lead ECG along with a clinical history, a physical examination and
biochemical marker analysis. For people in whom a regional ST segment elevation or presumed new left
branch bundle block is seen on ECG, management should follow NICE clinical guideline 167 (CG167)20
‘The acute management of AMI with ST segment elevation’. People without persistent ST-elevation
changes on ECG [i.e. with suspected non-ST segment elevation acute coronary syndrome (NSTE-ACS)],
should receive further investigation using cardiac biomarkers, with the aim of distinguishing NSTEMI from
UA. NICE CG9511 makes the following recommendations on the use of cardiac biomarkers:
l Take a blood sample for cTnI or cTnT on initial assessment in hospital. These are the preferred
biochemical markers to diagnose AMI.
l Take a second blood sample for cTnI or cTnT measurement 10–12 hours after the onset of symptoms.
l Do not use biomarkers such as natriuretic peptides and high-sensitivity C-reactive protein to diagnose
an ACS.
l Do not use biomarkers of myocardial ischaemia (such as ischaemia-modified albumin) as opposed to
markers of necrosis when assessing people with acute chest pain.
l Take into account the clinical presentation, from the time of onset of symptoms and the resting
12-lead ECG findings, when interpreting Tn measurements.
Clinical guideline 9511 recommends that a diagnosis of NSTEMI should be made using the universal
definition of AMI.8 However, the third universal definition of AMI has been updated since the publication
of CG95.21 The most recent version states that AMI is defined as ‘The detection of a rise and/or fall of
cardiac biomarker values (preferably cardiac Tn) with at least one value above the 99th percentile upper
reference limit and with at least one of the following: symptoms of ischaemia, new or presumed new
significant ST segment T wave changes or new left branch bundle block, development of pathological
Q waves in the ECG, imaging evidence of new loss of viable myocardium or new regional wall motion
abnormality, or identification of an intracoronary thrombus by angiography or autopsy’.
The Scottish Intercollegiate Guidelines Network guideline 93 (SIGN 93)12 provides similar recommendations
on the diagnostic work-up of people with suspected ACS, stating:
l immediate assessment with a 12-lead ECG
l repeat 12-lead ECG if there is diagnostic uncertainty or change in clinical status, and at discharge
l serum Tn measurement on arrival at hospital
l repeat serum Tn measurement 12 hours after the onset of symptoms
l Tn concentrations should not be interpreted in isolation but with regard to clinical presentation.
Guidelines from the ESC22 on the diagnostic assessment of people with a suspected NSTE-ACS are
consistent with those of NICE and SIGN, but additionally acknowledge the use of high-sensitivity
Tn assays and make recommendations on a fast-track rule-out protocol. The guidelines22 state that
hs-cTn assays have a negative predictive value (NPV) of > 95% for AMI on admission; including a second
sample of hs-cTn at 3 hours can increase this to 100%.
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Management/treatment
The NICE clinical guideline 94 (CG94), ‘Unstable angina and NSTEMI: The early management of unstable
angina and non-STEMI’,23 provides recommendations on the management of people with suspected
NSTE-ACS. The guideline23 states that initial treatment should include a combination of antiplatelet
(aspirin, clopidogrel and glycoprotein IIb/IIIa inhibitors) and antithrombin therapy, and should take into
account contraindications, risk factors and the likelihood of percutaneous coronary intervention. SIGN 9312
makes similar recommendations. It is recommended that people with a diagnosis of NSTEMI, who are
assessed as being at low risk of future complications, receive conservative treatment with aspirin and/or
clopidogrel, or aspirin in combination with ticagrelor. People at a higher risk of future complications
should be offered coronary angiography (within 96 hours of admission), with subsequent coronary
revascularisation by percutaneous coronary intervention or coronary artery bypass grafting where indicated.23
Additional testing to quantify inducible ischaemia may also be used, before discharge, to identify those who
may need further intervention23 and SIGN 9312 also recommends functional testing to identify people at higher
risk. SIGN 9312 states that people in whom an elevated Tn level is not observed may be discharged for further
follow-up according to clinical judgement and, in some cases, the results of ischaemia testing.12
Longer-term follow-up of people who have had an AMI is described in full in NICE clinical guideline
48 (CG48)24 ‘Secondary prevention in primary and secondary care for patients following a myocardial
infarction’. This includes recommendations on lifestyle changes, cardiac rehabilitation programmes, drug
therapy [including a combination of angiotensin-converting enzyme (ACE) inhibitors, aspirin, beta-blockers
and statins], and further cardiological assessment to determine whether coronary revascularisation
is required.
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Chapter 3 Assessment of clinical effectiveness
A systematic review was conducted to summarise the evidence on the clinical effectiveness of hs-cTnassays for the early rule-out or diagnosis of AMI in people with acute chest pain. Systematic review
methods followed the principles outlined in the Centre for Reviews and Dissemination (CRD) guidance for
undertaking reviews in health care25 and the NICE Diagnostics Assessment Programme manual.26,27
Systematic review methods
Search strategy
Search strategies were based on intervention (high-sensitivity Tn assays) and target condition, as
recommended in the CRD guidance for undertaking reviews in health care25 and the Cochrane Handbook
for Diagnostic Test Accuracy Reviews.27
Candidate search terms were identified from target references, browsing database thesauri [e.g. MEDLINE
medical subject heading (MeSH) and EMBASE Emtree], existing reviews identified during the rapid
appraisal process and initial scoping searches. These scoping searches were used to generate test sets of
target references, which informed text mining analysis of high-frequency subject-indexing terms using
EndNote X4 reference management software (Thomson Reuters, CA, USA). Strategy development involved
an iterative approach testing candidate text and indexing terms across a sample of bibliographic databases,
aiming to reach a satisfactory balance of sensitivity and specificity.
The following databases were searched for relevant studies from 2005 to October 2013:
l MEDLINE (OvidSP): 2005–2013/10/wk1.
l MEDLINE In-Process Citations and Daily Update (OvidSP): up to 2013/10/1.
l EMBASE (OvidSP): 2005–2013/10/10.
l Cochrane Database of Systematic Reviews (CDSR) (Wiley): Cochrane Library Issue 10 2005–2013/10/11.
l Cochrane Central Register of Controlled Trials (CENTRAL) (Wiley): Cochrane Library Issue 9
2005–2013/10/11.
l Database of Abstracts of Reviews of Effects (DARE) (Wiley): Cochrane Library Issue 3 2005–July 2013.
l Health Technology Assessment (HTA) Database (Wiley): Cochrane Library Issue 3 2005–July 2013.
l Science Citation Index (SCI) (Web of Science): 2005–2013/10/14.
l Conference Proceedings Citation Index – Science (CPCI) (Web of Science): 2005–2013/10/14.
l Latin American and Caribbean Health Sciences Literature (LILACS) (Internet): 2005–2013/10/11
(http://regional.bvsalud.org/php/index.php?lang = en).
l International Network of Agencies for Health Technology Assessment (INAHTA) Publications (Internet):
2005–2013/10/15 (www.inahta.org/).
l BIOSIS Previews (Web of Knowledge): 2005–2013/10/11.
l National Institute for Health Research (NIHR) Health Technology Assessment programme (Internet):
2005–2013/10/14.
l Aggressive Research Intelligence Facility (ARIF) database (Internet): 2005–2013/10/16 (www.birmingham.
ac.uk/research/activity/mds/projects/HaPS/PHEB/ARIF/index.aspx).
l Medion database (Internet): 2005–2013/10/16 (www.mediondatabase.nl/).
l PROSPERO (International Prospective Register of Systematic Reviews) (Internet): up to 2013/10/10
(www.crd.york.ac.uk/prospero/).
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Completed and ongoing trials were identified by searches of the following resources (2005 to October 2013):
l National Institutes of Health (NIH) ClinicalTrials.gov (Internet): up to 2013/10/1 (www.clinicaltrials.gov/).
l Current Controlled Trials (CCT) (Internet): up to 2013/10/10 (www.controlled-trials.com/).
l World Health Organization International Clinical Trials Registry Platform (ICTRP) (Internet): up to
2013/10/10 (www.who.int/ictrp/en/).
No restrictions on language or publication status were applied. Date restrictions were applied based on
expert advice on the earliest appearance of literature of high-sensitivity Tn assays. Searches took into
account generic and other product names for the intervention. The main EMBASE strategy for each set of
searches was independently peer reviewed by a second Information Specialist, using the Canadian Agency
for Drugs and Technologies in Health (CADTH) Peer Review Checklist.28 Search strategies were developed
specifically for each database and the keywords associated with high-sensitivity Tn T/I were adapted
according to the configuration of each database. Full search strategies are reported in Appendix 1.
Electronic searches were undertaken for the following conference abstracts (selected based on advice from
expert committee members):
l American Heart Association (AHA) Scientific Sessions (Internet): 2009–13 (http://my.americanheart.org/
professional/Sessions/ScientificSessions/Archive/Archive-Scientific-Sessions_UCM_316935_SubHomePage.jsp).
l American Association for Clinical Chemistry (AACC) (Internet): 2009–13 (www.aacc.org/
resourcecenters/meet_abstracts_archive/abstracts_archive/annual_meeting/Pages/default.aspx#).
l European Society of Cardiology (ESC) (Internet): 2009–13 (http://spo.escardio.org/abstract-book/search.aspx).
Identified references were downloaded in EndNote X4 software for further assessment and handling.
References in retrieved articles were checked for additional studies. The final list of included papers was
checked on PubMed for retractions, errata and related citations.29–31
Inclusion and exclusion criteria
Inclusion criteria for each of the clinical effectiveness questions are summarised in Table 2. Studies that
fulfilled these criteria were eligible for inclusion in the review.
Inclusion screening and data extraction
Two reviewers (MW and PW) independently screened the titles and abstracts of all of the reports identified
by searches, and any discrepancies were discussed and resolved by consensus. Full copies of all of the
studies that were deemed potentially relevant were obtained and the same two reviewers independently
assessed these for inclusion; any disagreements were resolved by consensus. Details of studies excluded at
the full paper screening stage are presented in Appendix 4.
Studies cited in materials provided by the manufacturers of hs-cTn assays were first checked against the
project reference database, in EndNote X4; any studies not already identified by our searches were
screened for inclusion following the process described above.
Data were extracted on the following: study details, inclusion and exclusion criteria, participant
characteristics (demographic characteristics and cardiac risk factors), target condition (NSTEMI or
AMI), details of the hs-cTnT or hs-cTnI test (manufacturer, timing, and definition of positive diagnostic
threshold), details of reference standard [manufacturer, timing, diagnostic threshold for conventional Tn T
or I testing, clinical and imaging components of the reference standard, method of adjudication (e.g.
two independent clinicians)] and test performance outcome measures [numbers of true-positive (TP),
false-positive (FP), false-negative (FN) and true-negative (TN) test results]. Data were extracted by one
reviewer, using a piloted, standard data extraction form and checked by a second (MW and PW); any
disagreements were resolved by consensus. Full data extraction tables are provided in Appendix 2.
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Quality assessment
The methodological quality of included diagnostic test accuracy (DTA) studies was assessed using
QUADAS-2.33 Quality assessments was undertaken by one reviewer and checked by a second (MW and PW);
any disagreements were resolved by consensus.
The results of the quality assessments are summarised and presented in tables and graphs in the results of
the systematic review and are presented in full, by study, in Appendix 3.
Methods of analysis/synthesis
Sensitivity and specificity were calculated for each set of 2 × 2 data, and plotted in receiver operating
characteristic (ROC) space. The bivariate/hierarchical summary receiver operating characteristic (HSROC)
model was used to estimate summary sensitivity and specificity with 95% confidence intervals (CIs) and
prediction regions around the summary points, and to derive HSROC curves for meta-analyses involving
four or more studies.34–36 This approach allows for between-study heterogeneity in sensitivity and
TABLE 2 Inclusion criteria
Question
What is the accuracy of hs-cTn assays
(used singly or in series, such that
results are available within 3 hours of
presentation) for the diagnosis of AMI
in adults with acute chest pain?
What is the effectiveness of hs-cTn assays
(used singly or in series) compared with
conventional diagnostic assessment, for
achieving successful early discharge of
adults with acute chest pain within
4 hours of presentation?
Participants Adults (≥ 18 years) presenting with acute ‘pain, discomfort or pressure in the chest,
epigastrium, neck, jaw, or upper limb without an apparent non-cardiac source’32 attributable to
a suspected, but not proven, AMI
Setting Secondary or tertiary care
Interventions (index test) Any hs-cTnT or hs-cTnI test,a listed in Table 1, hs-cTn assays (used singly or in series,b such that
results were available within 3 hours of presentation)
Comparators Any other hs-cTn test, as specified above,
or no comparator
Tn T or I measurement on presentation and
10–12 hours after the onset of symptoms
Reference standard Universal definition of AMI, including
measurement of Tn T or I (using any method
not defined as a hs-cTn test) on presentation
and 10–12 hours after the onset of
symptoms in ≥ 80% of the populationc or
occurrence of MACE (any definition used in
identified studies) during 30-day follow-up
NA
Outcomesd Test accuracy (the numbers of TP, FN, FP and
TN test results)
Early discharge (≤ 4 hours after initial
presentation) without MACE during follow-up,
incidence of MACE during follow-up,
re-attendance at or re-admission to hospital
during follow-up, time to discharge, patient
satisfaction or HRQoL measures
Study design Diagnostic cohort studies RCTs (CCTs) will be considered if no RCTs are
identified)
CCT, controlled clinical trial; FN, false-negative; FP, false-positive; HRQoL, health-related quality of life; NA, not applicable;
TN, true-negative; TP, true-positive.
a A high-sensitivity assay is defined as one that has a CV of ≤ 10% at the 99th percentile value for the healthy reference
population, and for which the LoD allows measurable concentrations to be attained for at least 50% of healthy
individuals.
b For serial hs-cTn assays, both data on change in Tn levels and peak Tn values were considered.
c Studies that used only new diagnostic ECG changes or outcome-based MACE (cardiac death, non-fatal AMI,
revascularisation or hospitalisation for myocardial ischaemia) alongside a Tn-based reference standard were eligible for
inclusion.7
d Any estimates of the relative accuracy/effectiveness of different hs-cTnT or hs-cTnI tests were derived from direct,
within-study comparisons.
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specificity, and for the trade-off (negative correlation) between sensitivity and specificity commonly seen in
diagnostic meta-analyses. For meta-analyses with fewer than four studies we estimated separate pooled
estimates of sensitivity and specificity, using random-effects logistic regression.37 Heterogeneity was
assessed visually using summary receiver operating characteristic (SROC) plots and statistically using the
variance of logit (sensitivity) and logit (specificity), where ‘logit’ indicates the logistic function: the smaller
these values, the less heterogeneity between studies. Summary positive and negative likelihood ratios
(LR+ and LR–) were derived from the summary estimates of sensitivity and specificity. Analyses were
performed in Stata 10 (StataCorp LP, College Station, TX, USA), mainly using the metandi command. For
analyses that would not run in Stata we used MetaDiSc version 1.4 (freeware, available to download from
www.hrc.es/investigacion/metadisc_en.htm).38
Analyses were conducted separately for each of the three hs-cTn assays. Analyses were stratified according
to whether the study evaluated the prediction of AMI or MACE, timing of collection of blood sample for
testing, and the threshold used to define a positive hs-cTn result. We investigated possible sources of
heterogeneity using stratified analyses based on the following variables:
l population – studies included mixed populations compared with those that excluded patients
with STEMI
l age > 70 years compared with age ≤ 70 years
l patients with pre-existing CAD at baseline compared with patients without pre-existing CAD
l time from symptom onset to presentation < 3 hours compared with > 3 hours
l time from symptom onset to presentation < 6 hours compared with > 6 hours
l low to moderate pre-test probability of disease compared with high pre-test probability of disease.
Stratified analyses were conducted for all time points and thresholds for which sufficient data were
available. To investigate the influence of risk of bias on the studies, we restricted analyses to studies
conducted in patients at low or unclear risk of bias for the two QUADAS items considered to have the
greatest potential to have introduced bias into these studies: the item on patient spectrum (1) and the item
on patient flow (4). As the focus of this review was the diagnosis of NSTEMI, we conducted these analyses
in studies that excluded patients with STEMI. We used SROC plots to display summary estimates from the
various primary and stratified analyses.
We compared the accuracy of the three different hs-cTn assays by tabulating summary estimates from
analyses for common time points and thresholds assessed for all assays. Only one study39 provided a direct
comparison of all three assays. Estimates of sensitivity, specificity, and LR+ and LR– for each assay derived
from this study were included in the summary tables.
Results of the assessment of clinical effectiveness assessment
The literature searches of bibliographic databases identified 6766 references. After initial screening of titles
and abstracts, 261 were considered to be potentially relevant and ordered for full paper screening; of
these, 35 were included in the review.19,40–72 All potentially relevant studies cited in documents supplied by
the test manufacturers had already been identified by bibliographic database searches. One additional
study73 was identified from hand-searching of conference abstracts, and two additional studies39,74 were
identified from information supplied by clinical experts. Figure 1 shows the flow of studies through the
review process, and Appendix 4 provides details, with reasons for exclusions, of all of the publications
excluded at the full paper screening stage.
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Overview of included studies
Based on the searches and inclusion screening described above, 37 publications19,39,40–74 of
18 studies19,39,40,42,44,46,48,49,51,54,55,57,58,63,64,67,70,73 were included in the review; the results sections of this report
cites studies using the primary publication and, where this is different, the publication in which the
referenced data were reported. Fifteen studies19,39,40,42,44,46,49,51,54,55,57,58,64,67,70 reported accuracy data for
the Roche Elecsys hs-cTnT assay, four studies39,48,58,63 reported accuracy data for the Abbott ARCHITECT
hs-cTnI assay, and two studies39,73 reported accuracy data for the Beckman Coulter Access hs-cTnI assay;
two studies39,58 reported data for more than one assay. No RCTs or current controlled trials (CCTs) were
identified; no studies provided data on the effects on patient-relevant outcomes of management based on
hs-cTn assays within 4 hours of presentation compared with management based on standard cTn assays at
presentation and after 10–12 hours. All studies included in the systematic review were diagnostic cohort
studies, which reported data on the diagnostic or prognostic accuracy hs-cTn assays.
Information from clinical experts
(n = 2) 
Titles and abstracts identified
from bibliographic databases and
screened for potential relevance
(n = 6766)
Potentially relevant publications
obtained for full-text screening
(n = 257)
Total number of studies included in the review
[n = 18* studies (37 publications)
*1 study assessed two tests and 1 study
assessed all three tests]
Excluded at full-paper
screening
(n = 222)
Unobtainable studies
(n = 1)
Conference abstracts
(n = 1)
Roche hs-cTnT
[n = 15 studies (33 publications)]
Excluded at title and
abstract screening
(n = 6509)
Beckman Coulter hs-cTnI
[n = 2 studies (3 publications)]
Abbott hs-cTnI
[n = 4 studies (5 publications)]
FIGURE 1 Flow of studies through the review process.
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Thirteen19,39,40,42,44,48,49,51,55,57,64,67,73 of the 18 included studies19,39,40,42,44,46,48,49,51,54,55,57,58,63,64,67,70,73 were
conducted in Europe (two in the UK19,67), four were conducted in Australia and New Zealand,46,54,58,63
and one was conducted in the USA.70 Thirteen39,40,42,46,48,49,51,54,55,57,63,64,70 of the 18 included
studies19,39,40,42,44,46,48,49,51,54,55,57,58,63,64,67,70,73 reported receiving some support from test manufacturers,
including supply of assay kits; two studies58,73 did not report any information on funding.
Full details of the characteristics of study participants, study inclusion and exclusion criteria, and hs-cTn
assay used and reference standard, and detailed results are reported in the data extraction tables
presented in Appendix 2.
Study quality
The main potential sources of bias in the 18 studies19,39,40,42,44,46,48,49,51,54,55,57,58,63,64,67,70,73 included in this
assessment relate to patient spectrum and patient flow. There were also concerns regarding the
applicability of the patient population and the reference standard in some of the included studies. The
results of QUADAS-2 assessments are summarised in Table 3 and Figure 2; full QUADAS-2 assessments
for each study are provided in Appendix 3. A summary of the risks of bias and applicability concerns within
each QUADAS-2 domain is provided in Table 3.
Patient spectrum
Three studies42,46,51 were rated as ‘high risk of bias’ for patient selection and a further six44,55,58,64,67,70 were
rated as ‘unclear risk of bias’. Most studies rated as ‘unclear risk of bias’ did not provide sufficient details
to make a judgement on whether appropriate steps were taken to minimise bias when enrolling patients
into the study.44,58,64,67,70 In one study,55 a large number of patients were not enrolled because of ‘technical
reasons’ that were not fully defined and so it was not possible to judge whether these constituted
inappropriate exclusions; this study55 was also judged as unclear risk of bias for this domain. One study46
enrolled patients presenting only between 05.30 and 20.00 and so patients who presented outside
these hours were excluded; as these patients may differ in their presenting characteristics (e.g. time from
symptom onset) this was considered to introduce a potential bias into the study. A further study51 stated
that consecutive patients were enrolled except for temporary interruptions of the study as a result of high
work load in the coronary care unit. This was also considered to have the potential to lead to the inclusion
of a different spectrum of patients than if consecutive patients had been enrolled. The last study42 judged
at ‘high risk of bias’ for patient enrolment excluded certain patient groups, including those with a Tn
elevation in any two serial determinations, a prior diagnosis of ischaemic heart disease, structural heart
disease, concomitant HF or significant bradyarrhythmia.
Although this assessment included studies that enrolled both mixed populations (i.e. when the target
condition was any AMI) and studies restricted to populations in which patients with STEMI were excluded
(i.e. target condition NSTEMI), the primary focus was the population of patients with STEMI excluded.
Studies not restricted to this specific patient group were therefore considered to have high concerns
regarding applicability. Seven studies19,40,44,46,51,55,64 were restricted to patients in whom STEMI had been
excluded; an additional study39 enrolled a mixed population but also presented data for patients in whom
STEMI had been excluded. Three of these studies44,51,55 were restricted to patients admitted to coronary
care/chest patients units and so were considered to represent patients with more severe disease. A further
study19 had strict inclusion criteria, which resulted in the inclusion of a very-low-risk population. These four
studies19,44,51,55 were not considered to be representative of patients with chest pain presenting to the ED,
who are the main focus of this assessment, and so were also rated as having high concerns regarding
applicability. Therefore, only four studies39,40,46,75 (one39 only for a subset of data) were considered to have
low concerns regarding the applicability of the included patients.
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TABLE 3 QUADAS-2 results for studies of hs-cTn assays
Study
Risk of bias Applicability concerns
Patient
selection
Index
test
Reference
standard
Flow and
timing
Patient
selection
Index
test
Reference
standard
Aldous (2011)54 █☺ █☺ █☺ █☹ █☹ █☺ █☹
Aldous (2012)46 █☹ █☺ █☺ █☺ █☺ █☺ █☹
Body (2011)67 █? █☺ █☺ █☺ █☹ █☺ █☹
Christ (2010)57 █☺ █☺ █? █☺ █☹ █☺ █☹
Collinson (2013)19 █☺ █☺ █☺ █☹ █☹ █☺ █☺
Cullen (2013)63 █☺ █☺ █☺ █☺ █☹ █☺ █☺
Eggers (2012)44 █? █☺ █? █☹ █☹ █☺ █☹
Freund (2011)49 █☺ █☺ █☺ █☺ █☹ █☺ █☹
Hoeller (2013)39 █☺ █☺ █☺ █☹ █☹/█☺ █☺ █☺
Keller (2011)48 █☺ █☺ █☺ █☹ █☹ █☺ █☹
Kurz (2011)55 █? █☺ █☺ █☺ █☹ █☺ █☹
Lippi (2012)73 █☺ █☹ █? █? █☹ █☺ █☹
Melki (2011)51 █☹ █☺ █☺ █☺ █☹ █☺ █☺
Parsonage (2013)58 █? █☺ █☺ █? █☹ █☺ █☹
Saenger (2010)70 █? █☺ █? █? █☹ █☺ █☹
Sanchis (2012)42 █☹ █☺ █? █☺ █☹ █☺ █☺
Santalo (2013)40 █☺ █☺ █? █☺ █☺ █☺ █?
Sebbane (2013)64 █? █☺ █☺ █☹ █☺ █☺ █☹
█☺, low risk; █☹, high risk; █? , unclear risk.
Flow and timing
Low
High
Unclear
Proportion of studies with low, high, or unclear
concerns regarding applicability
Proportion of studies with low,
high, or unclear risk of bias
Reference standard
Index text
Patient selection
Q
U
A
D
A
S-
2 
d
o
m
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n
0% 20% 40% 60% 80% 100% 0% 20% 40% 60% 80% 100%
FIGURE 2 Summary of QUADAS-2 results for studies of hs-cTn assays.
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Index test
All but one of the studies19,39,40,42,44,46,48,49,51,54,55,57,58,63,64,67,70 were rated as ‘low risk of bias’ for the index test,
as all reported data for at least one threshold that was prespecified [generally the 99th centile threshold,
LoD or limit of blank (LoB) threshold]. The study73 that was rated as high risk of bias on this domain
assessed the accuracy of the Beckman Coulter Access hs-cTnI assay at a single threshold which was
derived from the ROC curve. As the reference standard (diagnosis of AMI or MACE) was interpreted after
the high-sensitivity Tn test, blinding was not considered important for these studies. Inclusion criteria were
very tightly defined in terms of the high-sensitivity Tn assays in which we were interested and so all studies
were considered to have low concerns regarding the applicability of the index test.
Reference standard
Six studies40,42,44,55,70,71 were rated as unclear risk of bias for reference standard. In five studies,39,41,43,54,56 this
was because it was unclear whether the diagnosis of AMI/MACE was made without knowledge of the
high-sensitivity Tn results. Two studies71,74 reported as abstracts provided insufficient details on how
the diagnosis of AMI was made, including whether adjudicators were blinded to the high-sensitivity Tn
results, to judge whether an appropriate reference standard had been used. No studies were rated as high
risk of bias for this domain, as these would not have fulfilled the inclusion criteria for the review. In our
review question, we specified that an appropriate reference standard had to include a standard Tn
measurement at baseline and at 10–12 hours after the onset of symptoms in 80% of the population.11
Only five studies19,39,42,51,63 met this criterion for standard Tn measurement and were judged to have
low concerns regarding the applicability of the reference standard; all but one of the remaining
studies44,46,48,49,54,55,57,58,64,67,70,73 were judged at high risk of bias, the other study did not provide exact details
on the timing of the standard Tn assay.39
Patient flow
Six studies19,39,44,48,54,64 were considered at high risk of bias for patient flow and a further three studies58,70,73
were considered at unclear risk of bias. In all cases this was related to withdrawals from the study;
verification bias was not considered to be a problem in any of the studies. The three studies58,70,71 that
were rated as unclear risk of bias were reported only as abstracts and did not provide sufficient details to
judge whether there were any withdrawals in the study. The studies judged at high risk of bias on this
domain generally excluded patients for whom samples or high sensitive Tn results were not available.
Diagnostic accuracy of the Roche Elecsys high-sensitivity cardiac
troponin T assay
Study details
Fifteen diagnostic cohort studies,19,39,40,42,44,46,49,51,54,55,57,58,64,67,70 reported in 34 publications,19,39,40–47,49–62,64–68,
70–72,74 provided data on the diagnostic performance of the Roche Elecsys hs-cTnT assay. Fourteen19,39,40,44,46,
49,51,54,55,57,58,64,67,70 of the 15 studies19,39,40,42,44,46,49,51,54,55,57,58,64,67,70 in this section assessed the accuracy of the
Roche Elecsys hs-cTnT assay for the detection of AMI, and the remaining study42 assessed accuracy for
the prediction of MACE within 30 days of the index presentation. Eight studies19,39,40,44,46,51,55,64 provided
data specific to the population of interest for this assessment; participants with STEMI were excluded
(i.e. the target condition was NSTEMI rather than any AMI).
All 14 of the studies19,39,40,44,46,49,51,54,55,57,58,64,67,70 that assessed accuracy for the detection of AMI reported
data on the diagnostic performance of a single sample taken on presentation. All but one of the
studies19,39,40,44,46,49,51,55,57,58,64,67,70 reported data for the 99th centile for the general population; the remaining
study54 reported data for a ROC-derived threshold of 9.5 ng/l. Studies additionally assessed the diagnostic
performance of a LoD/LoB threshold (5 ng/l or 3 ng/l) in a single sample taken on presentation,39,46,53,54,67 of
a single sample taken 1–3 hours after presentation,46,51 and/or the diagnostic performance of a specified
change in, or peak value of, hs-cTnT level over the initial 3 hours from presentation.39,40,46,58,70 Table 4
provides summary estimates of the diagnostic performance of all combinations of population, diagnostic
threshold and hs-cTnT test timing, which were assessed by more than one study. For analyses based on
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NSTEMI patients only when sufficient data were available, sensitivity analyses that excluded studies rated as
‘high risk of bias’ on one or more QUADAS domains were also reported. When combinations were
assessed by a single study, diagnostic performance estimates derived from that study alone are provided.
Key results used in the cost-effectiveness modelling conducted for this assessment are highlighted in bold
text. Full results (including numbers of TP, FP, FN and TN test results) for all studies and all data sets are
provided in Appendix 2 (see Study results).
Presentation samples
The summary estimates of sensitivity and specificity, where the diagnostic threshold was defined as the
99th centile for the general population, were 89% (95% CI 85% to 92%) and 82% (95% CI 77% to 86%),
based on data from 13 studies;19,39,40,44,46,49,51,54,57,58,64,68,70 the SROC curve for this analysis is shown in Figure 3.
The LR+ and LR– were 4.94 (95% CI 3.84 to 6.39) and 0.13 (95% CI 0.10 to 0.19), respectively. These
estimates were similar when the analysis was restricted to studies that excluded participants with STEMI;
summary estimates of sensitivity and specificity were 88% (95% CI 78 to 93%) and 84% (95% CI 74 to
90%), respectively (SROC curve shown in Figure 4) and the LR+ and LR– were 5.41 (95% CI 3.40 to 8.63)
and 0.15 (95% CI 0.08 to 0.26), respectively, based on six studies.19,40,44,46,51,64 The only study40 conducted in a
population which excluded participants with STEMI, which was rated as ‘low or unclear risk of bias’ on all
QUADAS domains, reported similar sensitivity and negative LR (see Table 4) to the summary estimates, but
lower estimates of specificity [71% (95% CI 66% to 76%)] and LR+ [3.11 (95% CI 2.55 to 3.79)]. Results
were also similar when the analysis was restricted to eight studies39,41,49,54,57,58,67,70 with a mixed population
(i.e. where the target condition was any AMI); summary estimates of sensitivity and specificity were 89%
(95% CI 86% to 91%) and 81% (95% CI 76% to 85%), respectively (SROC curve shown in Figure 5) and
the LR+ and LR– were 4.64 (95% CI 3.73 to 5.76) and 0.14 (95% CI 0.11 to 0.17), respectively. Based on
these data, it is unlikely that hs-cTnT testing on a single admission sample, using the 99th centile diagnostic
threshold, would be considered adequate for either rule-out or rule-in of any AMI or NSTEMI. Although
there was little apparent variation in the estimates of test performance derived from the three meta-analyses
described above, the result of the second analysis (studies that excluded participants with STEMI) was
selected to inform our cost-effectiveness analyses, as it best matched the main population of interest for this
assessment (i.e. the target condition was NSTEMI rather than any AMI). The approach of, where possible,
selecting data based on a population that excluded STEMI rather than a mixed population to inform
cost-effectiveness modelling was applied throughout.
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FIGURE 3 Summary receiver operating characteristic for the Roche Elecsys hs-cTnT assay using the 99th centile
threshold and a presentation sample (13 studies19,39–41,46,49,51,54,57,58,64,67,70).
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Limited data were identified on additional clinical subgroups (age > 70 years vs. ≤ 70 years,39,53 without
pre-existing CAD compared with pre-existing CAD,39,46 and high pre-test probability compared with low
to moderate pre-test probability (determined by clinical judgement based on cardiovascular risk factors,
type of chest pain, physical findings and ECG abnormalities49). None of these studies excluded participants
with STEMI. The study that stratified participants by age39,52 reported a higher estimate of sensitivity
[97% (95% CI 92% to 99%)] and a lower estimate of LR– [0.05 (95% CI 0.02 or 0.18)] in participants
> 70 years of age than for patients ≤ 70 years of age [88% (95% CI 78% to 94%) and 0.14 (95% CI 0.07
to 0.28), respectively]; the estimates of sensitivity and LR– for people > 70 years of age were also higher
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FIGURE 4 Summary receiver operating characteristic for the Roche Elecsys hs-cTnT assay using the 99th centile
threshold and a presentation sample (six studies19,40,44,46,51,64 that excluded participants with STEMI).
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FIGURE 5 Summary receiver operating characteristic for the Roche Elecsys hs-cTnT assay using the 99th centile
threshold and a presentation sample (eight studies39,41,49,54,57,58,67,70 with a mixed population, target condition
any AMI).
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and lower, respectively, than the corresponding summary estimates derived from all 13 studies19,39,40,44,46,49,
51,52,57,58,64,67,70 that used the 99th centile diagnostic threshold. A similar pattern was apparent for people
with a high pre-test probability compared with those with a low to moderate pre-test probability49 and
for participants without pre-existing CAD compared with those with pre-existing CAD39,47 (see Table 4).
As with the age stratification, the estimates of sensitivity and LR– were higher and lower, respectively,
than the corresponding summary estimates derived from all 13 studies19,39,40,44,46,49,51,54,57,58,64,67,70 which used
the 99th centile diagnostic threshold, for people with a high pre-test probability and for people without
pre-existing CAD. Figure 6 illustrates the variation in performance characteristics of a single admission
sample, using the 99th centile diagnostic threshold, when used in different clinical subgroups. These
data provide some indication that hs-cTnT testing on a single admission sample, using the 99th centile
diagnostic threshold, may be adequate for rule-out of AMI in certain selected populations [older people
(≥ 70 years), those without pre-existing CAD, and people classified by clinical judgement as having a high
pre-test probability].
Time from onset of chest pain to presentation was inconsistently reported across studies; when reported,
the median time from onset ranged from 2.7 hours to 8.25 hours. Full details of all information reported is
provided in Appendix 2 (see Baseline study details). Two studies39,67 specifically investigated variation in
test performance according to time from symptom onset to presentation. Both of these studies39,67 were
conducted in a mixed population (i.e. the target condition was any AMI). Study participants were stratified
by presentation before or after 3 hours,39,67 and before or after 6 hours.67 Summary estimates for the
3-hour stratification indicated that a presentation sample using the 99th centile threshold had higher
sensitivity [94% (95% CI 92% to 96%)] and lower specificity [77% (95% CI 75% to 79%)] for any AMI,
when used to assess people presenting at > 3 hours after the onset of chest pain than when used to
assess early presenters [sensitivity 78% (95% CI 71% to 83%) and specificity 84% (95% CI 81% to 86%)]
(see Table 4). The LR– was also lower when the test was used in people presenting after 3 hours from the
onset of chest pain [0.08 (95% CI 0.05 to 0.11)] than in early presenters [0.26 (95% CI 0.178 to 0.39)].
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FIGURE 6 Receiver operating characteristic space plot for the Roche Elecsys hs-cTnT assay using the 99th centile
threshold and a presentation sample in different clinical subgroups.
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Test performance in people presenting after 6 hours from the onset of chest pain was similar to that
observed in people presenting after 3 hours (see Table 4). Figure 7 illustrates the variation in performance
characteristics of a single admission sample, using the 99th centile diagnostic threshold, when used in
people presenting at different times from the onset of chest pain. These data provide some indication
that hs-cTnT testing on a single admission sample, using the 99th centile diagnostic threshold, may be
adequate for rule-out of AMI when people present after 3 hours from the onset of chest pain, but that
longer delays in presentation did not appear to further improve rule-out performance.
Five studies39,46,53,54,57,67 considered the performance of a presentation sample using a threshold equivalent
to the LoD (5 ng/l) or LoB (3 ng/l) of the assay for the diagnosis of AMI. Three studies39,46,53,54 reported
data for the 5 ng/l threshold; one of these studies39,52 reported data at this threshold only for participants
> 70 years of age. When this study39,52 was excluded, the summary estimates of sensitivity and specificity
were 95% (95% CI 92% to 97%) and 54% (95% CI 51% to 58%), respectively, and the LR+ and
LR– were 2.06 (95% CI 1.40 to 2.64) and 0.09 (95% CI 0.07 to 0.17), respectively (see Table 4). Three
studies reported data for the 3 ng/l threshold.42,46,67 The summary estimates of sensitivity and specificity
derived from these studies were 98% (95% CI 95% to 99%) and 40% (95% CI 38% to 43%),
respectively, and the LR+ and LR– were 1.63 (95% CI 1.24 to 1.86) and 0.05 (95% CI 0.02 to 0.21),
respectively (see Table 4). Only one study46 was conducted in a population that excluded people with
STEMI; however, estimates of test performance from this study were similar to the summary estimates. For
the 3-ng/l threshold, sensitivity and specificity derived from this study were 95% (95% CI 92% to 98%)
and 48% (95% CI 44% to 51%), respectively, and the LR+ and LR– were 1.83 (95% CI 1.70 to 1.97) and
0.10 (95% CI 0.05 to 0.18), respectively (see Table 4).46 For the 5-ng/l threshold, sensitivity and specificity
derived from this study were 93% (95% CI 89% to 96%) and 58% (95% CI 55% to 62%), respectively,
and the LR+ and LR– were 2.20 (95% CI 2.00 to 2.50) and 0.11 (95% CI 0.07 to 0.19), respectively (see
Table 4).46 These data provide some indication that hs-cTnT testing on a single admission sample may be
adequate to rule out any AMI or NSTEMI, where a lower diagnostic threshold (5 ng/l or 3 ng/l) is used.
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FIGURE 7 Receiver operating characteristic space plot for the Roche Elecsys hs-cTnT assay using the 99th centile
threshold and a presentation sample in people presenting at different times after symptom onset.
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Subsequent samples
The summary estimates of sensitivity and specificity, where the diagnostic threshold was defined as the
99th centile for the general population but the sample was taken 1–3 hours after presentation, were
95% (95% CI 92% to 97%) and 80% (95% CI 77% to 82%), based on data from two studies.46,51 The
LR+ and LR– were 4.75 (95% CI 3.98 to 5.23) and 0.06 (95% CI 0.00 to 0.63), respectively (see Table 4).
Both of these studies46,51 were conducted in populations that excluded people with STEMI. Unsurprisingly,
these data indicate a similar improvement in rule-out performance to that seen when the test is used only
in people presenting > 3 hours after the onset of chest pain.
Multiple samples
Six studies39,40,46,50,52,58,65,70 (data reported in multiple publications) provided data on the performance of a
variety of diagnostic strategies involving multiple sampling, most commonly involving a combination of
a peak hs-cTn value above the 99th centile diagnostic threshold and a 20% change in hs-cTnT over 2
or 3 hours following presentation (see Table 4). Figure 8 shows the results of these studies plotted in
ROC space. One study46,50 reported data for this combination over 2 hours in a population that excluded
people with STEMI, and this study46,50 was used in cost-effectiveness modelling. It is important to give full
consideration to the optimal way of interpreting combination data of this type. As can be seen from the
values reported in Table 4, a positive result from the ‘AND’ combination (defined as both a peak value
above the 99th centile AND a change of > 20% over 2 hours) provides the optimum rule-in performance
[LR+ 8.42 (95% CI 6.11 to 11.60)]; conversely, a negative result from the ‘OR’ combination (defined as
both no value above the 99th centile AND a change of < 20% over 2 hours) provides the optimum
rule-out performance [LR– 0.04 (95% CI 0.02 to 0.10)]. Where a patient has a negative result from
the ‘AND’ combination/positive result from the ‘OR’ combination (defined as either a peak value above the
99th centile OR a change of > 20% over 2 hours), further investigation is likely to be needed. This optimal
interpretation strategy is illustrated in Figure 9, along with a potential initial rule-out step, based on a
presentation sample below the LoB threshold (3 ng/l); this strategy is included in cost-effectiveness
modelling. Figure 9 shows the application of this two-stage approach to a theoretical cohort of 1000 people
presenting with symptoms suggestive of ACS (STEMI excluded); the estimated number of people with
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AMI and a negative test result who would be erroneously discharged based on this testing strategy is
14 (nine at the first stage and five at the second stage). The prevalence of NSTEMI was estimated to be
17%, based on data from three studies40,46,64 conducted in populations that excluded people with STEMI.
Four studies were excluded from the estimate of prevalence because they were considered to have
unrepresentative populations: three studies44,51,55 were conducted in coronary care unit populations and one
study76 was conducted in a low-risk population. It was assumed that the diagnostic performance of ‘AND’/’OR’
combinations of peak values of hs-cTnT and change over 2 hours, using the 99th centile diagnostic threshold,
are the same for people in whom NSTEMI is not ruled out by the initial test (hs-cTnT > LoB) as for the
initial population; this was because no test performance data were available for the combination of initial
hs-cTnT test using the LoB diagnostic threshold followed by combined peak hs-cTnT and change over
2 hours using the 99th centile threshold.
Prognostic accuracy
One study42 assed the performance of a presentation sample at the LoB (3 ng/l) threshold for the prediction
of MACE within 30 days of the index presentation. The results of this study indicate that a positive test
was a poor predictor of occurrence of MACE and a negative test was not adequate to rule out MACE
within 30 days (see Table 4).
Diagnostic accuracy of the Abbott ARCHITECT high-sensitivity cardiac
troponin I assay
Study details
Four diagnostic cohort studies39,48,58,63 provided data on the diagnostic performance of the Abbott
ARCHITECT hs-cTnI assay. Three of these studies39,48,58 assessed the accuracy of the Abbott ARCHITECT
hs-cTnI assay for the detection of AMI, and the remaining study63 assessed accuracy for the prediction of
MACE within 30 days of the index presentation. None of the studies in this section provided data specific
to the population of interest for this assessment; participants with STEMI excluded (i.e. the target condition
was NSTEMI rather than any AMI). All four studies39,48,58,63 were conducted in mixed populations. Full
details of the baseline characteristics of study populations, including baseline cardiac risk factors, are
provided in Appendix 2 (see Baseline study details).
Where a single diagnostic threshold was used to define a positive test result for AMI, all studies in this
section39,48,58,63 reported data for the 99th centile for the general population and a single sample taken
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FIGURE 9 Testing pathway for the Roche Elecsys hs-cTnT assay used in cost-effectiveness modelling.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
26
TA
B
LE
5
A
cc
u
ra
cy
o
f
th
e
A
b
b
o
tt
A
R
C
H
IT
EC
T
h
s-
cT
n
Ia
ss
ay
:
su
m
m
ar
y
es
ti
m
at
es
(9
5%
C
Is
)
G
ro
u
p
in
g
Po
p
u
la
ti
o
n
R
is
k
o
f
b
ia
s
n
Se
n
si
ti
vi
ty
(%
)
Sp
ec
if
ic
it
y
(%
)
LR
+
LR
–
Pr
ed
ic
ti
o
n
o
f
A
M
I
Pr
es
en
ta
ti
o
n
sa
m
p
le
s,
99
th
ce
n
ti
le
th
re
sh
o
ld
M
ix
ed
M
ix
ed
33
9 ,
48
,5
8
80
(7
7
to
83
)
93
(9
2
to
94
)
11
.4
7
(9
.0
4
to
16
.1
9)
0.
22
(0
.1
6
to
0.
27
)
Pr
es
en
ta
ti
o
n
sa
m
p
le
,
Lo
D
th
re
sh
o
ld
M
ix
ed
H
ig
h
ri
sk
fo
r
p
at
ie
n
t
fl
o
w
14
8
10
0
(9
8
to
10
0)
35
(3
2
to
38
)
1.
54
(1
.4
7
to
1.
62
)
0.
01
(0
.0
0
to
0.
08
)
3
h
o
u
rs
af
te
r
p
re
se
n
ta
ti
o
n
,
99
th
ce
n
ti
le
th
re
sh
o
ld
M
ix
ed
H
ig
h
ri
sk
fo
r
p
at
ie
n
t
fl
o
w
14
8
98
(9
6
to
99
)
90
(8
8
to
92
)
10
.1
6
(8
.3
8
to
12
.3
1)
0.
02
(0
.0
1
to
0.
05
)
Pr
es
en
ta
tio
n
an
d
2–
3
ho
ur
s,
pe
ak
ab
ov
e
99
th
ce
nt
ile
th
re
sh
ol
d
M
ix
ed
U
nc
le
ar
ris
k
fo
r
pa
tie
nt
sp
ec
tr
um
an
d
flo
w
15
8
91
(8
1
to
96
)
93
(9
1
to
95
)
12
.9
4
(9
.7
4
to
17
.1
9)
0.
09
(0
.0
4
to
0.
23
)
A
bo
ve
Lo
D
th
re
sh
ol
d
on
ad
m
is
si
on
an
d
Δ
20
%
M
ix
ed
H
ig
h
ris
k
fo
r
pa
tie
nt
flo
w
14
8
82
(7
8
to
86
)
52
(4
9
to
55
)
1.
73
(1
.5
9
to
1.
88
)
0.
34
(0
.2
6
to
0.
43
)
O
n
pr
es
en
ta
tio
n
an
d
at
3
ho
ur
s,
Δ
20
%
M
ix
ed
H
ig
h
ris
k
fo
r
pa
tie
nt
flo
w
14
8
77
(7
2
to
82
)
26
(2
3
to
29
)
1.
04
(0
.9
7
to
1.
12
)
0.
87
(0
.6
9
to
1.
11
)
Pr
ed
ic
ti
o
n
o
f
M
A
C
E
Pr
es
en
ta
tio
n
sa
m
pl
es
,
99
th
ce
nt
ile
th
re
sh
ol
d
M
ix
ed
H
ig
h
ris
k
fo
r
pa
tie
nt
flo
w
fo
r
on
e
st
ud
y
23
9 ,
63
88
(8
5
to
91
)
93
(9
1
to
94
)
12
.5
7
(8
.8
8
to
15
.3
5)
0.
13
(0
.0
6
to
0.
28
)
K
ey
re
su
lts
,
us
ed
in
co
st
-e
ff
ec
tiv
en
es
s
m
od
el
lin
g,
ar
e
hi
gh
lig
ht
ed
in
bo
ld
te
xt
.
DOI: 10.3310/hta19440 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 44
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
27
at presentation. Table 5 provides summary estimates of diagnostic performance for this testing strategy.
All other combinations of diagnostic threshold and hs-cTnI test timing were assessed by only one study.
Figure 10 shows the diagnostic performance of all testing strategies assessed plotted in ROC space.
Diagnostic performance estimates derived from these studies are also provided. Key results used in the
cost-effectiveness modelling conducted for this assessment are highlighted in bold text. Full results
(including numbers of TP, FP, FN and TN test results) for all studies and all data sets are provided in
Appendix 2 (see Study results).
Presentation samples
Summary estimates of sensitivity and specificity based on a diagnostic threshold defined as the 99th centile
for the general population were 80% (95% CI 77% to 83%) and 93% (95% CI 92% to 94%), based on
data from three studies.39,48,58 The LR+ and LR– were 11.47 (95% CI 9.04 to 16.19) and 0.22 (95% CI
0.16 to 0.27), respectively. All three studies39,48,58 were conducted in a mixed population (i.e. where the
target condition was any AMI). Based on these data, it is unlikely that hs-cTnI testing on a single admission
sample, using the 99th centile diagnostic threshold, would be considered adequate for rule-out of any
AMI, but a positive test result may be useful in ruling in AMI.
No studies reported clinical subgroup data, or data on the performance of the test in people presenting at
different times after symptom onset for the Abbott ARCHITECT hs-cTnI assay.
One study48 also considered the performance of a presentation sample using the LoD of the assay as
the threshold for diagnosing AMI. This study48 provided estimates of sensitivity and specificity of 100%
(95% CI 98% to 100%) and 35% (95% CI 32% to 38%), respectively, and the LR+ and LR– were
1.54 (95% CI 1.47 to 1.62) and 0.01 (95% CI 0.00 to 0.08), respectively (see Table 5). These data provide
some indication that hs-cTnI testing on a single admission sample may be adequate to rule out any AMI,
where a lower diagnostic threshold (the LoD of the assay) is used.
Subsequent samples
One study58 assessed the performance of hs-cTnI testing on a sample taken 3 hours after presentation,
where the diagnostic threshold was defined as the 99th centile for the general population. The summary
estimates of sensitivity and specificity, derived from this study, were 98% (95% CI 96% to 99%) and 90%
(95% CI 88% to 92%). The LR+ and LR– were 10.16 (95% CI 8.38 to 12.31) and 0.02 (95% CI 0.01 to
0.08), respectively (see Table 5). These data provide some indication that a sample taken at 3 hours after
presentation may be informative, at the 99th centile threshold, for both rule-out and rule-in of AMI.
Multiple samples
Two studies48,58 provided data on the performance of a variety of diagnostic strategies involving multiple
sampling (see Table 5). None of these strategies appeared to offer a performance advantage over testing
based on a single sample. Figure 11 illustrates our proposed optimal testing pathway for the Abbott
ARCHITECT hs-cTnI assay; this strategy is included in cost-effectiveness modelling. As with Figure 9, which
presents the Roche Elecsys hs-cTnT optimal strategy, Figure 11 shows the application of this two-stage
approach to a theoretical cohort of 1000 people presenting with symptoms suggestive of ACS (STEMI
excluded), with a prevalence of NSTEMI of 17%; the estimated number of people with AMI and a negative
test result who would be erroneously discharged based on this testing strategy is three (zero at the first
stage and three at the second stage). It was assumed that the diagnostic performance of hs-TnI using the
99th centile diagnostic threshold on a sample taken 3 hours after presentation is the same for people in
whom NSTEMI is not ruled out by the initial test (hs-cTnI > LoD) as for the initial population; this was
because no test performance data were available for the combination of initial hs-cTnI test using the LoD
diagnostic threshold followed by 3-hour hs-cTnI and using the 99th centile threshold.
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Prognostic accuracy
One study39,63 assessed the performance of a presentation sample at the 99th centile for the prediction of
MACE within 30 days of the index presentation. The results of this study39,63 indicate that a positive test
may be helpful in predicting the occurrence of MACE, whereas a negative test is not adequate to rule out
MACE within 30 days (see Table 5).
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FIGURE 10 Receiver operating characteristic space plot of the Abbott ARCHITECT hs-cTnT assay.
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FIGURE 11 Testing pathway for the Abbott ARCHITECT hs-cTnI assay used in cost-effectiveness modelling.
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Diagnostic accuracy of the Beckman Coulter Access high-sensitivity cardiac
troponin I assay
Study details
Two diagnostic cohort studies,39,73 reported in three publications,39,64,73 provided data on the diagnostic
performance of the Beckman Coulter Access hs-cTnI assay. Both studies assessed a precommercial version
of the assay and both reported accuracy data for the diagnosis of AMI (any AMI65,73 or NSTEMI39). No study
assessed the performance of the Beckman Coulter Access hs-cTnI assay for the prediction of MACE within
30 days of the index admission. The diagnostic performance estimates, for all combinations of diagnostic
threshold and test timing assessed by included studies, are summarised in Table 6. Figure 12 shows the
diagnostic performance of all testing strategies assessed, plotted in ROC space.
Presentation samples
Both studies16,39 assessed the diagnostic performance of a single sample taken at presentation. One study39
used the 99th centile for the general population as the diagnostic threshold. This study39 was considered
to be the most relevant to our assessment and was used to inform cost-effectiveness analyses; this was the
only testing strategy modelled for the Beckman Coulter Access hs-cTnI assay and, for a theoretical cohort
of 1000 people presenting with symptoms suggestive of ACS (STEMI excluded) with a prevalence of
NSTEMI of 17%, the estimated number of people with AMI and a negative test result who would be
erroneously discharged based on this testing strategy is 14. However, it should be noted that the Beckman
Coulter hs-cTnI assay evaluated in this study39 was described as ‘an investigational prototype’; the 99th
centile (9 ng/l), described as ‘according to the manufacturer’, differs from the 99th centile given in the
current product information leaflet (40 ng/l).16 The estimates of sensitivity and specificity derived from this
study were 92% (95% CI 88% to 95%) and 75% (95% CI 72% to 78%), respectively, and the LR+ and
LR– were 3.67 (95% CI 3.26 to 4.13) and 0.11 (95% CI 0.07 to 0.17), respectively (see Table 6). The
summary estimates, for the two studies16,39 combined, were very similar (see Table 6).
No studies reported clinical subgroup data, or data on the performance of the test in people presenting at
different times after symptom onset, for the Beckman Coulter Access hs-cTnI assay.
Subsequent samples
Neither of the studies reported data for single samples taken at time points other than presentation.
Multiple samples
One study39 assessed the diagnostic performance of a > 27% change in hsTnI from presentation to 1 hour.
This testing strategy produced results indicating a decline in both rule-in and rule-out performance
compared with the single presentation sample described above (see Table 6).
Comparative diagnostic accuracy of the Roche Elecsys high-sensitivity
troponin T assay, the Abbott ARCHITECT high-sensitivity troponin I assay
and the Beckman Coulter Access high-sensitivity troponin I assay
Only one study39 provided data for a direct comparison of the diagnostic performance of all thee hs-cTn
assays in the same population. These data were for the use of the 99th centile threshold in a sample taken
at presentation. This was also the only time point and threshold assessed for each study by individual
included studies. As can be seen from Tables 7 and 8, below, the summary estimates of the performance
of each test, derived from all studies reporting data for this threshold, were similar to estimates derived
from the direct comparison study alone.
Selection of diagnostic strategies for inclusion in cost-effectiveness modelling
Diagnostic strategies for each hs-cTn assay were selected for inclusion in cost-effectiveness modelling
based on optimal diagnostic performance as indicated by data from the systematic review. In addition,
wherever possible, data from studies that excluded patients with STEMI (i.e. where the target condition
was NSTEMI) were preferentially selected.
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FIGURE 12 Receiver operating characteristic space plot of the Beckman Coulter Access hs-cTnI assay.
TABLE 7 Comparison between assays (presentation samples, 99th centile threshold): sensitivity and specificity
(95% CI)
Assay
Indirect comparison Direct comparison39
n Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%)
Beckman Coulter
Access hs-cTnI
2 92 (88 to 95) 75 (72 to 77) 92 (88 to 98) 75 (72 to 78)
Abbott ARCHITECT
hs-cTnI
3 80 (77 to 83) 93 (92 to 94) 77 (72 to 82) 93 (91 to 94)
Roche Elecsys hs-cTnT 13 89 (84 to 91) 82 (77 to 86) 90 (86 to 92) 78 (76 to 79)
TABLE 8 Comparison between assays (presentation samples, 99th centile threshold): likelihood ratios (95% CI)
Assay
Indirect comparison Direct comparison39
n LR+ LR– LR+ LR–
Beckman Coulter
Access hs-cTnI
2 3.32 (2.46 to 4.48) 0.11 (0.07 to 0.16) 3.68 (3.27 to 4.14) 0.11 (0.07 to 0.17)
Abbott ARCHITECT
hs-cTnI
3 12.10 (9.04 to 16.19) 0.21 (0.16 to 0.27) 10.42 (8.49 to 12.79) 0.25 (0.20 to 0.30)
Roche Elecsys hs-cTnT 13 4.96 (3.84 to 6.96) 0.14 (0.10 to 0.19) 4.02 (3.65 to 4.43) 0.13 (0.10 to 0.18)
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Chapter 4 Assessment of cost-effectiveness
This chapter explores the cost-effectiveness of hs-cTn assays (used singly or in series, up to 4 hours fromthe onset of chest pain/presentation) compared with the current standard of serial Tn T and/or I testing
on admission and at 10–12 hours after the onset of symptoms for the early rule-out of AMI in people with
acute chest pain.
Review of economic analyses of high-sensitivity cardiac
troponin assays
Search strategy
Searches were undertaken to identify cost-effectiveness studies of high-sensitivity TnT/I. As with the clinical
effectiveness searching, the main EMBASE strategy for each set of searches was independently peer
reviewed by a second Information Specialist, using the Canadian Agency for Drugs and Technologies in
Health (CADTH) Peer Review Checklist.28 Search strategies were developed specifically for each database
and keywords associated with high-sensitivity TnT/I were adapted according to the configuration of each
database. Full search strategies are reported in Appendix 1.
The following databases were searched for relevant studies from 2005 to October 2013:
l MEDLINE (OvidSP): 2005–2013/10/wk1.
l MEDLINE In-Process & Other Non-Indexed Citations and Daily Update (OvidSP): up to 2013/10/1.
l EMBASE (OvidSP): 2005–2013/10/17.
l NHS Economic Evaluation Database (NHS EED) (Wiley): Cochrane Library Issue 3 2005 to July 2013.
l Health Economic Evaluation Database (HEED) (Wiley): 2005–2013/10/18.
l EconLit (EBSCO): 2005–2013/09/01.
l Science Citation Index (SCI) (Web of Science): 2005–2013/10/21.
l Conference Proceedings Citation Index – Science (CPCI) (Web of Science): 2005–2013/10/21.
l Research Papers in Economics (REPEC) (Internet): up to 2013/10/21 http://repec.org/.
Identified references were downloaded in EndNote X4 software for further assessment and handling.
References in retrieved articles were checked for additional studies.
Inclusion criteria
Studies reporting a full economic analysis, which related explicitly to the cost-effectiveness of hs-cTn or
standard cTn (with cTn implying either cTnI or cTnT) testing, with survival and/or quality-adjusted life-years
(QALYs) as an outcome measure, were eligible for inclusion. Specifically, one of the strategies had to
include cTn testing. Studies that reported only a cost-analysis of cTn testing were not included in the review.
Quality assessment
Full cost-effectiveness studies were appraised using the Drummond checklist.77
Results
The literature search identified 152 reports. After initial screening of titles and abstracts, five reports7,19,78–80
were considered to be potentially relevant: two full papers79,80 and three HTA reports.7,19,78 Two additional
reports81,82 were provided by a clinical expert: a Canadian optimal use report82 (similar to an HTA report) and
an abstract81 that was referred to in this report. All seven identified reports7,19,78–82 fulfilled inclusion criteria
based on full-text assessment. The seven publications related to five studies. Figure 13 shows the flow of
studies through the review process, Table 9 lists the study details and the results of the quality assessment are
shown in Table 10.
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Information from clinical experts
n = 2
Titles and abstracts identified
from bibliographic databases and
screened for potential relevance
n = 152 
Excluded at title and
abstract screening
n = 145 
Potentially relevant publications
obtained for full-text screening
n = 7
Total number of studies included in the
review
n = 5 studies (9 publications)
Goodacre (2013)7
(1 HTA, 1 JA)
Excluded at full-paper
screening
n = 0
Unobtainable studies
n = 0 
Goodacre (2011)78
(1 HTAs, 1 JA)
Vaidya (2012)81
(1 CA) 
CADTH (2013)82
(1 HTA)
Collinson (2013)19
(1 HTA)
FIGURE 13 Flow of studies through the review process. CA, conference abstract; HTA, Health Technology Assessment;
JA, journal article.
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TABLE 10 Checklist of study quality for full papers included
Goodacre et al.78 and
Fitzgerald et al.79
Vaidya
et al.81
Thokala et al.80 and
Goodacre et al.7
CADTH
report82
Collinson
et al.19
Study design
The research question is stated ✓ ✓ ✓ ✓ ✓
The economic importance of the
research question is stated
✓ ✗ ✓ ✓ ✓
The viewpoint(s) of the analysis are
clearly stated and justified
✓ ✓ ✓ ✓ ✓
The rationale for choosing
alternative programmes or
interventions compared is stated
✓ ✗ ✓ ✓ ✓
The alternatives being compared
are clearly described
✓ ✓ ✓ ✓ ✓
The form of economic evaluation
used is stated
✓ ✓ ✓ ✓ ✓
The choice of form of economic
evaluation is justified in relation to
the questions addressed
✓ ✓ ✓ ✓ ✓
Data collection
The source(s) of effectiveness
estimates used are stated
✓ ✗ ✓ ✓ ✓
Details of the design and results
of effectiveness study are given
(if based on a single study)
✓ ✗ ✓ ✓ ✓
Details of the methods of synthesis
or meta-analysis of estimates are
given (if based on a synthesis of a
number of effectiveness studies)
✓ ✗ ✓ ✓ ✓
The primary outcome measure(s)
for the economic evaluation are
clearly stated
✓ ✓ ✓ ✓ ✓
Methods to value benefits are
stated
✓ ✗ ✓ ✓ ✗
Details of the subjects from whom
valuations were obtained were
given
✓ ✗ ✗ ✗ ✗
Productivity changes (if included)
are reported separately
NA ✗ NA NA NA
The relevance of productivity
changes to the study question is
discussed
NA ✗ NA NA NA
Quantities of resource use are
reported separately from their unit
costs
✓ ✗ ✗ ✗ ✗
Methods for the estimation of
quantities and unit costs are
described
✓ ✗ ✓ ✓ ✓
Currency and price data are
recorded
✓ ✗ ✓ ✓ ✓
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TABLE 10 Checklist of study quality for full papers included (continued )
Goodacre et al.78 and
Fitzgerald et al.79
Vaidya
et al.81
Thokala et al.80 and
Goodacre et al.7
CADTH
report82
Collinson
et al.19
Details of currency of price
adjustments for inflation or
currency conversion are given
✓ ✗ ✗ ✗ ✗
Details of any model used are
given
✓ ✗ ✓ ✓ ✓
The choice of model used and the
key parameters on which it is
based are justified
✓ ✗ ✓ ✓ ✓
Analysis and interpretation of results
Time horizon of costs and benefits
is stated
✓ ✓ ✓ ✓ ✓
The discount rate(s) is stated ✗ ✗ ✗ ✓ ✗
The choice of discount rate(s) is
justified
NA ✗ NA ✓ NA
An explanation is given if costs and
benefits are not discounted
✗ ✗ ✗ NA ✗
Details of statistical tests and CIs
are given for stochastic data
✓ ✗ ✓ ✓ ✓
The approach to sensitivity analysis
is given
✓ ✗ ✓ ✓ ✓
The choice of variables for
sensitivity analysis is justified
✓ ✗ ✓ ✓ ✓
The ranges over which the
variables are varied are justified
✓ ✗ ✓ ✓ ✓
Relevant alternatives are compared ✓ ✓ ✓ ✓ ✓
Incremental analysis is reported ✓ ✗ ✓ ✓ ✓
Major outcomes are presented
in a disaggregated as well as
aggregated form
✓ ✗ ✓ ✓ ✓
The answer to the study question
is given
✓ ✓ ✓ ✓ ✓
Conclusions follow from the data
reported
✓ ✓ ✓ ✓ ✓
Conclusions are accompanied by
the appropriate caveats
✓ ✗ ✓ ✓ ✓
NA, not applicable.
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Goodacre (2011)78 and Fitzgerald (2011)79
This study was based on the multicentre, pragmatic controlled trial ‘Randomised Assessment of Treatment
using Panel Assay of Cardiac Markers’ (RATPAC). An economic evaluation was undertaken to assess
the cost-effectiveness of management based on testing with a panel of point-of-care cardiac markers
compared with management without point-of-care panel assessment. The included population consisted
of patients presenting to hospital with chest pain attributable to suspected, but not proven, AMI and no
other potentially serious alternative pathology or comorbidity. The analysis was performed from an NHS
perspective, using trial data to estimate the mean costs per patient of chest pain-related care and the
mean number of QALYs accrued by patients in each arm of the trial, with a time horizon of 3 months.
In addition, a decision-analytic model was constructed to duplicate (validate) trial results and extrapolate
results to a longer time horizon.
Resource-use data were collected for all patients. Cost and outcome data were collected using patient
notes and self-completed questionnaires. Unit prices were based partly on a microcosting study on a sample
of patients, partly on a study previously undertaken by the investigators, and partly on purchase price and
national unit costs. QALYs were calculated based on European Quality of Life-5 Dimensions (EQ-5D)
measurements. In a sensitivity analysis, productivity costs were included as reported by the patients.
As it was anticipated that the trial would have limited power to detect a difference in major adverse
events, the decision-analytic model was intended to explore whether uncertainty around the effect of
the intervention upon the major adverse event rate could influence the potential cost-effectiveness of the
intervention. The model used trial data to estimate costs and QALYs up to 3 months. Beyond this, lifetime
cost and QALYs were estimated from a previous study.86 It was assumed that patients who had died at
3 months would accrue no further costs or QALYs. Those who had survived non-fatal myocardial infarction
(MI) would accrue costs and QALYs associated with CHD (estimated at £10,079 and 6.829, respectively).
Those without CHD were assigned zero costs and 20 QALYs.
Empirical results showed that the point-of-care test strategy was dominated by standard care, which delivered
slightly more QALYs at a lower cost. The probability that point-of-care testing would be more cost-effective
than standard care at a willingness-to-pay threshold of £20,000 per QALY was < 1%. The decision-analytic
model again resulted in higher costs and less effect for the point-of-care panel assay compared with standard
care, also when extrapolated to lifetime survival. The probability of the point-of-care panel assay being
cost-effective for the 3-month and lifetime model was 22.3% and 33.6%, respectively.
The main conclusion was that point-of-care panel assay testing is unlikely to be considered cost-effective
in the NHS, with an 89% probability that standard care was dominant. Cost-effectiveness was mainly
driven by differences in mean cost, with point estimates suggesting that, per patient, point-of-care panel
assessment was £211 more expensive than standard care.
Vaidya (2012)81
This study aimed to assess the cost-effectiveness of a hs-TnT assay, alone or in combination with the H-FABP
assay in comparison with the conventional cTnT assay for the diagnosis of AMI in patients presenting
to hospital with chest pain. A decision-analytic model was developed to perform both a cost–utility analysis
(cost per QALY gained) and a cost-effectiveness analysis [cost per life-year (LY) gained and cost per AMI
averted], using a health-care perspective and a lifetime time horizon. One-way and probabilistic sensitivity
analyses (PSAs) were conducted.
The incremental cost-effectiveness ratio (ICER) for hs-TnT compared with conventional cTnT was €3748 per
QALY gained. For hs-cTnT in combination with H-FABP compared with conventional cTnT the ICER was
€5717 per QALY gained. For LY and AMI averted, no ICERs were reported in the abstract. The PSA
showed the hs-TnT assay to be the preferable strategy, with a probability of > 90%, at a ceiling ratio of
€4800 per QALY. This led to the conclusion that the hs-TnT assay is very cost-effective relative to the
conventional cTnT assay. Combining hs-TnT with H-FABP did not seem to offer any additional economic or
health benefit over the hs-TnT test alone.
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Goodacre (2013)7 and Thokala (2012)80
This study aimed to estimate the cost-effectiveness of using alternative biomarker strategies to diagnose MI,
and using biomarkers, computed tomography coronary angiography (CTCA) and exercise ECG to risk-stratify
Tn-negative patients. As the second aim was outside the scope of this review, we have summarised only the
analysis that compares the biomarker strategies for diagnosing MI, referred to in the HTA report as ‘the
diagnostic phase model’. The different diagnostic strategies were applied to a hypothetical cohort of patients
attending the ED with suspected, but not proven, ACS. Patient characteristics were defined using data from the
RATPAC trial,87 as well as patients’ arrival times during the day at the ED. The model assigned each patient a
probability of re-infarction or death depending on their characteristics and whether or not they had treatment.
The model took a lifetime time horizon. The economic perspective was that of the NHS in England and Wales.
The following strategies were applied to each patient:
l no testing – discharge all patients without treatment (hypothetical)
l standard Tn assay measured at presentation using the 10% CV as the threshold for positivity
l standard Tn assay measured at presentation using the 99th percentile threshold
l high-sensitivity Tn assay measured at presentation using the 99th percentile threshold
l standard Tn assay measured at presentation and 10 hours after symptom onset using the 99th
percentile threshold.
Blood tests at presentation were assumed to be taken in the ED, and so a decision could be made within
1 hour of the test results becoming available. For the 10–12 hours’ Tn measurement, three different
scenarios were tested:
l ‘doctor-on-demand’ scenario, with medical staff available 24 hours a day to make a disposition
decision within 1 hour of the results being available
l twice-daily ward round scenario, with medical staff only available at twice daily ward rounds to make
disposition decisions
l once-daily ward round scenario, with medical staff only available at a once daily ward round to make
disposition decisions.
Sensitivity and specificity estimates for the presentation Tn tests were obtained by performing meta-analysis
of estimates from individual primary studies included in the accompanying review. The 10-hour Tn test was
assumed to have perfect sensitivity and specificity as it was the reference standard for the review. This
implies that FPs of the hs-Tn testing at presentation will still be discharged home after the 10- to 12-hour Tn
test but FNs will be discharged home without treatment. The ‘discharge without testing or treatment’ by
definition has perfect specificity, but a sensitivity of 0%.
The risk of re-infarction and death for patients with MI was based on a study by Mills et al.83 Life expectancy
of patients with MI, and MI with re-infarction, was estimated from Polanczyk et al.,88 whereas the utility of
patients with MI was based on Ward et al.85 The utility of patients with re-infarction was estimated by using
a multiplicative factor of 0.8 for patients with MI (expert opinion). Patients without MI were assigned the life
expectancy and utility scores of the general population. Lifetime costs for patients with MI were based on
Ward et al.85 One-way sensitivity analyses were performed, as well as a PSA. In a secondary analysis, a
strategy was added that involved alternative biomarkers in combination with the presentation Tn testing.
The results showed that measuring a 10-hour Tn level in all patients was the most effective strategy
(ICER £27,546–103,560). However, at a threshold of £30,000 per QALY, the optimal strategy in all but
one scenario was measurement of high-sensitivity Tn at presentation, with a 10-hour Tn test if positive
and discharge home if negative (ICER £7487–17,191 per QALY). The exception was a scenario involving
patients without known CAD and a doctor available on demand to discharge the patient, where, using the
£30,000 per QALY threshold, the strategy of measuring a 10-hour Tn level in all patients was optimal
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(ICER of £27,546 per QALY). Sensitivity analyses showed the optimal strategy to vary with different levels
of sensitivity and timing of the tests.
The report concluded that the additional costs that are likely to be incurred by measuring a 10-hour Tn
level, compared with a presentation high-sensitivity Tn level, are unlikely to represent a cost-effective use
of NHS resources in most of the scenarios tested.
Canadian Agency for Drugs and Technologies in Health optimal use report
This report82 aimed to determine the cost-effectiveness of hs-cTnT and hs-cTnI assays compared with each
other, as well as with cTnI assays in patients with suspected ACS symptoms in the ED. For this purpose,
three comparators were considered: hs-cTnT, hs-cTnI and cTnI. As cTnT is no longer available in Canada,
it was not taken into account in the analysis. The target population consisted of 65-year-old patients
presenting to the ED, without ST segment elevation, who required cTn testing for diagnosis of NSTEMI.
For the economic evaluation, a decision tree was constructed, which calculated lifetime cost per QALY
from the perspective of a publicly funded health-care system.
The model consisted of a short-term part, which had a time horizon of 1 year, and a long-term part. The
short-term part incorporated the testing and treatment procedures and short-term outcomes. Patients
were tested at presentation at the ED and, if they were not admitted to hospital after the first test, they
were tested again after 6 hours. When the patient was admitted after the first test, treatment was said to
be initiated early, and when a patient was admitted after the second test, treatment was late. One-year
mortality depended on whether a patient had NSTEMI and whether they were treated early, treated late,
or untreated (in the case of FN test results). Those not suffering from NSTEMI were further stratified into
UA or not having ACS (non-ACS). The annual probability of death in the long-term part of the model was
dependent on patient age, sex, and whether or not they had suffered a NSTEMI, UA or did not have any
type of ACS in the short-term part of the model.
The sensitivity and specificity for each cTn test at presentation to the ED was derived from the systematic
review which was also part of this study. In the model, patients with a negative cTn test at presentation
were assumed to be observed and have a second cTn test 6 hours later. After the second cTn test, 90% of
these FNs were assumed to become TPs.
Short-term mortality rates and relative risks (RRs) for treated/non-treated were taken from published clinical
studies and one non-referenced study. The RR for late treatment compared with early treatment was
derived from expert opinion. Long-term mortality rates were taken from published clinical studies, and one
non-referenced study. QALYs were calculated by incorporating an age-specific utility decrement for
patients with NSTEMI. A number of one-way sensitivity analyses were performed, as well as a PSA.
The base-case results indicated that hs-cTnI was dominated by hs-cTnT, when compared with cTnI, at an ICER
of US$119,377 per QALY. The PSA showed that, for willingness-to-pay thresholds of up to US$124,000,
cTnI had the highest probability of being cost-effective. For thresholds >US$124,000, hs-cTnT had the
highest probability of being cost-effective. The hs-cTnI test was not likely to be cost-effective for any value
of the threshold.
The authors concluded that hs-cTnT would be considered the most cost-effective testing strategy if
willingness to pay for a QALY is US$119,377 or more, otherwise cTnI would be the most cost-effective
test. However, there was a lot of uncertainty in results when model assumptions were changed.
Collinson (2013)19
This study used the decision tree developed in the related HTA by Goodacre et al.7 to compare the
cost-effectiveness of five diagnostic strategies to a hypothetical cohort of patients presenting to hospital
with symptoms suggestive of MI but with no diagnostic ECG changes, no known history of CHD and no
major comorbidities requiring inpatient treatment. Essentially, this was a substudy of the point-of-care arm
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of the RATPAC trial. All methods and model inputs were identical to the study by Thokala et al.80 and the
HTA report by Goodacre et al.,7 but with slightly different strategies applied to the cohort of patients:
l No testing – discharge all patients without treatment (theoretical ‘zero’ option)
l high-sensitivity cTnT at presentation – discharge home if test is negative or admit to hospital for
Tn-testing at 10–12 hours if positive
l high-sensitivity cTnT and H-FABP at presentation – discharge home if both tests are negative or admit
to hospital for Tn testing at 10–12 hours if either test is positive
l high-sensitivity cTnT at presentation and at 90 minutes as in the RATPAC protocol – discharge home if
both tests are negative or admit to hospital testing at 10–12 hours if either test is positive
l standard Tn testing at 10–12 hours (current standard as per NICE guidelines).
The difference with the other studies is in the addition of H-FABP in the third strategy and in the second
high-sensitive Tn test at 90 minutes in the fourth strategy. In a secondary analysis, cTnT was replaced by
cTnI. Sensitivity and specificity of presentation biochemical testing were estimated using data from within
the study (RATPAC). Standard Tn testing at 10–12 hours was assumed to have perfect sensitivity and
specificity as this was again the reference standard.
At the £20,000 per QALY threshold, 10-hour Tn testing was cost-effective (£12,090 per QALY) in the
doctor-on-demand scenario, but not in the other scenarios (once-daily ward round and twice-daily ward
rounds), when high-sensitivity cTnT and H-FABP measurement at presentation was cost-effective. At the
£30,000 per QALY threshold, 10-hour Tn testing was cost-effective in the doctor-on-demand scenario and
twice-daily ward rounds scenario (£24,600 per QALY), whereas the TnT and H-FABP measurement at
presentation strategy was cost-effective (£14,806 per QALY) in the once-daily ward round scenario.
Secondary analysis using cTnI instead of cTnT showed that cTnI testing at presentation and at 90 minutes
was cost-effective in all three scenarios at the £20,000 per QALY threshold, and in two of the scenarios at
the £30,000 per QALY threshold, with 10-hour Tn being cost-effective only in the doctor-on-demand
scenario (£24,327 per QALY). The overall conclusion was that 10-hour Tn testing is likely to be cost-effective
compared with rapid rule-out strategies only if patients can be discharged as soon as a negative result is
available and a £30,000 per QALY threshold is used.
Summary of studies included in the cost-effectiveness review
Most of the studies identified in this review have found that the question of whether hs-Tn testing is
cost-effective cannot be answered unequivocally. In favour of hs-Tn testing, the abstract by Vaidya et al.81
concluded that hsTnT testing is ‘very cost-effective’ and the study by Goodacre et al.7 concluded that
‘the optimal strategy in all but one scenario was high-sensitivity Tn at presentation, with a 10 hour Tn test
if positive and discharge home if negative’ (p. xv). The other papers reported ICERs that were considerably
higher and with substantial uncertainty. The accuracy of high-sensitivity tests and the efficiency of
decision-making based on test results were important drivers of cost-effectiveness.
Model structure and methodology
Troponin tests considered in the model
The health-economic analysis will estimate the cost-effectiveness of different Tn testing methods for
diagnosing or ruling out NSTEMI, in patients presenting at the ED with suspected NSTE-ACS, who have no
major comorbidities requiring hospitalisation (e.g. as HF or arrhythmia) and in whom STEMI has been ruled
out. Those diagnosed with NSTEMI will then be admitted to the hospital for AMI treatment and those
diagnosed as without NSTEMI can be discharged without AMI treatment and further hospital stay. AMI
treatment might include aspirin, statins and ACE inhibitors and consideration of coronary revascularisation
for high-risk cases.7 Initiating AMI treatment for NSTEMI will reduce the probability of MACEs, particularly
cardiac death and re-infarction.
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Standard serial Tn testing, for patients with acute chest pain attributable to possible ACS, does not achieve
optimal sensitivity in detecting AMI until 10–12 hours after onset of symptoms. Waiting for 10–12 hours
after symptom onset is burdensome for patients and induces additional health-care costs. Therefore,
various alternatives have been proposed, using more sensitive Tn tests, for the early rule-out of NSTEMI
(within the 4-hour NHS ED target).89
Two hs-cTn assays (Roche Elecsys hs-cTnT and Abbott ARCHITECT hs-cTnI) are currently used in NHS
laboratories in England and Wales. One additional assay (Beckman Coulter hs-cTnI) was listed in the scope
for this assessment, pending CE marking. However, each of these tests can be used at different time
points and with different diagnostic thresholds, resulting in multiple possible strategies for each test.
Whether or not a test strategy was included in the economic model was decided based on optimal
diagnostic performance, given the available evidence on accuracy for a population with STEMI ruled out,
and on applicability in clinical practice (see Results of the assessment of clinical effectiveness assessment,
above). The test strategies evaluated in the model are:
l Standard Tn at presentation and at 10–12 hours (reference standard).
l Roche Elecsys hs-cTnT at presentation: 99th centile threshold.
l Roche Elecsys hs-cTnT (optimal strategy): LoB threshold at presentation followed by 99th centile
threshold peak within 3 hours and/or Δ20% (compared with presentation test) at 1–3 hours
(see Figure 9).
l Abbott ARCHITECT hs-cTnI at presentation: 99th centile threshold.
l Abbott ARCHITECT hs-cTnI (optimal strategy): LoD threshold at presentation, followed by 99th centile
threshold at 3 hours (see Figure 11).
l Beckman Coulter hs-cTnI at presentation: 99th centile threshold.
l No testing, discharge all patients without testing or treatment (only in sensitivity analyses). A Tn test
may not be indicated when clinical judgement assesses the probability that a patient is experiencing an
AMI as low. Therefore, consistent with the protocol, this hypothetical strategy is included in sensitivity
analyses wherein the AMI prevalence is varied.
In the base case, it was assumed that standard Tn had perfect sensitivity and specificity (reference case) for
diagnosing AMI. Using this assumption, all patients testing positive on a hs-cTn test but negative on the
standard Tn would be classified as FPs. This implies that their risk for adverse events would be the same
as for those patients testing negative on both the hs-cTn test and the standard Tn, and that they ought to
be discharged home without further immediate treatment. However, recent evidence has shown that
patients with a negative standard Tn, but a positive hs-cTn, may be at higher risk for adverse events
than patients who test negative on both the standard and the high-sensitive Tn (Goodacre S, Medstar
Washington Hospital Center, Washington, DC, USA; Lipinski M, University of Sheffield, Sheffield, UK:
2014, personal communication). A secondary analysis was therefore performed, which attributed a higher
risk of adverse events to a proportion of patients testing FP with the hs-cTn test.
Based on the available evidence, two analyses were performed:
l Base-case analysis.
l Secondary analysis, assuming that FPs in the hs-cTn testing strategies do not have the same risk for
adverse events as TNs. Instead, these patients were assigned a higher risk for (re-)infarction and death,
to reflect the idea that when the hs-cTn test gives a positive result, in some cases this must be caused
by a disease process, whether or not the strict definition of AMI is met. The risk of adverse events in
patients with positive hs-cTn but a negative standard Tn is higher than the patients testing negative on
both the hs-cTn test and the standard Tn, but lower than risk of adverse events in patients diagnosed
with NSTEMI (i.e. both positive hs-cTn and standard Tn).
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Model structure
This assessment uses the HTA report by Goodacre et al.7 as a starting point for cost-effectiveness modelling.
The Goodacre report compared the cost-effectiveness of several diagnostic strategies for ACS. The assessment
group received the health-economic model (in SIMUL8 2011, Simul8 Corporation, Boston, MA, USA) that this
HTA was based on, and this model was used as a starting point to develop a de novo model (in Microsoft
Excel 2003: Microsoft Corporation, Redmond, WA, USA) adapted to better fit the scope of the current
assessment. In the health-economic model the mean expected costs and QALYs were calculated for each
alternative strategy. These long-term consequences were estimated based on the accuracy of the different
testing strategies followed by AMI treatment or discharge from the hospital without AMI treatment for
patients presenting at the ED with suspected NSTE-ACS, including patients with NSTEMI and patients without
NSTEMI, who are further subdivided into ‘No ACS, no UA’ and ‘Unstable angina’. For this purpose a decision
tree and a Markov model were developed. The decision tree was used to model the 30-day outcomes after
presentation, based on test results and the accompanying treatment decision. These outcomes consisted
of ‘No ACS, no UA’, ‘Unstable angina’, ‘Non-fatal AMI (untreated)’, ‘Non-fatal AMI (treated)’ and ‘Death’.
The decision tree is shown in Figure 14.
The long-term consequences in terms of costs and QALYs were estimated using a Markov cohort model
(Figure 15) with a lifetime time horizon (60 years). The cycle time was 1 year, except for the first cycle,
Patients with
suspect NSTE-ACS
presenting at ED
Single/serial
hs Troponin test A
Serial Troponin T/I
(comparator)
Single/serial
hs Troponin test C
AMI treatment 
Discharge
No ACS, no UA
Death
Non-fatal AMI
(untreated)
As above 
As above 
As above 
Unstable angina
Non-fatal AMI 
(treated)
Single/serial
hs Troponin test B As above 
POPULATION ALTERNATIVES TREATMENT
(based on test result)
OUTCOME
(short term)
FIGURE 14 Decision tree structure.
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which was adjusted to 335.25 days (365.25–30) to ensure that the decision tree period (30 days) and the
first cycle combined summed to 1 year. The following health states were included:
l ‘No acute coronary syndrome and no unstable angina (no ACS, no UA)’
l ‘Unstable angina’
l ‘Post AMI (treated and untreated)’
l ‘Post AMI with re-infarction’
l ‘Death’.
Model parameters
Estimates for the model input parameters were retrieved from the literature and by consulting experts for
unpublished data. Accuracy estimates were derived from the systematic review component of this
assessment (see Results of the assessment of clinical effectiveness assessment, above).
Transition probabilities
An overview of transition probabilities is provided in Table 11.
Decision tree
The proportions of patients testing positive or negative (and thus commencing AMI treatment or being
discharged from the hospital) were based on the estimated accuracy of the testing strategies considered
(Table 12) and the estimated prevalence of NSTEMI in the UK [17.0% with standard error (SE) 2.8%; see
Table 11].39,40,46,64 This prevalence was higher than that derived from the RATPAC trial78 and used in the
Goodacre model,7 because the RATPAC study population was a low-risk population.79,87 The proportion of
TPs, FPs, FNs and TNs were calculated as follows:
l TP=NSTEMI prevalence × sensitivity
l FP= (1 –NSTEMI prevalence) × (1 – specificity)
l FN=NSTEMI prevalence × (1 – sensitivity)
l TN= (1 –NSTEMI prevalence) × specificity.
Subsequently, the proportions of patients who receive AMI treatment (TP+ FP), and who are discharged
without AMI treatment (TN+ FN) were calculated. These results are listed in Table 13.
No ACS, no UA Unstable angina
Post AMIa
Death
Post AMI with
re-infarction
FIGURE 15 Markov model structure. a, During the first year post AMI, a distinction is made between treated and
untreated AMI.
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TABLE 11 Transition probabilities
Parameter Estimate SE/95% CI Distribution Source
Decision tree (short term)
NSTEMI prevalencea 0.170 0.028 Beta Santalo (2013),40 Aldous (2012),46
Sebbane (2013),64 APACE39
Proportion of UA (of all non-NSTEMI
patients)
0.160 0.038 Beta CADTH (2013)82
Decision tree (30 day) probabilities
Mortality (30 day) treated AMI 0.097 0.012 Beta Pope (2000)90
Mortality (30 day) untreated AMI 0.105 0.069 Beta Pope (2000)90
Mortality (30 day) treated UA 0.021 0.005 Beta Pope (2000)90
Mortality (30 day) no ACS b – Fixed ONS91
Markov model (long term)
AMI incidence c – Fixed British Heart Foundation92
Annual re-infarction (treated)d 0.023 0.001 Beta Smolina (2012)93
RR re-infarction (untreated vs. treated)e 2.568 1.366 to 5.604 Log-normal Mills (2011)83
Annual mortality no ACS b – Fixed ONS91
Annual mortality post MId 0.066 0.000 Beta Smolina (2012)93
Annual mortality post re-infarctiond 0.142 0.002 Beta Smolina (2012)93
HR mortality (UA vs. NSTEMI) 0.781 0.581 to 1.053 Log-normal Allen (2006)94
RR mortality (untreated vs. treated)d 1.877 0.951 to 4.239 Log-normal Mills (2011)83
Secondary analysis (adjusted RR for patients tested FP)
OR AMIf 0.840 0.578–1.235 Log-normal Goodacre S, Lipinski M, personal
communication; Lipinski et al.95
OR deathf 0.649 0.465–0.901 Log-normal Goodacre S, Lipinski M, personal
communication; Lipinski et al.95
Proportion of AMIg 0.105 0.011 Beta Goodacre S, Lipinski M, personal
communication; Lipinski et al.95
Proportion of death
g
0.114 0.011 Beta Goodacre S, Lipinski M, personal
communication; Lipinski et al.95
RR AMIf,h 0.855 0.602–1.197 Log-normal Goodacre S, Lipinski M, personal
communication; Lipinski et al.95
RR deathf,h 0.676 0.500–0.911 Log-normal Goodacre S, Lipinski M, personal
communication; Lipinski et al.95
HR, hazard ratio; OR, odds ratio; SE, standard error.
a Prevalence was used to calculate the proportions of TPs/FPs and TNs/FNs based on test accuracy. Prevalence was
calculated using identified studies that included NSTEMI data (see Multiple samples, above).
b Based on age-dependent mortality from the general population.
c Age-dependent incidence from the general population.
d Weighted average based on sex (58.1% males7).
e Increased re-infarction and mortality risk for untreated (vs. treated) was assumed for the first year after presentation at
ED, after which no increased risk was assumed (RR= 1.0).
f For patients with both positive high-sensitivity and standard Tn tests vs. patients with positive high-sensitivity and
negative standard Tn tests.
g Proportion for patients with both positive high-sensitivity and standard Tn tests. This proportion is only used to covert
ORs to RRs.
h ORs were converted to RRs using the method described by Zhang and Yu.96
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TABLE 12 Test accuracy
Strategy
Sensitivity
(SE)a
Specificity
(SE)a Distribution Source
Serial standard Tn testing 1.00 (–) 1.00 (–) Fixed Assumption
Roche Elecsys hs-cTnT (99th centile at
presentation)
0.88 (0.04) 0.84 (0.04) Multivariate
normal
Chapter 3
Roche Elecsys hs-cTnT (optimal strategy)b 0.93 (0.02)c 0.82 (0.01)c Multivariate
normal
Chapter 3
Abbott ARCHITECT hs-cTnI (99th centile at
presentation)
0.80 (0.02) 0.93 (0.00) Multivariate
normal
Chapter 3
Abbott ARCHITECT hs-cTnI (optimal strategy)d 0.98 (0.01)c 0.94 (0.01)c Multivariate
normal
Chapter 3
Beckman Coulter hs-cTnI (99th centile) 0.92 (0.02) 0.75 (0.01) Multivariate
normal
Chapter 3
No Tn teste 0.00 (–) 1.00 (–) Fixed Assumption
a Correlation between sensitivity and specificity was calculated to be –0.262 based on the covariance matrix from the
metandi output for the Roche Elecsys hs-cTnT (99th centile at presentation) test (see also Chapter 3). This correlation was
assumed to be equal for other tests as it was not possible to obtain the covariance matrix for the other tests included in
the economic analyses (a minimum of four studies is required).
b Calculated based on accuracy data for the Roche Elecsys hs-cTnT optimal testing strategy.
c Standard error based on PSA.
d Calculated based on accuracy data for the Abbott ARCHITECT optimal testing strategy.
e The no-testing strategy is considered only in sensitivity analyses.
TABLE 13 Test outcomes
Strategy TP FP FN TN PPV NPV LR+ LR–
Serial standard Tn testing 0.17 0.00 0.00 0.83 1.00 1.00 1.00 0.00
Roche Elecsys hs-cTnT (99th centile at presentation) 0.15 0.13 0.02 0.70 0.53 0.97 5.41 0.15
Roche Elecsys hs-cTnT (optimal strategy) 0.16 0.15 0.01 0.68 0.51 0.98 5.05 0.09
Abbott ARCHITECT hs-cTnI (99th centile at presentation) 0.14 0.06 0.03 0.77 0.70 0.96 11.47 0.21
Abbott ARCHITECT hs-cTnI (optimal strategy) 0.17 0.05 0.00 0.78 0.76 1.00 15.67 0.02
Beckman Coulter hs-cTnI (99th centile) 0.16 0.21 0.01 0.62 0.43 0.98 3.67 0.11
No Tn testa 0.00 0.00 0.17 0.83 0.00 0.83 0.00 1.00
PPV, positive predictive value.
a The no-testing strategy is considered only in sensitivity analyses; the FN rate represents the prevalence of NSTEMI.
ASSESSMENT OF COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
50
After treatment, TP patients in the decision tree were allocated to ‘Non-fatal AMI (treated)’ and FP patients
were further subdivided between ‘No ACS, no UA’ and ‘Unstable angina’ (based on the proportion of UA
among non-NSTEMI patients; see Table 11). After being discharged, TN patients were also subdivided
between ‘No ACS, no UA’ and ‘Unstable angina’, whereas FN patients were allocated to ‘Non-fatal AMI
(untreated)’. The proportions of FNs, reported in Table 13, can be considered as the proportions of AMIs
that would have been missed when assuming that standard Tn testing has perfect accuracy. Finally, to
calculate the total number of deaths in the decision tree, the probability of 30-day mortality was assigned
based on abovementioned subdivision (see Table 11). It was assumed that UA is always correctly
diagnosed, hence the mortality probability for treated UA was used.
Markov model
The age-dependent AMI incidence in the UK92 was used to model the occurrence of AMI for patients in
the health states ‘No ACS’ and ‘Unstable angina’. It was assumed that all AMIs in the Markov trace are
diagnosed correctly and thus receive treatment. For patients in the ‘Post-MI’ health state, the probability of
re-infarction after treated AMI was retrieved from a UK record linkage study (n= 387,452), which assessed
long-term survival and recurrence after AMI.93 For the current assessment the probabilities for females
and males were weighted according to the estimated proportion of females and males in the population
(males= 58.1%7). The re-infarction probability for the ‘Post-MI with re-infarction’ health state is equal to
the re-infarction probability for the ‘Post-MI’ health state. The re-infarction RR for people with untreated
AMI compared with treated AMI was calculated from a recent study by Mills et al.83 based on patients with
a Tn concentration of 5–19 ng/l. This RR was assumed only for the first year after presentation at ED, after
which no increased risk was assumed (i.e. RR= 1.0 for untreated vs. treated AMI after year 1).
Age-dependent mortality from the general population was used for patients in the ‘No ACS, no UA’ health
state.91 For the ‘Post-MI’ and ‘Post-MI with re-infarction’ health states, mortality was extracted from the
record linkage study.93 Again, the study by Mills et al.83 was used to calculate the mortality RR for
untreated AMI compared with treated AMI for the first year, after which an RR of 1.0 was used. Finally, a
multivariate adjusted mortality hazard ratio (HR) for UA compared with NSTEMI was retrieved from a study
by Allen et al.94 to calculate mortality after UA.
All input parameters for the Markov model are reported in Table 11.
Health-state utilities
Age-dependent utility scores, from the UK general population, were calculated for patients in the ‘No ACS,
no UA’ health state based on a linear regression model.85 These age-dependent utility scores from the
general population were combined with age-dependent disutilities for AMI82 to calculate utilities for the
‘Post-MI’ health states (with or without re-infarction). Utility scores for the ‘Unstable angina’ health state
were calculated based on Post-MI utility scores and a utility increment of 0.010 (Table 14).85
Resource use and costs
Test-specific resource use consisted of the number of tests performed and the duration of hospital stay
(hours) before discharge/AMI treatment (Table 15).
Health-state costs (Table 16) were mainly retrieved from previous economic evaluations conducted in the
UK.85,97 Health-state costs for the ‘Unstable angina’, ‘Post-MI’ and ‘Post-MI with re-infarction’ consisted
of costs for three 15-minute general practitioner consultations and medication costs.85 For the first year in
the ‘Unstable angina’ health state, costs for clopidogrel (for 60%) and hospitalisation (for 50%) were
added to this. The first year costs for both ‘Post-MI’ health states were based on resource data from the
Nottingham Heart Attack Register.97
Additionally, costs of fatal events, retrieved from a UK economic evaluation,85 were accumulated for
all fatal AMIs. For this purpose, it was assumed that all 30-day deaths after ‘true’ NSTEMI were due
to a fatal AMI event. In addition, AMI treatment costs were calculated based on the national tariff for
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TABLE 15 Resource use (test specific)
Parameter Estimate SE/range Distribution Source
Number of tests
Serial standard Tn testing 2.00 – Fixed Assumption
Roche Elecsys hs-cTnT (99th centile at presentation) 1.00 – Fixed Assumption
Roche Elecsys hs-cTnT (optimal strategy) 1.60 0.02 Betaa Chapter 3
Abbott ARCHITECT hs-cTnI (99th centile at presentation) 1.00 – Fixed Assumption
Abbott ARCHITECT hs-cTnI (optimal strategy) 1.71 0.02 Betaa Chapter 3
Beckman Coulter hs-cTnI (99th centile) 1.00 – Fixed Assumption
No Tn testb 0.00 – Fixed Assumption
Hospital stay (hours) before discharge/AMI treatmentb
Serial standard Tn testing 14 13–15 Beta PERT Assumption
Roche Elecsys hs-cTnT (99th centile at presentation) 3 – Fixed Assumption
Roche Elecsys hs-cTnT optimal strategy (patients with AMI ruled
out on first test)
3 – Fixed Assumption
Roche Elecsys hs-cTnT optimal strategy (patients receiving both
tests)
5 4–6 – Assumption
Abbott ARCHITECT hs-cTnI (99th centile at presentation) 3 – Fixed Assumption
Abbott ARCHITECT hs-cTnI optimal strategy (patients with AMI
ruled out on first test)
3 – Fixed Assumption
Abbott ARCHITECT hs-cTnI optimal strategy (patients receiving
both tests)
6 – Fixed Assumption
Beckman Coulter hs-cTnI (99th centile at presentation) 3 – Fixed Assumption
No Tn testb 0 – Fixed Assumption
a Beta distribution is used to estimate the probability of patients receiving a second test (all patients receive the
presentation test).
b The no-testing strategy is considered only in sensitivity analyses.
c Includes delay from the time at which sampling could be performed to the time at which results became available
(2 hours) and delay between arrival at hospital and Tn assessment commencing (1 hour).
TABLE 14 Utility scores
Parameter Estimate SE Distribution Source
No ACS, no UA
Intercept 1.060 0.029 Normal Ward et al.85
Disutility for age 0.004 0.001 Normal Ward et al.85
Post-MI [disutility compared with no ACS by age (years)]
Age= 45 0.060 0.001 Normal CADTH82
Age= 55 0.051 0.001 Normal CADTH82
Age= 65 0.025 0.001 Normal CADTH82
Age= 75 0.007 0.001 Normal CADTH82
UA
Utility increment compared with AMI 0.010 0.042 Normal Ward et al.85
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non-elective AMI without complications [Healthcare Resource Group (HRG) code: EB10Z].98 To calculate
the hospital stay costs for patients, based on the number of hours before the test results become
available, non-elective NHS reference costs for the general medical ward were used (HRG code: EB01Z).98
For this purpose, it was assumed that doctors were available on demand, and the time to discharge was
delayed because of time between arrival at the ED and start of first sampling (1 hour) and the time
between sampling and the results being available (2 hours). In the case of multiple testing, the 1-hour
delay between arrival at the ED and start of sampling was applied to only the first test; however, this
also affected the timing of the second test if applicable. The 2-hour delay before test results become
available applies to all tests performed. Incorporating these time delays effectively implies that only tests
at presentation and tests performed 1 hour after presentation could inform decisions within the NHS
4-hour ED target. All other multiple testing strategies, as well as standard Tn testing at 10–12 hours,
would require a transfer from the ED to the general ward (patients are transferred to the general ward
4 hours after presentation at the ED). Finally, the test costs include panel (including reagent, machine and
maintenance), calibration and quality control costs. Depending on the annual number of panels, the test
costs varied between £16.18 and £21.33, for annual rates of testing of 1500 and 3000, respectively.80
Based on clinical expert input, the average test costs were estimated to be £20 (2011 price level).7,80
Overview of main model assumptions
The main assumptions in the health-economic analyses were:
l Serial Tn testing (comparator) has perfect accuracy (sensitivity= 1.0 and specificity= 1.0).
l For the Roche Elecsys hs-cTnT and Abbott ARCHITECT hs-cTnI optimal strategies it was assumed
that the sensitivity and specificity for the subpopulation not discharged after the presentation test is
equal to the sensitivity and specificity for the initial group (presenting at the ED).
l The life expectancy, quality of life and costs for FP patients is, in the base-case analysis, equal to the life
expectancy, quality of life and costs of TN patients. This assumption was amended in the secondary
and sensitivity analyses.
l In contrast with AMIs occurring during the decision tree period, all AMIs (either first or re-infarction)
occurring in the Markov trace are diagnosed correctly and thus treated.
TABLE 16 Health-state costs, event costs and unit prices
Parameter Estimate (£) SE/range (£) Distribution Source
Health-state costs
No ACS, no UA first year 0 – Fixed Assumption
No ACS, no UA subsequent year 0 – Fixed Assumption
UA first yeara 548 – Fixed Ward et al.85
UA subsequent yeara 213 – Fixed Ward et al.85
Post-MI first yeara,b 5835 488 Gamma Palmer et al.97
Post-MI subsequent yearsa,b 213 – Fixed Ward et al.85
Event costs
Costs of fatal AMIa 1451 – Fixed Ward et al.85
AMI treatment costs 3436 – Fixed Department of Health98
Unit prices
Hospital stay costs (per hour)c 27 – Fixed Department of Health98
Test costsa 20 18–26 Beta PERT Goodacre et al.,7 Thokal et al.80
a Price inflated to the 2012–13 price level based on price indices from The Hospital and Community Health Services index.99
b Post MI with or without re-infarction.
c NHS reference costs were divided by 24 to obtain the hourly costs.
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l UA is always correctly diagnosed and thus treated.
l The re-infarction probability for the ‘Post-MI with re-infarction’ health state is equal to the re-infarction
probability for the ‘Post-MI’ health state.
l The increased ‘Post-MI’ re-infarction and mortality probabilities for untreated AMI were assumed to last
1 year: afterwards a RR of 1.0 was applied (for untreated vs. treated AMI).
l There is no additional benefit of starting treatment early, so treatment effect for high-sensitive
strategies is equal to treatment effect for standard Tn strategy.
l All 30-day deaths (after presentation at the ED) are due to fatal AMI events and will receive the
associated costs.
Model analyses
Expected costs, LYs and QALYs were estimated for all Tn testing methods. Discount rates of 3.5% and a
half-cycle correction were applied for both costs and effects. Incremental cost and QALYs for each strategy
compared with standard Tn, and compared with the next best alternative, were calculated. The ICER was
then calculated by dividing the incremental costs by the incremental QALYs. PSAs (10,000 simulations)
were performed, and cost-effectiveness acceptability curves (CEACs) and cost-effectiveness acceptability
frontiers (CEAFs) were constructed. Although CEACs can be used to illustrate decision uncertainty,
the option with the highest probability of being cost-effective may not necessarily be the most
cost-effective option according to the expected values. Moreover, CEAFs can be used to illustrate the
decision uncertainty surrounding the most cost-effective option.100
Secondary analysis
For the base case, it was assumed that patients who tested negative on standard Tn and positive on
hs-cTn tests would experience life expectancy and quality of life equal to TN patients. This assumption is,
however, debatable, as unpublished data (Goodacre S, Lipinski M, personal communication) show that
patients with a negative standard Tn test and positive hs-cTn test have an increased risk of (re-)infarction
and mortality compared with those who test negative on both standard Tn and hs-cTn tests. Although this
risk was not as high as in patients with both positive standard Tn and positive hs-cTn tests, it could still
be considered prognostically important. Therefore, in this secondary analysis the risk of re-infarction and
mortality was adjusted for patients who tested FP (see Table 11). It was assumed that for this proportion of
patients, the relative treatment benefit would be equal to that for TP patients. As the prevalence of this
‘higher risk subgroup’ is likely to be the same for all comparators, it was assumed that this proportion was
equal to the lowest proportion of FP patients for all hs-cTn tests (see Table 13). This ‘higher risk subgroup’
was assumed to be treated for all hs-cTn tests (as they tested positive with these tests) and untreated for
the standard Tn test (as they tested negative with this test), thus affecting the probability of adverse
outcomes and treatment costs. In addition, the post-MI utility and health-state costs were used for this
‘higher-risk subgroup’.
Sensitivity analysis
For both the base case and the secondary analysis, the following one-way sensitivity analyses were
performed to assess the impact of model assumptions and input parameters on the estimated outcomes:
Model assumptions:
l The assumption that the increased post AMI re-infarction and mortality probabilities for untreated AMI
lasts for only 1 year was replaced by the assumption that these probabilities would remain elevated for
a lifetime.
l The assumption that a doctor will be available on demand and thus that a decision could be made
immediately (as in the base case) was replaced with an assumed delay (1, 2 or 3 hours) before a doctor
is available and a decision could be made.
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l As for the previous sensitivity analysis, except that the delay (1, 2 or 3 hours) applies only once patients
are transferred to the general ward 4 hours after presentation (no delay in the ED).
l A total delay of 1.5 hours is assumed (includes delay from the time at which sampling could be
performed to the time at which results became available and delay between arrival at hospital and Tn
assessment commencing) rather than assuming a total delay of 3 hours (base case).
l AMI treatment costs are applied for patients who tested FP rather than using no treatment costs, as
assumed in the base-case analysis.
l In addition to the health-state costs of UA during the first year, the AMI treatment costs are also
applied for patients with UA (during the first year), rather than assuming no additional treatment costs.
Model input parameters (varied to lower and upper boundary of the 95% CI unless stated otherwise):
l test costs [test costs was varied over a wider range (£5–40) than the 95% CI]
l AMI treatment costs (±25%)
l post-MI first-year health-state costs
l utility increment for UA compared with AMI
l post-MI disutility compared with no ACS
l mortality (30 day) treated AMI (decision tree)
l mortality (30 day) untreated AMI (decision tree)
l annual re-infarction (after initial AMI)
l RR re-infarction (untreated vs. treated AMI)
l annual post-MI mortality
l annual post-MI mortality after re-infarction
l HR mortality (UA vs. NSTEMI)
l RR mortality (untreated vs. treated AMI).
Subgroup analysis
For both the base case and the secondary analysis, a number of subgroup analyses were performed.
The main subgroup analyses were based on age- and sex-dependent re-infarction probabilities, mortality
probabilities (for all health states), AMI incidence and quality of life, and could be applied to all test
strategies. Accuracy was thus assumed to be subgroup independent (equal to the base case values). The
following subgroups were identified:
l Sex.
l Age (45, 55, 65, 75 and 85 years).
l People with a history of previous NSTEMI. For this purpose, a proportion of 0% UA was assumed and
the probabilities for the initial ‘Post-MI’ health state were used for the ‘No ACS, no UA’ health state
and the probabilities for ‘Post-MI with re-infarction’ were used for the ‘Post-MI’ and ‘Post-MI with
re-infarction’ health states. This subgroup analysis was performed for only the base case, as for the
secondary analysis this would lead to lower mortality probabilities for FP patients than TN patients
(which seems implausible).
l Subgroups with varying AMI prevalence (1%, 5%, 10%, 20%, 30%). In these analyses the no-testing
strategy was included as a comparator, as a Tn test may not be indicated when clinical judgement
assesses that the probability that a patient is experiencing an AMI is low. For the no-testing strategy it
is assumed that patients will be discharged immediately.
It should be noted that the main subgroup analyses (described above) differ from the subgroups described
in the systematic review component of this assessment (see Chapter 3, Presentation samples), for which
specific accuracy and prevalence data were available. Additional subgroup analyses were performed based
on these subgroup-specific accuracy data. However, these analyses could be performed for only the Roche
Elecsys hs-cTnT assay at presentation sample, using the 99th centile diagnostic threshold, compared with
DOI: 10.3310/hta19440 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 44
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
55
standard Tn testing; no subgroup-specific accuracy data were available for the other two hs-cTn assays.
The following subgroups were considered:
l age ≤ 70 years and age > 70 years
l patients with pre-existing CAD and patients without pre-existing CAD
l symptom onset at < 3 hours before presentation and symptom onset at ≥ 3 hours before presentation.
The subgroups with high pre-test probability and low-to-moderate pre-test probability were not
considered, as the prevalence data for these subgroups were unknown.
Results of cost-effectiveness analyses
This section describes the results using probabilistic analyses for the base-case analysis and the secondary
analysis. In addition, the sensitivity analyses (deterministic) and subgroup analyses are described (these
deterministic analyses are also presented in tabulated form in Appendices 5–9.
Base-case analysis
The base-case analysis includes six test strategies. Tables 17 and 18 show the probabilistic results of this
analysis. Standard Tn testing was both most effective (15.101 LYs, 11.730 QALYs) and most expensive
(£2697). The Abbott ARCHITECT hs-cTnI assay at presentation, using the 99th centile diagnostic threshold,
was least effective (15.076 LYs, 11.712 QALYs) and least expensive (£2253). Compared with standard Tn
testing, hs-cTn testing resulted in ICERs ranging between £90,725 and £24,019 savings per QALY lost.
Comparisons based on the next best alternative showed that for willingness-to-pay values of < £6600 per
QALY, the Abbott ARCHITECT hs-cTnI assay at presentation, using the 99th centile diagnostic threshold,
would be cost-effective. For thresholds between £6600 and £30,631 per QALY, the Beckman Coulter
hs-cTnI assay at presentation, using the 99th centile diagnostic threshold, was cost-effective; above
£30,631 per QALY the Abbott ARCHITECT hs-cTnI optimal strategy was cost-effective. Standard Tn
becomes cost-effective at a threshold of £90,725 or higher (see Table 18).
At willingness-to-pay thresholds of £20,000 and £30,000 per QALY, the Beckman Coulter hs-cTnI assay at
presentation, using the 99th centile diagnostic threshold, had probabilities of being cost-effective of 47%
and 35%, respectively. Although the Beckman Coulter hs-cTnI assay at presentation, using the 99th centile
diagnostic threshold, was cost-effective at a willingness-to-pay threshold of £30,000 per QALY, the Abbott
ARCHITECT hs-cTnI optimal strategy had the highest probability of being cost-effective (35%) at this
threshold (Figures 16 and 17).
TABLE 17 Probabilistic results for base-case analysis: LYs
Strategy LYs (95% CI) Compared with standard Tn
Abbott ARCHITECT hs-cTnI (99th centile at presentation) 15.076 (14.321 to 15.764) –0.024
Roche Elecsys hs-cTnT (99th centile at presentation) 15.085 (14.332 to 15.770) –0.016
Beckman Coulter hs-cTnI (99th centile at presentation) 15.090 (14.338 to 15.774) –0.010
Roche Elecsys hs-cTnT optimal strategy 15.091 (14.340 to 15.776) –0.009
Abbott ARCHITECT hs-cTnI optimal strategy 15.098 (14.351 to 15.780) –0.003
Standard Tn 15.101 (14.356 to 15.781)
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FIGURE 16 Cost-effectiveness acceptability curve and incremental cost-effectiveness plane (incremental costs and
QALYs compared with standard Tn) for base-case analysis.
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Secondary analysis
The secondary analysis includes the same six test strategies. This analysis assumed that in a proportion of
patients with a FP hs-cTn test (i.e. positive hs-cTn test and a negative standard Tn test), there is prognostic
significance [i.e. it is associated with an increased risk of adverse events (mortality and re-infarction)].
Standard Tn testing was least effective (14.785 LYs, 11.464 QALYs) and most expensive (£3058). The
Abbott ARCHITECT hs-cTnI assay at presentation, using the 99th centile diagnostic threshold, was the least
effective hs-cTn test strategy (14.833 LYs, 11.501 QALYs) and, overall, the least expensive strategy (£2781).
The Abbott ARCHITECT hs-cTnI optimal strategy was most effective (14.855 LYs, 11.518 QALYs). Standard
Tn testing was dominated by all hs-cTn testing strategies.
Comparisons based on the next best alternative showed that for willingness-to-pay values of < £13,623
per QALY, the Abbott ARCHITECT hs-cTnI assay at presentation, using the 99th centile diagnostic
threshold, was cost-effective. For thresholds between £13,623 and £14,562 per QALY, the Roche Elecsys
hs-cTnT assay at presentation, using the 99th centile diagnostic threshold, was cost-effective; above
£14,562 per QALY the Abbott ARCHITECT hs-cTnI optimal strategy was cost-effective (Tables 19 and 20).
At willingness-to-pay thresholds of £20,000 and £30,000 per QALY, the Abbott ARCHITECT hs-cTnI
optimal strategy had the highest probability of being cost-effective (53% and 67%, respectively;
Figures 18 and 19).
TABLE 19 Probabilistic results for secondary analysis: LYs
Strategy LYs (95% CI) Compared with standard Tn
Abbott ARCHITECT hs-cTnI (99th centile at presentation) 14.833 (14.104 to 15.487) 0.048
Roche Elecsys hs-cTnI (99th centile at presentation) 14.837 (14.111 to 15.491) 0.052
Beckman Coulter hs-cTnI (99th centile at presentation) 14.839 (14.114 to 15.488) 0.054
Roche Elecsys hs-cTnT (optimal strategy) 14.843 (14.119 to 15.494) 0.058
Abbott ARCHITECT hs-cTnI (optimal strategy) 14.855 (14.129 to 15.502) 0.070
Standard Tn 14.785 (14.061 to 15.436)
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FIGURE 17 Cost-effectiveness acceptability frontier for base-case analysis.
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FIGURE 18 Cost-effectiveness acceptability curve and incremental cost-effectiveness plane (incremental costs and
QALYs compared with standard Tn) for secondary analysis.
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Sensitivity analysis
The deterministic analysis for the base-case analysis is presented in Appendix 5. When it was assumed
that the post-MI re-infarction and mortality probabilities would remain elevated for untreated AMI for
a life-time period, the Abbott ARCHITECT hs-cTnI assay at presentation, using the 99th centile diagnostic
threshold, was cost-effective for thresholds of < £1642 per QALY, at which point the Beckman Coulter
hs-cTnI assay at presentation, using the 99th centile diagnostic threshold, became cost-effective up to a
threshold of £7602 per QALY. The Abbott ARCHITECT hs-cTnI optimal strategy was cost-effective for
thresholds between £7602 and £26,532 per QALY. Standard Tn testing was cost-effective for thresholds
of > £26,532 per QALY. Consistent with the base-case analysis, all ‘no doctor on demand’ sensitivity
analyses (1, 2 or 3 hours) showed that the Beckman Coulter hs-cTnI assay at presentation, using the
99th centile diagnostic threshold, was cost-effective for thresholds between approximately £8000 and
£40,000 per QALY. Similarly, where the total delay decreased to 1.5 hours (and assuming availability of a
doctor on demand), the Beckman Coulter hs-cTnI assay at presentation, using the 99th centile diagnostic
threshold, was cost-effective for thresholds between £7778 and £29,653 per QALY, at which point the
ARCHITECT hs-cTnI optimal strategy became cost-effective. Adding AMI treatment costs for the patients
with a FP test substantially impacted upon the results: standard Tn testing was cost-effective for all
threshold values of > £16,050 per QALY. Adding AMI treatment costs to the UA health state for the
first year had a negligible impact on the incremental outcomes.
The following input parameters had a noticeable impact on the estimated cost-effectiveness: 30-day
mortality for treated and untreated AMI (decision tree) and the mortality RR for treated AMI compared
with untreated AMI (Markov trace). Varying the remaining parameters did not have a substantial impact
on the results (i.e. the Beckman Coulter hs-cTnI assay at presentation, using the 99th centile diagnostic
threshold, was cost-effective for thresholds between approximately £10,000 and £35,000 per QALY).
The deterministic analysis for the secondary analysis is presented in Appendix 6. When assuming that the
post-AMI re-infarction and mortality probabilities would remain elevated for untreated AMI for a life-time
period, the Abbott ARCHITECT hs-cTnI assay at presentation, using the 99th centile diagnostic threshold,
was cost-effective for thresholds of < £1853 per QALY, at which point the Roche Elecsys hs-cTnT assay at
presentation, using the 99th centile diagnostic threshold, became cost-effective up to a threshold of £2017
per QALY. The Beckman Coulter hs-cTnI assay at presentation, using the 99th centile diagnostic threshold,
was cost-effective for thresholds between £2017 and £5889 per QALY. The Abbott ARCHITECT hs-cTnI
optimal strategy was cost-effective for thresholds of > £5889 per QALY. For all ‘no doctor-on-demand’
sensitivity analyses, the Abbott ARCHITECT hs-cTnI assay at presentation, using the 99th centile diagnostic
threshold, was cost-effective for thresholds of < £18,000 per QALY for 1, 2 and 3 hours’ delay. The Roche
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FIGURE 19 Cost-effectiveness acceptability frontier for secondary analysis.
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Elecsys hs-cTnT assay at presentation, using the 99th centile diagnostic threshold, was cost-effective for
thresholds between £18,000 and £19,000, £20,000 and £22,000 per QALY in case of 1, 2 and 3 hours’
delay, respectively. The Abbott ARCHITECT hs-cTnI optimal strategy was cost-effective for higher thresholds.
Similarly to the deterministic base case, for which the total delay decreased to 1.5 hours (assuming
availability of a doctor on demand), the Abbott ARCHITECT hs-cTnI assay at presentation, using the 99th
centile diagnostic threshold, was cost-effective for thresholds of below £14,956, at which point the
ARCHITECT hs-cTnI optimal strategy became cost-effective. Adding AMI treatment costs for all patients with
a FP test gave similar results to the deterministic analysis: the Abbott ARCHITECT hs-cTnI assay at
presentation, using the 99th centile diagnostic threshold, was cost-effective for all threshold values of
< £15,508 per QALY, at which point the Abbott hs-cTnI optimal strategy became the preferred option.
Adding AMI treatment costs to the ‘Unstable angina’ health state for the first year had a negligible impact
on the incremental outcomes.
The following input parameters had a noticeable impact on the estimated cost-effectiveness of the
secondary analysis: increased test cost (of £40 per test), 30-day mortality for treated and untreated AMI
(decision tree), and the re-infarction and mortality RR for treated AMI compared with untreated AMI
(Markov trace). Varying the remaining parameters did not have a substantial impact on the results.
Subgroup analysis
Additional analyses were performed for subgroups based on age, sex, people with a history of previous
NSTEMI, and AMI prevalence. These deterministic subgroup analyses (for the base case) analysis are
presented in Appendix 7. Consistent with the base-case analyses, analyses based on age and sex
subgroups indicated that, up to an age of 75 years, the Beckman Coulter hs-cTnI assay at presentation,
using the 99th centile diagnostic threshold, was cost-effective for thresholds between approximately
£10,000 and £35,000 per QALY. The Abbott ARCHITECT hs-cTnI optimal strategy was cost-effective for
higher thresholds up to £115,000–170,000, at which point standard Tn testing became cost-effective.
For females aged > 85 years, the Beckman Coulter hs-cTnI assay at presentation, using the 99th centile
diagnostic threshold, was cost-effective for thresholds between £15,793 and £74,597 per QALY; the
Abbott ARCHITECT hs-cTnI optimal strategy was cost-effective for thresholds between £74,597 and
£259,592 per QALY, and standard Tn testing was cost-effective for thresholds of £259,592 per QALY and
higher. For males aged > 85 years, the Abbott ARCHITECT hs-cTnI assay at presentation, using the 99th
centile diagnostic threshold, was cost-effective for thresholds of < £28,711 per QALY; the Beckman
Coulter hs-cTnI assay at presentation, using the 99th centile diagnostic threshold, was cost-effective for
thresholds between £28,711 and £143,225 per QALY and the Abbott ARCHITECT hs-cTnI optimal strategy
was cost-effective for thresholds between £143,225 and £503,476 per QALY, at which point standard Tn
testing became cost-effective. The results for the subgroup with a history of previous NSTEMI were almost
identical to the base-case analysis.
For subgroup analyses considering AMI prevalence, no testing was included as additional comparator. For an
AMI prevalence of 1%, the no-testing strategy was cost-effective up to thresholds of £27,409 per QALY,
at which point the Beckman Coulter hs-cTnI (99th centile) test became cost-effective up to a threshold of
£447,934 per QALY. For an AMI prevalence of 5–20%, the no-testing strategy was cost-effective up to
thresholds of £8759–11,703 per QALY, at which point the Beckman Coulter hs-cTnI (99th centile) test became
cost-effective up to thresholds of £32,042–97,709 per QALY. For an AMI prevalence of 30%, the
no-testing strategy was cost-effective up to a threshold of £8431 per QALY, at which point the Beckman
Coulter hs-cTnI (99th centile) test became cost-effective up to a threshold of £24,745 per QALY. The Abbott
ARCHITECT hs-cTnI optimal strategy was cost-effective for thresholds between £24,745 and £70,942 per QALY.
In addition, cost-effectiveness estimates for the subgroups, described in Chapter 3 (see Presentation
samples), based on subgroup-specific accuracy and prevalence, are reported in Appendix 9 (only comparing
the Roche Elecsys hs-cTnT assay at presentation, using the 99th centile diagnostic threshold, and standard
Tn testing). The results of these analyses indicated that differences in accuracy and AMI prevalence
between subgroups had a substantial impact on the cost-effectiveness of the Roche Elecsys hs-cTnT assay
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at presentation, using the 99th centile diagnostic threshold, compared with standard Tn testing
(ICER range: £22,111–355,571; deterministic base case: £41,233).
The deterministic subgroup analyses for the secondary analysis are presented in Appendix 8. For females
aged 45 years and males aged 45 or 55 years, the Abbott ARCHITECT hs-cTnI assay at presentation, using
the 99th centile diagnostic threshold, was cost-effective for thresholds of < £16,023–17,836 per QALY.
The Abbott ARCHITECT hs-cTnI optimal strategy became cost-effective for higher thresholds. For females
aged 55 or 65 years and males aged 65 or 75 years, the Abbott ARCHITECT hs-cTnI assay at presentation,
using the 99th centile diagnostic threshold, was cost-effective for thresholds of < £13,064–16,994 per QALY.
From this threshold up to £18,999–25,149 per QALY, the Roche Elecsys hs-cTnT assay at presentation,
using the 99th centile diagnostic threshold, was most cost-effective. The Abbott ARCHITECT hs-cTnI optimal
strategy was cost-effective for higher thresholds. For females aged 75 or 85 years, the Abbott ARCHITECT
hs-cTnI assay at presentation, using the 99th centile diagnostic threshold, was cost-effective up to thresholds
of £12,392£21,140 per QALY, at which point the Roche Elecsys hs-cTnT assay at presentation, using the
99th centile diagnostic threshold, became cost-effective up to thresholds of £16,407–26,911 per QALY.
The Abbott ARCHITECT hs-cTnI optimal strategy became cost-effective for thresholds of > £24,020–45,709
per QALY. For males aged 85 years, the Abbott ARCHITECT hs-cTnI assay at presentation, using the
99th centile diagnostic threshold, was cost-effective for thresholds of < £66,418 per QALY. The Abbott
ARCHITECT hs-cTnI optimal strategy became cost-effective for higher thresholds.
For subgroup analyses considering AMI prevalence, no testing was included as additional comparator. For an
AMI prevalence of 1%, the no-testing strategy was cost-effective up to a threshold of £4563 per QALY, at
which point the Abbott ARCHITECT hs-cTnI assay at presentation, using the 99th centile diagnostic threshold,
became cost-effective up to a threshold of £109,991 per QALY, where the Abbott ARCHITECT hs-cTnI
optimal strategy became cost-effective. Similarly, for AMI prevalences of 5% and 10% the thresholds
were £5209 and £35,574, and £5820 and £22,684, respectively. For a AMI prevalences of 20% and 30%,
the Abbott ARCHITECT hs-cTnI optimal strategy was cost-effective for thresholds of > £16,319 and
£15,410, respectively.
In contrast with the base-case analysis (described above), the subgroup-specific accuracy and prevalence
(only comparing the Roche Elecsys hs-cTnT assay at presentation, using the 99th centile diagnostic
threshold, and standard Tn testing) did not have an important impact on the cost-effectiveness
(see Appendix 9). The Roche Elecsys hs-cTnT assay at presentation, using the 99th centile diagnostic
threshold, was dominant for all subgroups.
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Chapter 5 Discussion
Statement of principal findings
Clinical effectiveness
All 18 studies19,39,40,42,44,46,48,49,51,54,55,57,58,63,64,67,70,73 (37 publications19,39,40–74) included in the systematic review
assessed the accuracy of one or more hs-cTn tests for the diagnosis of any AMI or for NSTEMI. There were no
controlled trials comparing clinical outcomes in people assessed using hs-cTn tests to those assessed using
conventional Tn assays. The majority (15/18) of the included studies reported data for the Roche Elecsys
hs-cTnT assay; four studies39,48,58,63 reported data for the Abbott ARCHITECT hs-cTnI assay and two studies39,73
reported data for precommercial versions of the Beckman Coulter Access hs-cTnI assay. Not all of the
included studies reported data on accuracy for the diagnosis of NSTEMI (i.e. for a population that excluded
people with STEMI), which was the target population for this assessment. However, where data were
available for both any AMI (population with symptoms suggestive of ACS) and NSTEMI (population which
excluded people with STEMI), estimates of test performance were generally similar (see Tables 4 and 6).
When diagnosis was based on a single sample taken at presentation, using the 99th centile for the general
population as the diagnostic threshold, positive LRs derived from summary estimates of sensitivity and
specificity indicated that neither the Roche Elecsys hs-cTnT assay nor the Beckman Coulter Access hs-cTnI
would be adequate to rule in a diagnosis of NSTEMI. The LR+ for the Roche Elecsys hs-cTnT assay was
5.41 (95% CI 3.40 to 8.63) and the LR+ for the Beckman Coulter Access hs-cTnI was 3.67 (95% CI 3.26
to 4.13). By contrast, the LR+ for the Abbott ARCHITECT hs-cTnI assay, in a population that did not
exclude STEMI, was 11.47 (95% CI 9.04 to 16.19), indicating that a positive test using this assay may
have some utility in confirming a diagnosis of AMI. The corresponding LR–s indicated that a negative test
result on a single sample taken at presentation, using the 99th centile for the general population as the
diagnostic threshold, would not be adequate to rule out NSTEMI using any of the three assays assessed.
LR– was 0.15 (95% CI 0.08 to 0.26) for the Roche Elecsys hs-cTnT, 0.11 (95% CI 0.07 to 0.17) for the
Beckman Coulter Access hs-cTnI, and 0.22 (95% CI 0.16 to 0.27) for the Abbott ARCHITECT hs-cTnI assay.
Although these LRs are fairly low, the consequences of missing an AMI are so great that a test needs to
be able to rule out an AMI with a very high degree of certainty. It should be noted that the Beckman
Coulter hs-cTnI assay evaluated in the APACE study39 was described as ‘an investigational prototype’; the
99th centile (9 ng/l), described as ‘according to the manufacturer’, differs from the 99th centile given in
the current product information leaflet (40 ng/l),16 and from values reported in a conference abstract,
(41 ng/l for the Access II analyser and 34 ng/l for the DxI analyser).17 When a hypothetical cohort of
1000 people is considered, assuming a prevalence of NSTEMI of 17% [derived from studies included in
our systematic review (see Chapter 3, Presentation samples)] the estimated number of people with AMI
and a negative test result who would be erroneously discharged based on this testing protocol is 20 for
the Roche Elecsys hs-cTnT assay, 14 for the Beckman Coulter Access hs-cTnI assay, and 34 for the Abbott
ARCHITECT hs-cTnI assay.
Some limited data were available on the diagnostic performance of the Roche Elecsys hs-cTnT assay in
clinical subgroups, using a single sample taken at presentation and the 99th centile diagnostic threshold.
These data indicated a lower LR– when the test is used in certain population groups [e.g. people aged
> 70 years LR– 0.05 (95% CI 0.02 to 0.18); people without pre-existing CAD LR– 0.07 (95% CI 0.04 to
0.16)] and with a high pre-test probability (determined by clinical judgement based on cardiovascular risk
factors, type of chest pain, physical findings and ECG abnormalities; LR– 0.09, 95% CI 0.02 to 0.45). Using
the hypothetical cohort of 1000 people described above, the estimated number of people with AMI and a
negative test result who would be erroneously discharged if the test were used to rule out AMI in these
selected populations is five for people aged > 70 years, 10 for people without pre-existing CAD, and 10 for
people with a clinical assessment of high pre-test probability. When the performance of the Roche Elecsys
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hs-cTnT assay was assessed in a population restricted to people who presented at > 3 hours after the
onset of symptoms, a similar fall in the LR– was observed (LR– 0.08, 95% CI 0.05 to 0.11); the estimated
number of people with AMI and a negative test result who would be erroneously discharged if the test
were used to rule out AMI in this populations is 10.
We constructed optimal testing strategies for the Roche Elecsys hs-cTnT assay (see Figure 9 and Chapter 3,
Diagnostic accuracy of the Roche Elecsys hs-cTnT assay, Multiple samples) and for the Abbott ARCHITECT
hs-cTnI assay (see Figure 11 and Chapter 3, Diagnostic accuracy of the Abbott ARCHITECT hs-cTnI assay,
Multiple samples). Both strategies use a two-step process, which provides two potential opportunities to
rule out AMI and hence to discharge patients within the 4-hour window specified in the scope for this
assessment. This potential is conditional upon the achievement of short (< 1 hour) turnaround times for
hs-cTn testing, as recommended by the joint National Academy of Clinical Biochemistry and IFCC
guidelines on Tn testing101 and in line with clinical opinion; a study of 1355 ED physicians in the USA
indicated that 75% believed that the results of Tn testing should be available to them within 45 minutes.102
The initial step for both the Abbott ARCHITECT hs-cTnI optimal strategy and Roche Elecsys hs-cTnT optimal
strategy was based on the use of an LoB (3 ng/l) diagnostic threshold in a sample taken at presentation
and was selected for optimal rule-out potential (low LR–), regardless of poor rule-in performance. For the
Roche Elecsys hs-cTnT optimal strategy, the second step involves an additional sample taken 2– 3 hours
after admission and was selected to provide the best possible combination of rule-out and rule-in
performance. Using the hypothetical cohort of 1000 people previously described, the initial step of the
proposed Roche Elecsys hs-cTnT optimal strategy would result in discharge of 407 people, nine of whom
would have been erroneously discharged with AMI. The second step of this strategy involves a combination
of testing on admission and after 2 hours, where a negative result is defined as both no sample above the
99th centile AND a change of < 20% over 2 hours and provides the optimum rule-out performance
(LR– 0.04, 95% CI 0.02 to 0.10); conversely, a positive result is defined as both a peak value above the
99th centile AND a change of > 20% over 2 hours and provides the optimum rule-in performance
(LR+ 8.42, 95% CI 6.11 to 11.60). Application of the rule-out component of the second step would result
in discharge of a further 286 people, five of whom would have been erroneously discharged. For the
proposed Abbott ARCHITECT hs-cTnI optimal strategy, the initial rule-out step would result in discharge of
291 people, all of whom would have been appropriately discharged. The second step of this strategy
involves repeat testing on a sample taken 3 hours after admission, using the 99th centile diagnostic
threshold. Application of the rule-out component of the second step would result in discharge of a further
486 people, three of whom would have been erroneously discharged. Available data on the Beckman
Coulter hs-TnI assay were insufficient to support construction of an optimal testing strategy.
Cost-effectiveness
The review of economic analyses of hs-cTn (i.e. either hs-cTnI or hs-cTnT) testing for the early rule-out of
AMI in people with acute chest pain found four HTA reports, two full papers and one abstract. Based
on all of these publications, it can be said that, in general, the question of whether hs-cTn testing is
cost-effective cannot yet be answered unequivocally. The majority of papers reported substantial ICERs,
with considerable uncertainty. In particular, the accuracy of high-sensitivity tests, as well as the efficiency of
decision-making based on test results, were found to be important drivers of cost-effectiveness.
In our health-economic analysis, the cost-effectiveness of different testing strategies – involving hs-cTn
for the early rule-out of AMI in people with acute chest pain presenting to the ED with suspected
ACS and STEMI ruled out – was assessed. All analyses had the same comparator: standard Tn testing at
10–12 hours, which is considered the reference standard and therefore was assumed to have perfect
sensitivity and specificity. In addition to the base-case analysis, given some evidence that FPs compared
with this reference standard also have a poor prognosis, a secondary analysis was conducted, which
assumed an increased adverse event risk for patients with FP hs-cTn tests. A number of subgroup and
sensitivity analyses were also performed.
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In the base-case analysis, standard Tn testing was both most effective and most costly. Strategies considered
cost-effective depending upon ICER thresholds were Abbott ARCHITECT hs-cTnI assay at presentation,
using the 99th centile diagnostic threshold (thresholds of < £6597), Beckman Coulter hs-cTnI assay at
presentation, using the 99th centile diagnostic threshold (thresholds between £6597 and £30,042), Abbott
ARCHITECT hs-cTnI optimal strategy (LoD threshold at presentation, followed by 99th centile threshold at
3 hours) (thresholds between £30,042 and £103,194), and the standard Tn test (thresholds of > £103,194).
The Roche Elecsys hs-cTnT assay at presentation, using the 99th centile diagnostic threshold, and the Roche
Elecsys hs-cTnT optimal strategy [LoB threshold at presentation followed by 99th centile threshold and/or
Δ20% (compared with presentation test) at 1–3 hours] were extendedly dominated in this analysis (one of
the more effective strategies was better value in that the ICER was lower).
In the secondary analysis, which assumed that a proportion of FPs in the hs-cTn testing strategies had an
increased risk of adverse events, standard Tn was least effective and most costly and, therefore, a dominated
strategy. The most effective strategy here was the Abbott ARCHITECT hs-cTnI optimal strategy. The Roche
Elecsys hs-cTnT optimal strategy was extendedly dominated (one of the more effective strategies was better
value in that the ICER was lower), as was the Beckman Coulter hs-cTnI assay at presentation, using the 99th
centile diagnostic threshold, in this analysis. Strategies considered cost-effective were Abbott ARCHITECT
hs-cTnI assay at presentation, using the 99th centile diagnostic threshold (thresholds of < £12,217), Roche
Elecsys hs-cTnT assay at presentation, using the 99th centile diagnostic threshold (thresholds between
£12,217 and £14,992), and Abbott ARCHITECT hs-cTnI optimal strategy (thresholds of > £14,992).
Sensitivity analyses showed that, in general, there were no major changes in the relative cost-effectiveness
of strategies. That is, dominancy and order of relative cost-effectiveness were comparable, although the
ICERs were different. Exceptions included assuming that the increased 30-day mortality for treated MI
compared with untreated MI applied to a lifetime (instead of only during the first year after presentation
at ED), which meant that standard Tn could be cost-effective from a threshold of ≥ £26,352. The same
assumption applied to the secondary analysis meant that the Beckman Coulter hs-cTnI assay at
presentation, using the 99th centile diagnostic threshold, was no longer extended dominated but was
considered cost-effective at thresholds of between £2017 and £5889. Another sensitivity analysis that
resulted in substantial changes was assigning AMI treatment costs to patients who tested FP. In the base
case, under this assumption, standard Tn became cost-effective at an ICER threshold of £20,000 (ICER
£16,050 compared with the Abbott ARCHITECT hs-cTnI optimal strategy). In the secondary analysis,
however, assigning treatment costs to FP patients did not have an impact on the position of standard Tn;
it was still dominated by another strategy (i.e. less effective and more costly).
Subgroup analyses (with non-subgroup specific accuracy data) for the base case showed that ICERs
compared with the next best strategy were slightly higher for males at all ages. Also, for both females and
males, ICERs increased with age. In addition, from ages ≥ 55 years (base case 53 years), the Roche Elecsys
hs-cTnT assay at presentation, using the 99th centile diagnostic threshold, became extendedly dominated.
In the subgroup with previous NSTEMI, again the Roche Elecsys hs-cTnT assay at presentation, using the
99th centile diagnostic threshold, was extendedly dominated, and ICERs are slightly higher than in
the whole group. Subgroup analysis based on MI prevalence (including a no-testing strategy) indicated
that only when MI prevalence is as low as 1% (base case 17%) was the no-testing strategy considered
cost-effective up to an ICER threshold of £27,409, after which the Beckman Coulter hs-cTnI assay at
presentation, using the 99th centile diagnostic threshold, strategy takes over. The higher the prevalence,
the lower the point at which the Beckman Coulter hs-cTnI assay at presentation, using the 99th centile
diagnostic threshold, strategy became cost-effective (i.e. £11,703 for prevalence 5%, £9740 for prevalence
10%, and £6597 for 17%).
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For the secondary analysis, again, the ICERS for males were slightly higher than for females. For the
various age categories, results were rather diffuse, but, as in the base case, ICERs appeared to increase
with age. There did not appear to be a substantial difference between the MI prevalence subgroups
[i.e. the no-testing strategy was cost-effective only up to rather modest ICER thresholds (£4563–7109) for
all values of prevalence].
The subgroup analyses using subgroup-specific accuracy and prevalence could be performed for only the
Roche Elecsys hs-cTnT assay at presentation, using the 99th centile diagnostic threshold, as there were no
subgroup data on Beckman Coulter hs-cTnI and Abbott ARCHITECT hs-cTnI assays. The comparator was
the standard Tn at 10–12 hours, which was assumed to have perfect sensitivity and specificity. For the
base case, the Roche Elecsys hs-cTnT assay at presentation, using the 99th centile diagnostic threshold,
was always less costly and less effective, but ICERs were more favourable for the following subgroups
compared with their counterparts: age ≤ 70 years, with pre-existing CAD, and symptom onset at
< 3 hours. For the secondary analysis, the standard Tn was dominated by the Roche Elecsys hs-cTnT assay
at presentation, using the 99th centile diagnostic threshold, overall, as this test was both less costly and
more effective. However, the subgroups that rendered the highest savings per QALY gained were
consistent with the base-case analysis (i.e. age ≤ 70 years, with pre-existing CAD, and symptom onset at
< 3 hours). Although data are lacking, it seems likely that these differences between subgroups can be
extrapolated, at least partly, to the other tests considered in the base-case analysis.
Strengths and limitations of assessment
Clinical effectiveness
Extensive literature searches were conducted in an attempt to maximise retrieval of relevant studies. These
included electronic searches of a variety of bibliographic databases, as well as screening of clinical trials
registers and conference abstracts to identify unpublished studies. Because of the known difficulties in
identifying test accuracy studies using study design-related search terms,103 search strategies were
developed to maximise sensitivity at the expense of reduced specificity. Thus, large numbers of citations
were identified and screened, relatively few of which met the inclusion criteria of the review.
The possibility of publication bias remains a potential problem for all systematic reviews. Considerations
may differ for systematic reviews of test accuracy studies. It is relatively simple to define a positive result for
studies of treatment, for example a significant difference between the treatment and control groups that
favours treatment. This is not the case for test accuracy studies, which measure agreement between index
test and reference standard. It would seem likely that studies finding greater agreement (high estimates of
sensitivity and specificity) will be published more often. In addition, test accuracy data are often collected
as part of routine clinical practice, or by retrospective review of records; test accuracy studies are not
subject to the formal registration procedures applied to RCTs and are therefore more easily discarded
when results appear unfavourable. The extent to which publication bias occurs in studies of test accuracy
remains unclear; however, simulation studies have indicated that the effect of publication bias on
meta-analytic estimates of test accuracy is minimal.104 Formal assessment of publication bias in systematic
reviews of test accuracy studies remains problematic and reliability is limited.27 We did not undertake a
statistical assessment of publication bias in this review. However, our search strategy included a variety of
routes to identify unpublished studies and resulted in the inclusion of a number of conference abstracts.
Clear inclusion criteria were specified in the protocol for this review, a copy of which is available on the
PROSPERO website (registration number CRD42013005939). The eligibility of studies for inclusion is
therefore transparent. In addition, we have provided specific reasons for exclusion for all of the studies
which were considered potentially relevant at initial citation screening and were subsequently excluded on
assessment of the full publication (see Appendix 4). The review process followed recommended methods
to minimise the potential for error and/or bias;25 studies were independently screened for inclusion by
two reviewers, and data extraction and quality assessment were done by one reviewer and checked by a
second (MW and PW). Any disagreements were resolved by consensus.
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Studies included in this review were assessed for risk of bias and applicability using the QUADAS-2 tool
developed by the authors33 and recommended by the Cochrane Collaboration.27 QUADAS-2 is structured
into four key domains covering participant selection, index test, reference standard, and the flow of
patients through the study (including timing of tests). Each domain is rated for risk of bias (low, high or
unclear); the participant selection, index test and reference standard domain are, also, separately rated for
concerns regarding the applicability of the study to the review question (low, high or unclear). The results
of the QUADAS-2 assessment are reported, in full, for all included studies in Appendix 3 and are
summarised in Chapter 3 (see Study quality). The main potential sources of bias in the studies included in
this assessment were related to patient spectrum and patient flow (QUADAS domains 1 and 4). Reporting
of the participant selection process was frequently unclear; a further study55 was rated as unclear for this
domain as a large number of patients were not enrolled as a result of ‘technical reasons’ that were not
fully defined and so it was not possible to judge whether or not these comprised inappropriate exclusions.
The most common feature of studies rated as ‘high risk of bias’ for patient selection was the inclusion of
participants based on staffing or work flow considerations; for example, participants were excluded if they
presented at night or during busy periods.42,46,51 All ratings of ‘high risk of bias’ for patient flow were due
to high proportions of withdrawals. There were also concerns regarding the applicability of the patient
population and the reference standard in some of the included studies. The main area of concern, with
respect to population, was for studies that enrolled mixed populations (i.e. when the target condition was
any AMI); because the primary focus of this assessment was the diagnosis of NSTEMI in populations where
patients with STEMI were excluded (i.e. target condition NSTEMI), the primary focus was the population
of patients with STEMI excluded, mixed population studies that were not restricted to this specific
patient group were considered to have high concerns regarding applicability. However, as noted above
(see Clinical effectiveness), where data were available for both any AMI (mixed population) and NSTEMI
(population which excluded people with STEMI), estimates of test performance were generally similar.
In accordance with current NICE guidance,11 our review question specified that an appropriate reference
standard had to include a standard Tn measurement at baseline and at 10–12 hours after the onset of
symptoms in 80% of the population. Although studies generally included a baseline and a second, later,
standard Tn measurement, only five19,39,42,51,63 met the specific timing criterion for the second standard Tn
measurement; studies that did not meet this criterion were classified as having high concerns
regarding applicability.
We identified one recently published systematic review which included an assessment of the accuracy of
hs-cTn assays for the diagnosis of AMI and prediction of MACE.7 This review, by Goodacre et al.,7 also
evaluated standard cTn assays (alone and in combination with other cardiac biomarkers) and the
diagnostic accuracy of other cardiac biomarkers, as well as including prediction modelling studies, all
of which were outside the scope of this assessment. Our systematic review represents an advance on
Goodacre et al.,7 as it provides a more up-to-date and comprehensive assessment of the performance of
hs-cTn assays. Although the Goodacre review7 was published in 2013, search dates were reported as 1995
to November 2010; hence it included only two studies,57,72 which met the definition of a hs-cTn assay used
in our assessment. Both of these studies57,72 assessed the diagnostic performance of the Roche Elecsys
hs-cTnT assay when applied to a single sample taken at presentation, using the 99th centile diagnostic
threshold, and neither excluded participants with STEMI. Both studies57,72 were also included in our
systematic review and one study57 contributed data to our summary estimates (based on a total of
15 studies) of the performance of the Roche Elecsys hs-cTnT assay for the diagnosis of any AMI at this
threshold studies; the other72 was an early publication of the APACE study, the most recent publication
that contributed data to our main analysis (accuracy for the diagnosis of NSTEMI), which included a total
of six studies.39 The summary estimate of sensitivity derived from our systematic review was lower (88% for
both any AMI or NSTEMI analyses) than that reported by the Goodacre review (96% for any AMI),7 and
our summary estimate of specificity was higher (82% for any AMI and 84% for NSTEMI) than that
reported by the Goodacre review7 (72% for any AMI). A more recent systematic review, published as
a conference abstract, reported summary estimates of the sensitivity and specificity of hs-cTn on an
admission sample of 88% and 82%, respectively, based on data from 17 studies.105 This review pooled
data from different hs-cTn assays in one analysis and also included data from some studies that assessed
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assays that do not meet the definition of a hs-cTn assay used in our assessment. Despite these limitations,
the summary estimates of sensitivity and specificity matched the summary estimates from our review
for the performance of the Roche Elecsys hs-cTnT assay for the diagnosis of any AMI; this is unsurprising,
as 13 of the 17 studies included in the analysis assed the Roche Elecsys hs-cTnT assay, using the 99th
centile diagnostic threshold.105 Our assessment represents an advance on both of these systematic reviews
in that we provide up-to-date estimates of the diagnostic performance of assays meeting a strict definition
for hs-cTn, which are stratified by hs-cTn assay type, diagnostic threshold and timing of the Tn test.
We believe that our assessment provides information of direct relevance to UK clinical practice as we focus
on the performance of hs-cTn within the 4-hour time window corresponding to the target for NHS EDs,
which specifies that ‘no one should be waiting more than four hours in the ED from arrival to admission,
transfer or discharge’.89 Furthermore, we have used the data from our systematic review to propose
strategies for how hs-cTn assays might be applied and interpreted in order to maximise diagnostic
performance. These strategies were devised with consideration to test timing, diagnostic threshold and
interpretation of combinations of multiple test results. One limitation of this approach is that our estimates
of the effectiveness and cost-effectiveness of the proposed two-step strategies require the assumption that
the diagnostic performance of the second step is the same when used in people in whom NSTEMI is not
ruled out by the first step as it is when used in the whole population (see Chapter 3, Diagnostic accuracy
of the Roche Elecsys hs-cTnT assay, Multiple samples, and Diagnostic accuracy of the Abbott ARCHITECT
hs-cTnI assay, Multiple samples). This assumption was necessary because no combined test performance
data were available for the proposed strategies. However, it can be argued that the assumption is
reasonable as the first step in both strategies focuses on rule-out performance and thus has a low LR+.
This means that there is a relatively small change in the prevalence of AMI between the first and second
steps (17–27% for the Roche Elecsys hs-cTnT optimal strategy and 17–24% for the Abbott ARCHITECT
hs-cTnI optimal strategy).
Our assessment was less comprehensive for the Abbott ARCHITECT hs-cTnI assay and the Beckman
Coulter hs-cTnI assay than for the Roche Elecsys hs-cTnT, because available data were limited for these
two assays.
Cost-effectiveness
Our cost-effectiveness analysis is the most comprehensive to date in terms of the number of relevant
hs-cTn test strategies for the early rule-out of AMI in people presenting to the ED with acute chest pain
and suspected ACS. Moreover, the de novo probabilistic model was based on one previously developed
for a published and peer reviewed HTA.80 This model was also used in a later assessments on the
cost-effectiveness of biomarkers in patients with suspected ACS.19 For the present analysis, a number of
adjustments were made to the model, but most of the assumptions were maintained.
The model was also informed by a comprehensive, high-quality, systematic review of DTA. Additional
parameters were either those from the original HTA model, or any of the further assessments, or, where
necessary, were based on a pragmatic literature review. Such a review is standard practice in economic
modelling given the large number of parameters required and we expect that the review has delivered the
most relevant information given that it focused on identifying the most recent large UK-based studies.
As in any economic model, a number of major and minor assumptions had to be made. It is important to
understand the impact of these assumptions in order to interpret correctly the results of the model. The
impact of most assumptions has been explored in sensitivity and secondary analyses. However, one major
assumption that was maintained throughout all analyses was the conservative assumption of no health
benefit of early treatment in the hs-cTn strategies compared with ‘late’ treatment in the standard cTn
strategy. Although many experts believe that there must be a benefit, at least to some extent, of treating
patients early, there is no evidence to support or quantify a timing effect, as yet. In addition, there may
well also be adverse effects associated with early treatment also (e.g. the risk of bleeding, unnecessary
percutaneous coronary interventions, etc.). The Canadian HTA report82 identified in the economic review
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(see Chapter 4, Canadian Agency for Drugs and Technologies in Health optimal use report) did include an
advantage for early treatment compared with late treatment, based on one study,106 which investigated
the effect of a 36-hour treatment delay. The RR found in this study106 was then recalculated, assuming a
constant effect of timing on treatment benefit, to a RR of 1.035 of mortality for a treatment delay of
6 hours compared with early treatment, was again adjusted to 1.01 based on expert opinion. Any possible
adverse effect of early treatment was not considered in this analysis. A similar approach would have
been possible in the present model, but, in our view, this would not be informative, given the level of
uncertainty underlying this final estimate. Therefore, it was decided to leave out a possible effect of timing
of treatment. This could be considered a conservative approach but even this is uncertain.
The assumption that standard Tn, as the reference standard, has perfect sensitivity and specificity was also
maintained throughout all analyses. Although a simplification, given that the actual reference standard is
standard Tn plus clinical information, this approach is consistent with previous modelling and incorporation
of the effect of clinical information to the hs-cTn test would be very difficult, given the current lack of
data. To some extent, clinical judgement might already be incorporated into the modelling because, for
the effect of treatment (RR for re-infarction and mortality), the study performed by Mills et al.83 was used.
In this study,83 not all patients with negative tests results were left untreated; we might therefore speculate
that, where patients who tested negative were treated, this was because of clinical judgement. However,
we cannot be certain that the observations from this trial reflect the true contribution of clinical
judgement. On the other hand, there is recent evidence that the prognostic performance of standard Tn
testing may be imperfect. For example, a negative Tn test might assess correctly that a patient is not
experiencing a NSTEMI, but some patients with negative test results may still benefit from treatment. To
take this possibility into account, a secondary analysis was performed, which resulted in the standard Tn
strategy being dominated by the hs-cTn testing strategies. In other words, it seems reasonable to conclude
that not only might hs-cTn be cost-effective, it might also be more effective than standard Tn.
Another assumption, which was varied in sensitivity analysis, with a rather substantial impact on results,
was how to attribute costs of treatment to patients testing FP in the hs-cTn treatment strategies. In the
base-case analysis, FP patients were assigned survival, quality of life, and costs of TN patients (i.e. they
were basically assumed not to be treated). However, if hs-cTn assays were incorporated in clinical practice,
patients with a positive result would be treated, at least up to the point where it is discovered they were
FP. Therefore, in a sensitivity analysis, FP patients were assigned treatment costs as if they were TP,
but mortality and quality of life as if they were TN. For the base case, this would change results quite
dramatically, as the hs-cTn strategies would become more expensive but not more effective, whereas for
the standard Tn nothing would change. For the secondary analysis (some hs-cTn FPs need and get
treatment) things are different, as in this case treatment costs would be incurred for a proportion of
patients (5%) but these patients would also receive the benefits of treatment. This approach had a very
limited effect on results, in terms of strategies that were cost-effective. In our opinion, the secondary
analysis, which assigns treatment costs to all FPs, but also assumes that some of these patients benefit
treatment, is the most plausible scenario.
Uncertainties
Clinical effectiveness
The performance of any test that uses the 99th centile for the general population as the diagnostic
threshold will be dependent upon the characteristics of the reference population from which this value
was derived. Although the product information leaflet for the Abbott ARCHITECT hs-cTnI assay
recommends that ‘each laboratory should verify that the 99th centile is transferable to its population or
establish its own 99th centile’,15 test accuracy data included in the assessment are predominantly based on
the 99th centiles for the three assays (Roche Elecsys hs-cTnT, Abbott ARCHITECT hs-cTnI, Beckman Coulter
hs-cTnI) as reported by their respective manufacturers.15,16,18 The 99th centile for the Roche Elecsys hs-cTnT
was reported as being derived from a study population of 616 apparently healthy volunteers and blood
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donors, with an age range of 20–71 years and equal proportions of males and females;107 no further
details were reported. The 99th centile for the Abbott ARCHITECT hs-cTnI assay was described as being
derived from a study of ‘1,531 apparently healthy individuals in a US population with normal levels of BNP,
HbA1c, and estimated GFR values’.15 Although a 2012 ‘in press’ reference for this study was given in the
APACE study,39 we were not able to identify any corresponding publication. It should also be noted that
the Beckman Coulter hs-cTnI assay evaluated in the APACE study39 was described as ‘an investigational
prototype’; the 99th centile (9 ng/l), described as ‘according to the manufacturer’, differs from the 99th
centile given in the current product information leaflet (40 ng/l).16 The product information leaflet describes
this value as being derived from general practice samples obtained from London, UK, and the surrounding
area; samples were from 1000 people aged > 40 years, with approximately equal numbers of males and
females, and samples from people with abnormal urea and electrolytes, liver function tests, glucose or
NT-proBNP (N-terminal pro-β-natiuretic peptide), were excluded.16 Expected values, and hence diagnostic
thresholds, derived from groups of healthy volunteers may have limited applicability to the population in
whom hs-cTn testing would be applied in practice, for example with respect to age range. Data provided in
the product information leaflets for the Roche Elecsys hs-cTnT assay and the Abbott ARCHITECT hs-cTnI
assay both indicated that 99th centile values differed between males and females; the Abbott ARCHITECT
hs-cTnI assay reported values of 15.6 ng/l and 34.2 ng/l for females and males, respectively,15 and the Roche
Elecsys hs-cTnT assay reported values of 10.0 ng/l and 14.2 ng/l for females and males, respectively.18
Despite this, we were unable to identify any data on whether the diagnostic performance of tests varies
according to sex, when a single common diagnostic threshold is used for both males and females; the
effectiveness of using sex-specific diagnostic thresholds therefore remains uncertain. Similarly, we were
unable to identify any data on the diagnostic performance of hs-cTn assays when used in people with
impaired renal function.
Differences in the populations used to derive the 99th centile diagnostic threshold, and hence in the Tn
level at which this threshold set, may also affect the ability of an assay to achieve the first point of the
accepted definition of a hs-cTn assay (i.e. a CV of ≤ 10% at the 99th centile for the general population).
A standardised definition of the required reference population would be useful in ensuring a ‘level playing
field’ for classification of assays as ‘high sensitive’ and would aid comparisons between tests.
We identified some data on the diagnostic performance of hs-cTn testing in clinically important subgroups
(older people,39,53 and people with and without pre-existing CAD).39,47 However, these data were very
limited and were available only for the Roche Elecsys hs-cTnT assay. Therefore, there remains some
uncertainty about how the diagnostic performance of individual hs-cTn assays may vary in clinically
relevant subgroups, as well as what may constitute the optimal testing strategy in these groups.
A significant limitation of this assessment follows from the design of the primary studies included in the
systematic review. The objective of these studies was to evaluate the diagnostic performance of hs-cTn
assays when compared with a reference standard based on the universal definition of AMI endorsed
by the ESC, the ACC, the AHA and the World Heart Federation (WHF).8,21,22 The scope for this assessment
did not include studies that evaluated the use of hs-cTn testing in combination with other tests, thus,
studies that assessed the combined accuracy of a clinical risk score and a hs-cTn test used together would
have been excluded; however, we did not identify any studies that were excluded on this basis. Studies
assessing the diagnostic performance of a hs-cTn test alone, in which participants were subgrouped by
clinical risk, met our inclusion criteria and were included in the systematic review. We identified only one
study of this type,49 which, as described above (see Clinical effectiveness), indicated that the rule-out
performance of hs-cTnT testing may be improved if the test is used in a population with high clinically
determined pre-test probability. There remains uncertainty around how hs-cTn testing would perform if
used, as it would be in clinical practice, in combination with a clinical assessment of pre-test probability
(with or without formal risk scoring). Full assessment of the independent predictive value of hs-cTn testing
requires multivariable prediction modelling.
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A final area of uncertainty exists with respect to the clinical significance of a ‘FP’ hs-cTn result [i.e. does a
positive hs-cTn result imply a clinically important change in cardiac risk, when a diagnosis of AMI is not
confirmed (based on standard Tns and the universal definition)]? Re-adjudication of the final diagnosis,
using later hs-cTn measurements in place of the conventional Tn results, can provide some insight into this
issue. The most recent publication from the APACE study39 reported that when hs-cTnT results (including a
6-hour time point) were included in the reference standard diagnosis, this resulted in 131 participants being
classified as having had a small AMI, which would have been classified as ‘no AMI’ where adjudication
was based on standard Tn results.
Cost-effectiveness
The main uncertainties for the cost-effectiveness analysis lie in the model assumptions, particularly
regarding the effect of actual clinical practice in terms of both other diagnostic information and treatment
given this information. Although many of these assumptions have been varied in one-way sensitivity
analysis, the precise implication of FN test results, where patients are discharged without essential
treatment, or of FP test results, where patients stay in hospital and may receive unnecessary interventions,
is unknown.
It should also be emphasised that the uncertainty resulting from the abovementioned assumptions was not
parameterised in the model and is therefore not reflected in the PSAs or in the CEACs.
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Chapter 6 Conclusions
Implications for service provision
We propose the use of two-step testing strategies to optimise the diagnostic performance of hs-cTn
testing. There is evidence to suggest that undetectable levels of Tn (below the LoB/LoD of the assay) on
presentation, measured using the Roche Elecsys hs-cTnT assay or the Abbott ARCHITECT hs-cTnI assay,
may be sufficient to rule out NSTEMI in people presenting with symptoms that are suggestive of ACS.
There is also evidence to suggest that a further rule-out step may be possible, within the 4-hour NHS ED
target. For the Abbott ARCHITECT hs-cTnI assay, this second rule-out step would be based on a Tn level
below the 99th centile in a sample taken 3 hours after presentation. For the Roche Elecsys hs-cTnT assay,
the second rule-out step would be based on a Tn level below the 99th centile in all samples and a change
in Tn level of < 20% between presentation and 2 hours. There is insufficient evidence to determine an
optimal testing strategy for the Beckman Coulter hs-cTnI assay. There is some limited evidence to suggest
that a Tn level below the 99th centile on presentation, measured using the Roche Elecsys hs-cTnT assay,
may be sufficient to rule out NSTEMI in some groups (people aged > 70 years, people without pre-existing
CAD and people with a clinically determined high pre-test probability).
When considering the base-case analysis it appears that the Beckman Coulter hs-cTnI assay at presentation,
using the 99th centile diagnostic threshold, would be the cost-effective strategy, given an ICER threshold of
£20,000–30,000. However, both cost and QALY differences between the strategies were small. This means
that within the hs-cTn testing strategies, ICERs can change substantially especially with small changes in
either costs or QALYs. Therefore, it is difficult to be confident that other hs-cTn strategies might not be
cost-effective.
Overall, the model does not provide strong evidence to prefer one hs-cTn testing strategy over another.
Results do, however, indicate that hs-cTn testing in general may be cost-effective compared with standard
Tn testing. This becomes more likely if one assumes that hs-cTn testing detects some patients who require
treatment despite their testing negative with standard Tn, as shown in the secondary analysis. In particular,
the Abbott ARCHITECT hs-cTnI optimal strategy, which involves multiple testing and varying diagnostic
thresholds, may be promising. The main issue, with regard to service provision, if implementation of a
hs-cTn testing strategy is considered, is the balance between the likely reduction in cost and the risk of
a reduction in effectiveness, albeit possibly small.
Suggested research priorities
Diagnostic cohort studies are needed to evaluate fully the performance of our proposed optimal testing
strategies in a clinical setting.
If adoption of the Beckman Coulter hs-cTnI is to be considered, further studies are needed to evaluate fully
the diagnostic accuracy of this test at the thresholds currently recommended by the manufacturer and to
inform the development of an optimal testing strategy.
Further diagnostic cohort studies, or subgroup analyses of existing data sets, are needed to explore fully
possible variation in the accuracy of hs-cTn assays and the optimal testing strategies for these assays in
relevant demographic and clinical subgroups: sex; age; ethnicity; renal function; previous CAD; and
previous AMI.
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It is important to explore further the effects of clinical judgement (assessment of pre-test probability) on
the diagnostic performance of hs-cTn testing. This could be achieved by assessing the combined diagnostic
accuracy of risk scoring tools, such as TIMI or GRACE, and hs-cTn tests, or by assessing the accuracy of
hs-cTn testing in subgroups stratified by pre-test probability.
Multivariable prediction modelling studies may be useful to assess the independent prognostic value of a
positive hs-cTn test result, in the context of other clinical risk factors and tests.
As most of the uncertainties in the economic model were caused by assumptions relating to clinical
effectiveness, this type of research would also facilitate economic analyses of hs-cTn testing.
CONCLUSIONS
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Appendix 1 Literature search strategies
Clinical effectiveness search strategies
MEDLINE (OvidSP): 1946 to 2013/10/Week 1
Searched: 11 October 2013
1. (Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs).ti,ab,ot. (229)
2. (Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or accutni or
accu-tni).ti,ab,ot. (99)
3. ((troponin t or tnt or ctnt or tropt or trop t) adj2 (sensitiv$ or hs or early or initial or rapid or present$
or ultra or high performance or ultrasensitive)).ti,ab,ot. (563)
4. ((troponin I or tni or ctni or tropI or trop I) adj2 (sensitiv$ or hs or early or initial or rapid or present$ or
ultra or high performance or ultrasensitive)).ti,ab,ot. (349)
5. (troponin$ adj2 (sensitiv$ or hs or early or initial or rapid or present$ or ultra or high performance or
ultrasensitive)).ti,ab,ot. (769)
6. (troponin$ adj5 (architect or elecsys or accutni or accu-tni or access or unicel)).ti,ab,hw,ot. (66)
7. or/1-6 (1215)
8. troponin t/ or troponin I/ or (60304-72-5 or 77108-40-8).rn. (8642)
9. (sensitiv$ or hs or early or initial or rapid or present$ or ultra or high performance or ultrasensitive).
ti,ab,ot. (4,878,300)
10. 8 and 9 (4209)
11. 7 or 10 (4559)
12. chest pain/ (9293)
13. ((chest or thorax or thoracic) adj2 (pain$ or discomfort or tight$ or pressure)).ti,ab,ot,hw. (28,602)
14. exp myocardial ischemia/ (357,748)
15. (acute adj2 coronary adj2 syndrome$).ti,ab,ot. (16,495)
16. (preinfarc$ Angina$ or pre infarc$ Angina$).ti,ab,ot. (285)
17. Unstable angina$.ti,ab,ot. (10,718)
18. ((heart$ or myocardi$ or cardiac or coronary) adj2 (preinfarc$ or infarc$ or attack$ or arrest$ or
occlusion$ or isch?emia$)).ti,ab,ot. (194,088)
19. (MI or ACS or STEMI or NSTE-ACS or NSTEACS or nonSTEMI or NSTEMI or AMI or UAP or OMI).ti,ab,
ot. (53,168)
20. or/12-19 (444,673)
21. 11 and 20 (2503)
22. animals/ not (animals/ and humans/) (3,957,888)
23. 21 not 22 (2336)
MEDLINE In-Process & Other Non-Indexed Citations (OvidSP): up to 2013/10/01;
MEDLINE Daily Update (OvidSP): up to 2013/10/01
Searched: 11 October 2013
1. (Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs).ti,ab,ot. (32)
2. (Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or accutni or
accu-tni).ti,ab,ot. (9)
3. ((troponin t or tnt or ctnt or tropt or trop t) adj2 (sensitiv$ or hs or early or initial or rapid or present$
or ultra or high performance or ultrasensitive)).ti,ab,ot. (62)
4. ((troponin I or tni or ctni or tropI or trop I) adj2 (sensitiv$ or hs or early or initial or rapid or present$ or
ultra or high performance or ultrasensitive)).ti,ab,ot. (29)
5. (troponin$ adj2 (sensitiv$ or hs or early or initial or rapid or present$ or ultra or high performance or
ultrasensitive)).ti,ab,ot. (99)
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6. (troponin$ adj5 (architect or elecsys or accutni or accu-tni or access or unicel)).ti,ab,hw,ot. (3)
7. or/1-6 (125)
8. troponin t/ or troponin I/ or (60304-72-5 or 77108-40-8).rn. (5)
9. (sensitiv$ or hs or early or initial or rapid or present$ or ultra or high performance or ultrasensitive).
ti,ab,ot. (388,942)
10. 8 and 9 (3)
11. 7 or 10 (127)
12. chest pain/ (13)
13. ((chest or thorax or thoracic) adj2 (pain$ or discomfort or tight$ or pressure)).ti,ab,ot,hw. (1742)
14. exp myocardial ischemia/ (170)
15. (acute adj2 coronary adj2 syndrome$).ti,ab,ot. (1544)
16. (preinfarc$ Angina$ or pre infarc$ Angina$).ti,ab,ot. (3)
17. Unstable angina$.ti,ab,ot. (378)
18. ((heart$ or myocardi$ or cardiac or coronary) adj2 (preinfarc$ or infarc$ or attack$ or arrest$ or
occlusion$ or isch?emia$)).ti,ab,ot. (8220)
19. (MI or ACS or STEMI or NSTE-ACS or NSTEACS or nonSTEMI or NSTEMI or AMI or UAP or OMI).
ti,ab,ot. (4224)
20. or/12-19 (12,386)
21. 11 and 20 (76)
22. animals/ not (animals/ and humans/) (1462)
23. 21 not 22 (76)
EMBASE (OvidSP): 1974 to 2013/10/10
Searched: 11 October 2013
1. “high sensitivity cardiac troponin T”/ or high sensitivity troponin t assay/ (12)
2. “high sensitivity cardiac troponin I”/ or high sensitivity troponin i assay/ (3)
3. (Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs).ti,ab,ot. (565)
4. (Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or accutni or
accu-tni).ti,ab,ot. (190)
5. ((troponin t or tnt or ctnt or tropt or trop t) adj2 (sensitiv$ or hs or early or initial or rapid or present$
or ultra or high performance or ultrasensitive)).ti,ab,ot,hw. (1052)
6. ((troponin I or tni or ctni or tropI or trop I) adj2 (sensitiv$ or hs or early or initial or rapid or present$ or
ultra or high performance or ultrasensitive)).ti,ab,ot,hw. (598)
7. (troponin$ adj2 (sensitiv$ or hs or early or initial or rapid or present$ or ultra or high performance or
ultrasensitive)).ti,ab,ot,hw. (1478)
8. (troponin$ adj5 (architect or elecsys or accutni or accu-tni or access or unicel)).ti,ab,hw,ot. (106)
9. or/1-8 (2142)
10. troponin t/ or troponin I/ or (60304-72-5 or 77108-40-8).rn. (18,661)
11. (sensitiv$ or hs or early or initial or rapid or present$ or ultra or high performance or ultrasensitive).
ti,ab,ot,hw. (6,591,905)
12. 10 and 11 (9505)
13. 9 or 12 (10,097)
14. thorax pain/ (44,504)
15. ((chest or thorax or thoracic) adj2 (pain$ or discomfort or tight$ or pressure)).ti,ab,ot,hw. (64,208)
16. acute coronary syndrome/ (24,295)
17. (acute adj2 coronary adj2 syndrome$).ti,ab,ot,hw. (34,428)
18. exp heart muscle ischemia/ (73,551)
19. exp heart infarction/ (266,027)
20. exp Unstable-Angina-Pectoris/ (16,552)
21. (preinfarc$ Angina$ or pre infarc$ Angina$).ti,ab,ot,hw. (374)
22. Unstable angina$.ti,ab,ot. (14,593)
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23. ((heart$ or myocardi$ or cardiac or coronary) adj2 (preinfarc$ or infarc$ or attack$ or arrest$ or
occlusion$ or isch?emia$)).ti,ab,ot,hw. (406,203)
24. (MI or ACS or STEMI or NSTE-ACS or NSTEACS or nonSTEMI or NSTEMI or AMI or UAP or OMI).
ti,ab,ot,hw. (85,655)
25. or/14-24 (498,902)
26. 13 and 25 (6007)
27. animal/ (1,890,932)
28. animal experiment/ (1,720,343)
29. (rat or rats or mouse or mice or murine or rodent or rodents or hamster or hamsters or pig or pigs or
porcine or rabbit or rabbits or animal or animals or dogs or dog or cats or cow or bovine or sheep
or ovine or monkey or monkeys).ti,ab,ot,hw. (5,825,865)
30. or/27-29 (5,825,865)
31. exp human/ (15,014,990)
32. human experiment/ (317,206)
33. or/31-32 (15,016,431)
34. 30 not (30 and 33) (4,642,837)
35. 26 not 34 (5642)
36. limit 35 to yr=“2005 -Current” (4374)
37. remove duplicates from 36 (4282)
Cochrane Database of Systematic Reviews (CDSR) (Wiley), Issue 10/October,
up to 2013/10/11; Cochrane Central Register of Controlled Trials (CENTRAL)
(Wiley), Issue 9/September, 2013; Database of Abstracts of Reviews of
Effects (DARE) (Wiley), Issue 3/July, 2013; Health Technology Assessment
Database (HTA) (Wiley), Issue 3/July:2013; NHS Economic Evaluation
Database (NHS EED) (Wiley), Issue 3/July, 2013
Searched: 11 October 2013
1. (Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs):ti,ab,kw (5)
2. (Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or accutni or
accu-tni):ti,ab,kw (5)
3. ((troponin t or tnt or ctnt or tropt or trop t) near/2 (sensitiv* or hs or early or initial or rapid or
present* or ultra or high performance or ultrasensitive)):ti,ab,kw (12)
4. ((troponin I or tni or ctni or tropI or trop I) near/2 (sensitiv* or hs or early or initial or rapid or present*
or ultra or high performance or ultrasensitive)):ti,ab,kw (10)
5. (troponin* near/2 (sensitiv* or hs or early or initial or rapid or present* or ultra or high performance or
ultrasensitive)):ti,ab,kw (27)
6. (troponin* near/5 (architect or elecsys or accutni or accu-tni or access or unicel)):ti,ab,kw (2)
7. #1 or #2 or #3 or #4 or #5 or #6 (42)
8. MeSH descriptor: [Troponin T] this term only (265)
9. MeSH descriptor: [Troponin I] this term only (309)
10. #8 or #9 (543)
11. (sensitiv* or hs or early or initial or rapid or present* or ultra or high performance or ultrasensitive):ti,
ab,kw (170,016)
12. #10 and #11 (236)
13. #7 or #12 (249)
14. MeSH descriptor: [Chest Pain] this term only (335)
15. ((chest or thorax or thoracic) near/2 (pain* or discomfort or tight* or pressure)):ti,ab,kw (1793)
16. (acute near/2 coronary near/2 syndrome*):ti,ab,kw (1678)
17. MeSH descriptor: [Myocardial Ischemia] explode all trees (20,427)
18. (preinfarc* Angina* or pre infarc* Angina*):ti,ab,kw (90)
19. (Unstable angina*):ti,ab,kw (1818)
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20. ((heart* or myocardi* or cardiac or coronary) near/2 (preinfarc* or infarc* or attack* or arrest* or
occlusion* or isch?emia*)):ti,ab,kw (16,156)
21. (MI or ACS or STEMI or NSTE-ACS or NSTEACS or nonSTEMI or NSTEMI or AMI or UAP or OMI):ti,ab,
kw (4740)
22. #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 (28,923)
23. #13 and #22 from 2005 to 2013 (114)
CDSR search retrieved 0 references; CENTRAL search retrieved 108 references; DARE search retrieved 2
references; HTA search retrieved 1 references; NHS EED search retrieved 3 references.
Science Citation Index – Expanded (SCI) (Web of Science): 1970–2013/10/14;
Conference Proceedings Citation Index (CPCI-S) (Web of Science): 1990–2013/10/14
Searched: 14 October 2013
Databases= SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC Timespan= 2005–13
1. 228 TS=(Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs)
2. 90 TS=(Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or accutni
or accu-tni)
3. 1438 TS=((troponin* or tnt or ctnt or tropt or tni or ctni or tropI or “trop t” or “trop I”) NEAR/2
(sensitiv* or hs or early or initial or rapid or present* or ultra or “high performance” or ultrasensitive))
4. 1470 #3 OR #2 OR #1
5. 13,963 TS=((chest or thorax or thoracic) NEAR (pain* or discomfort or tight* or pressure))
6. 19,298 TS=(acute NEAR/2 coronary NEAR/2 syndrome*)
7. 393 TS=(preinfarc* angina* or pre infarc* angina)
8. 5481 TS=unstable angina*
9. 115,395 TS=((heart* or myocard* or cardiac or coronary) NEAR/2 (preinfarc* or infarc* or attack*
or arrest* or occlusion* or isch?emia*))
10. 40,133 TS=(MI or ACS or STEMI or NSTE-ACS or NSTEACS or nonSTEMI or NSTEMI or AMI or UAP
or OMI)
11. 155,342 #10 OR #9 OR #8 OR #7 OR #6 OR #5
12. 835 #11 AND #4
Latin American and Caribbean Health Sciences (LILACS): 1982–2013/09/24
(http://regional.bvsalud.org/php/index.php?lang=en)
Searched: 14 October 2013
Terms Records
(Troponin$ or MH:D05.750.078.730.825.925 or MH:D12.776.210.500.910.925 or MH:
D12.776.220.525.825.925 or MH:D05.750.078.730.825.962 or MH:D12.776.210.500.910.962 or MH:
D12.776.220.525.825.962 or MH:D05.750.078.730.825 or MH:D12.776.210.500.910 or MH:
D12.776.220.525.825 or Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs or Hstni or
hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or accutni or accu-tni)
247
Total 247
Spanish and Portuguese translations of MeSH terms identified using the DECS (Health Sciences Descriptors) thesaurus:
http://decs.bvs.br/I/homepagei.htm.
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International Network of Agencies for Health Technology Assessment
(INAHTA): up to 2013/10/15 (www.inahta.org/Search2/?pub=1)
Searched: 15 October 2013
Search term Results
Troponin 9
Elecsys 2
Architect 0
Accutni 0/1
unicel 0
Total 11
BIOSIS Previews (Web of Knowledge): 1956–2013/10/11
Searched: 14 October 2013
1. Databases=BIOSIS Previews Timespan=2005-2013
2. 266 TS=(Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs)
3. 114 TS=(Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or accutni
or accu-tni)
4. 1055 TS=((troponin* or tnt or ctnt or tropt or tni or ctni or tropI or “trop t” or “trop I”) NEAR/2
(sensitiv* or hs or early or initial or rapid or present* or ultra or “high performance” or ultrasensitive))
5. 1095 #3 OR #2 OR #1
6. 7468 TS=((chest or thorax or thoracic) NEAR (pain* or discomfort or tight* or pressure))
7. 11,149 TS=(acute NEAR/2 coronary NEAR/2 syndrome*)
8. 196 TS=(preinfarc* angina* or pre infarc* angina)
9. 3025 TS=unstable angina*
10. 62,717 TS=((heart* or myocard* or cardiac or coronary) NEAR/2 (preinfarc* or infarc* or attack* or
arrest* or occlusion* or isch?emia*))
11. 28,931 TS=(MI or ACS or STEMI or NSTE-ACS or NSTEACS or nonSTEMI or NSTEMI or AMI or UAP
or OMI)
12. 83,999 #10 OR #9 OR #8 OR #7 OR #6 OR #5
13. 628 #11 AND #4
National Institute for Health Research Health technology Assessment (Internet)
(www.hta.ac.uk/) up to 2013/10/14
Searched: 14 October 2013
Browsed with Troponin terms – six results.
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Aggressive Research Intelligence Facility (Internet): 1996–2013/10/16
(www.birmingham.ac.uk/research/activity/mds/projects/HaPS/PHEB/ARIF/databases/
index.aspx)
Searched: 16 October 2013
Search terms Quick search
Troponin* 21
Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs 0
Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or accutni or accu-tni 0
Total 21
Medion database: up to 2013/10/16 (www.mediondatabase.nl/)
Searched: 16 October 2013
Searched: in ‘Whole Database’
Search term in ‘topics’ Results
Troponin 0
Troponins 0
Total 0
PROSPERO (International Prospective Register of Systematic Reviews)
(Internet): up to 2013/10/10 (www.crd.york.ac.uk/prospero/)
Searched: 10 October 2013
Searched: in ‘All fields’
Terms Records
Troponin* 8
Total 8
Clinicaltrials.gov (Internet) (http://clinicaltrials.gov/ct2/search/advanced)
Searched: 14 October 2013
Advanced search option – search terms box.
Search terms Condition Intervention Records
Troponin% AND (sensitiv% OR hs OR early OR initial OR rapid OR present% OR
ultra OR high performance OR ultrasensitive OR elecsys OR architect OR accutni
OR access OR unicel)
186
Troponin% 109
(Hstnt OR hs-tnt OR hsctnt Or hs-ctnt OR tnt-hs OR tnths OR ctnths OR ctnt-hs
OR Hstni OR hs-tni OR hsctni OR hs-ctni OR tni-hs OR tnihs OR ctnihs OR ctni-hs
OR ctni-ultra OR accutni OR accu-tni)
17
Total 312
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metaRegister of Controlled Trials (mRCT) (Internet) (www.controlled-trials.com/)
Searched: 10 October 2013
Search terms Results
(troponin* AND (sensitiv* or hs or early or initial or rapid or present* or ultra or high performance or
ultrasensitive))
333
Total 333
WHO International Clinical Trials Registry Platform (ICTRP) (Internet)
(www.who.int/ictrp/en/)
Searched: 10 October 2013
Advanced search option
Date of registration limited to 01/01/2005 to 10/10/2013
Title Condition Intervention Records
Troponin OR
Troponins
67
Troponins 2
Troponin This search does not work – the results are irrelevant and do not contain
the word troponin in the intervention field
Total 69
American Heart Association: Scientific Sessions (http://my.americanheart.org/
professional/Sessions/ScientificSessions/Archive/Archive-Scientific-Sessions_UCM_
316935_SubHomePage.jsp)
Searched: 29 October 2013
2013: Conference not yet taken place at time of searching
2012: http://circ.ahajournals.org/content/vol126/21_MeetingAbstracts
2011: http://circ.ahajournals.org/content/vol124/21_MeetingAbstracts
2010: http://circ.ahajournals.org/content/vol122/21_MeetingAbstracts
2009: http://circ.ahajournals.org/content/120/21/2152.full.pdf
Keyword 2013 2012 2011 2010 2009 Total
Troponin* N/A 138 131 109 1 379
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American Association for Clinical Chemistry (www.aacc.org/resourcecenters/
meet_abstracts_archive/abstracts_archive/annual_meeting/Pages/default.aspx#)
Searched: 29 October 2013
2013 Abstracts from: Clinical Chemistry, 59(S10):A1–295
www.aacc.org/events/Annual_Meeting/abstracts/Documents/AACC_13_AbstractBook_Complete.pdf
2012 Abstracts from: Clinical Chemistry, 58(S10):a1–A264
www.aacc.org/events/annualmtgdirectory/Documents/AACC_12_AbstractBook-Final-Complete.pdf
2011 Abstracts from: Clinical Chemistry, 57 (S10): A1–A235
www.aacc.org/events/annualmtgdirectory/documents/AACC_11_FullAbstract.pdf
2010 Abstracts from: Clinical Chemistry, 57 (6 Suppl): A1–276
www.aacc.org/events/annualmtgdirectory/Pages/2010PosterAbstracts.aspx#
2009 19–23 July, Chicago, IL, www.abstractsonline.com/viewer/searchAdvanced.asp?MKey={CA6D749E-
BE20-4F85-899B-8A84E2268F72}&AKey={B08F832C-9D23-4F0B-96C3-3FA22F3D94A1}
Keyword 2013 2012 2011 2010 2009 Totals
Troponin 48 21 32 40 29 170
European Society of Cardiology (http://spo.escardio.org/abstract-book/search.aspx)
Searched: 29 October 2013
Keyword 2013 2012 2011 2010 2009 Total
Troponin 52 51 61 51 25 240
Troponins 2 1 2 1 2 8
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Additional searches
Results sorted by Link Ranking (www.ncbi.nlm.nih.gov/pubmed/)
Searched: 10 December 2013
Nine of the included publications were not indexed on PubMed. Indexed publications were checked for
errata and comments. For each reference, the first 20 references were retrieved by carrying out a Related
Citations search using PubMed’s similarity matching algorithm. These records were downloaded for
screening. All related citations were checked against the EndNote Library to remove duplicates, and only
new unique references were imported and screened= 58 records.
Reference PMID Result retrieved
Santalo40 23764266 20/131
Aldous41 22109535 20/145
Sanchis42 22877804 20/203
Haaf43 22623715 20/203
Eggers44 22456003 20/145
Reiter45 22044927 20/280
Aldous46 22291171 20/277
Potocki47 22337952 20/304
Keller48 22203537 20/300
Meune108 22014790 20/252
Freund49 21663627 20/142
Aldous50 21784766 20/254
Melki51 21428843 20/210
Reichlin52 21709058 20/162
Reiter53 21362702 20/261
Aldous54 21441390 20/251
Kurz55 20852870 20/207
Hochholzer56 21138939 20/138
Christ57 20932502 20/201
Parsonage58 Not in PubMed
Collinson59 Not in PubMed
Body60 Not in PubMed
Melki61 Not in PubMed
Aldous62 Not in PubMed
Cullen63 23583250 20/133
Sebbane64 23816196 20/131
Irfan65 23870791 20/134
Collinson19 23597479 20/275
Reiter66 23514979 20/155
Body67 21920261 20/192
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Reference PMID Result retrieved
Aldous68 21441393 20/174
Keller69 Not in PubMed
Collinson58 Not in PubMed
Saenger70 Not in PubMed
Lippi73 Not in PubMed
Hoeller39 23604180 20/107
Total 640
Following duplicate removal, number of records screened 58
Cost-effectiveness searches
MEDLINE (OvidSP): 1946 to 2013/10/Week 1
Searched: 18 October 2013
1. economics/ (27,116)
2. exp “costs and cost analysis”/ (182,544)
3. economics, dental/ (1866)
4. exp “economics, hospital”/ (19,403)
5. economics, medical/ (8578)
6. economics, nursing/ (3879)
7. economics, pharmaceutical/ (2605)
8. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).
ti,ab. (427,344)
9. (expenditure$ not energy).ti,ab. (17,552)
10. (value adj1 money).ti,ab. (22)
11. budget$.ti,ab. (17,208)
12. or/1-11 (551,693)
13. ((energy or oxygen) adj cost).ti,ab. (2752)
14. (metabolic adj cost).ti,ab. (798)
15. ((energy or oxygen) adj expenditure).ti,ab. (16,662)
16. or/13-15 (19,503)
17. 12 not 16 (547,348)
18. letter.pt. (803,396)
19. editorial.pt. (334,975)
20. historical article.pt. (299,710)
21. or/18-20 (1,423,597)
22. 17 not 21 (519,320)
23. (Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs).ti,ab,ot. (229)
24. (Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or accutni or
accu-tni).ti,ab,ot. (99)
25. ((troponin t or tnt or ctnt or tropt or trop t) adj2 (sensitiv$ or hs or early or initial or rapid or present$
or ultra or high performance or ultrasensitive)).ti,ab,ot. (563)
26. ((troponin I or tni or ctni or tropI or trop I) adj2 (sensitiv$ or hs or early or initial or rapid or present$ or
ultra or high performance or ultrasensitive)).ti,ab,ot. (349)
27. (troponin$ adj2 (sensitiv$ or hs or early or initial or rapid or present$ or ultra or high performance or
ultrasensitive)).ti,ab,ot. (769)
28. (troponin$ adj5 (architect or elecsys or accutni or accu-tni or access or unicel)).ti,ab,hw,ot. (66)
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29. or/23-28 (1215)
30. troponin t/ or troponin I/ or (60304-72-5 or 77108-40-8).rn. (8642)
31. (sensitiv$ or hs or early or initial or rapid or present$ or ultra or high performance or ultrasensitive).
ti,ab,ot. (4,878,300)
32. 30 and 31 (4209)
33. 29 or 32 (4559)
34. chest pain/ (9293)
35. ((chest or thorax or thoracic) adj2 (pain$ or discomfort or tight$ or pressure)).ti,ab,ot,hw. (28,602)
36. exp myocardial ischemia/ (357,748)
37. (acute adj2 coronary adj2 syndrome$).ti,ab,ot. (16,495)
38. (preinfarc$ Angina$ or pre infarc$ Angina$).ti,ab,ot. (285)
39. Unstable angina$.ti,ab,ot. (10,718)
40. ((heart$ or myocardi$ or cardiac or coronary) adj2 (preinfarc$ or infarc$ or attack$ or arrest$ or
occlusion$ or isch?emia$)).ti,ab,ot. (194,088)
41. (MI or ACS or STEMI or NSTE-ACS or NSTEACS or nonSTEMI or NSTEMI or AMI or UAP or OMI).ti,ab,ot.
(53,168)
42. or/34-41 (444,673)
43. 33 and 42 (2503)
44. animals/ not (animals/ and humans/) (3,957,888)
45. 43 not 44 (2336)
46. limit 45 to yr=“2005 -Current” (1457)
47. 22 and 46 (43)
Costs filter: Centre for Reviews and Dissemination. NHS EED Economics Filter: MEDLINE (Ovid) monthly
search York: Centre for Reviews and Dissemination; 2010.
MEDLINE In-Process & Other Non-Indexed Citations (OvidSP): up to 2013/10/01,
MEDLINE daily update: up to 2013/10/01
Searched: 18 October 2013
1. economics/ (2)
2. exp “costs and cost analysis”/ (87)
3. economics, dental/ (0)
4. exp “economics, hospital”/ (8)
5. economics, medical/ (0)
6. economics, nursing/ (0)
7. economics, pharmaceutical/ (1)
8. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).
ti,ab. (39,821)
9. (expenditure$ not energy).ti,ab. (1172)
10. (value adj1 money).ti,ab. (4)
11. budget$.ti,ab. (1822)
12. or/1-11 (41,689)
13. ((energy or oxygen) adj cost).ti,ab. (218)
14. (metabolic adj cost).ti,ab. (67)
15. ((energy or oxygen) adj expenditure).ti,ab. (911)
16. or/13-15 (1160)
17. 12 not 16 (41,354)
18. letter.pt. (24,293)
19. editorial.pt. (14,525)
20. historical article.pt. (68)
21. or/18-20 (38,878)
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22. 17 not 21 (40,906)
23. (Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs).ti,ab,ot. (32)
24. (Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or accutni or
accu-tni).ti,ab,ot. (9)
25. ((troponin t or tnt or ctnt or tropt or trop t) adj2 (sensitiv$ or hs or early or initial or rapid or present$
or ultra or high performance or ultrasensitive)).ti,ab,ot. (62)
26. ((troponin I or tni or ctni or tropI or trop I) adj2 (sensitiv$ or hs or early or initial or rapid or present$ or
ultra or high performance or ultrasensitive)).ti,ab,ot. (29)
27. (troponin$ adj2 (sensitiv$ or hs or early or initial or rapid or present$ or ultra or high performance or
ultrasensitive)).ti,ab,ot. (99)
28. (troponin$ adj5 (architect or elecsys or accutni or accu-tni or access or unicel)).ti,ab,hw,ot. (3)
29. or/23-28 (125)
30. troponin t/ or troponin I/ or (60304-72-5 or 77108-40-8).rn. (5)
31. (sensitiv$ or hs or early or initial or rapid or present$ or ultra or high performance or ultrasensitive).
ti,ab,ot. (388,942)
32. 30 and 31 (3)
33. 29 or 32 (127)
34. chest pain/ (13)
35. ((chest or thorax or thoracic) adj2 (pain$ or discomfort or tight$ or pressure)).ti,ab,ot,hw. (1742)
36. exp myocardial ischemia/ (170)
37. (acute adj2 coronary adj2 syndrome$).ti,ab,ot. (1544)
38. (preinfarc$ Angina$ or pre infarc$ Angina$).ti,ab,ot. (3)
39. Unstable angina$.ti,ab,ot. (378)
40. ((heart$ or myocardi$ or cardiac or coronary) adj2 (preinfarc$ or infarc$ or attack$ or arrest$ or
occlusion$ or isch?emia$)).ti,ab,ot. (8220)
41. (MI or ACS or STEMI or NSTE-ACS or NSTEACS or nonSTEMI or NSTEMI or AMI or UAP or OMI).
ti,ab,ot. (4224)
42. or/34-41 (12,386)
43. 33 and 42 (76)
44. animals/ not (animals/ and humans/) (1462)
45. 43 not 44 (76)
46. limit 45 to yr=“2005 -Current” (75)
47. 22 and 46 (4)
Costs filter: Centre for Reviews and Dissemination. NHS EED Economics Filter: MEDLINE (Ovid) monthly
search. York: Centre for Reviews and Dissemination; 2010.
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EMBASE (OvidSP): 1974 to 2013/10/17
Searched: 18 October 2013
1. health-economics/ (33,273)
2. exp economic-evaluation/ (205,882)
3. exp health-care-cost/ (197,503)
4. exp pharmacoeconomics/ (169,588)
5. or/1-4 (471,813)
6. (econom$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).
ti,ab. (590,127)
7. (expenditure$ not energy).ti,ab. (23,360)
8. (value adj2 money).ti,ab. (1320)
9. budget$.ti,ab. (23,595)
10. or/6-9 (613,918)
11. 5 or 10 (885,833)
12. letter.pt. (844,056)
13. editorial.pt. (449,323)
14. note.pt. (587,506)
15. or/12-14 (1,880,885)
16. 11 not 15 (799,169)
17. (metabolic adj cost).ti,ab. (876)
18. ((energy or oxygen) adj cost).ti,ab. (3163)
19. ((energy or oxygen) adj expenditure).ti,ab. (19,981)
20. or/17-19 (23,208)
21. 16 not 20 (794,101)
22. “high sensitivity cardiac troponin T”/ or high sensitivity troponin t assay/ (12)
23. “high sensitivity cardiac troponin I”/ or high sensitivity troponin i assay/ (3)
24. (Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs).ti,ab,ot. (571)
25. (Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or accutni or
accu-tni).ti,ab,ot. (193)
26. ((troponin t or tnt or ctnt or tropt or trop t) adj2 (sensitiv$ or hs or early or initial or rapid or present$
or ultra or high performance or ultrasensitive)).ti,ab,ot,hw. (1059)
27. ((troponin I or tni or ctni or tropI or trop I) adj2 (sensitiv$ or hs or early or initial or rapid or present$ or
ultra or high performance or ultrasensitive)).ti,ab,ot,hw. (602)
28. (troponin$ adj2 (sensitiv$ or hs or early or initial or rapid or present$ or ultra or high performance or
ultrasensitive)).ti,ab,ot,hw. (1489)
29. (troponin$ adj5 (architect or elecsys or accutni or accu-tni or access or unicel)).ti,ab,hw,ot. (106)
30. or/22-29 (2155)
31. troponin t/ or troponin I/ or (60304-72-5 or 77108-40-8).rn. (18,726)
32. (sensitiv$ or hs or early or initial or rapid or present$ or ultra or high performance or ultrasensitive).ti,
ab,ot,hw. (6,601,404)
33. 31 and 32 (9548)
34. 30 or 33 (10,144)
35. thorax pain/ (44,662)
36. ((chest or thorax or thoracic) adj2 (pain$ or discomfort or tight$ or pressure)).ti,ab,ot,hw. (64,388)
37. acute coronary syndrome/ (24,412)
38. (acute adj2 coronary adj2 syndrome$).ti,ab,ot,hw. (34,558)
39. exp heart muscle ischemia/ (73,666)
40. exp heart infarction/ (266,475)
41. exp Unstable-Angina-Pectoris/ (16,570)
42. (preinfarc$ Angina$ or pre infarc$ Angina$).ti,ab,ot,hw. (374)
43. Unstable angina$.ti,ab,ot. (14,604)
DOI: 10.3310/hta19440 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 44
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
117
44. ((heart$ or myocardi$ or cardiac or coronary) adj2 (preinfarc$ or infarc$ or attack$ or arrest$ or
occlusion$ or isch?emia$)).ti,ab,ot,hw. (406,847)
45. (MI or ACS or STEMI or NSTE-ACS or NSTEACS or nonSTEMI or NSTEMI or AMI or UAP or OMI).
ti,ab,ot,hw. (85,913)
46. or/35-45 (499,787)
47. 34 and 46 (6035)
48. animal/ (1,890,937)
49. animal experiment/ (1,721,607)
50. (rat or rats or mouse or mice or murine or rodent or rodents or hamster or hamsters or pig or pigs or
porcine or rabbit or rabbits or animal or animals or dogs or dog or cats or cow or bovine or sheep or
ovine or monkey or monkeys).ti,ab,ot,hw. (5,828,979)
51. or/48-50 (5,828,979)
52. exp human/ (15,032,575)
53. human experiment/ (317,393)
54. or/52-53 (15,034,016)
55. 51 not (51 and 54) (4,644,866)
56. 47 not 55 (5669)
57. limit 56 to yr=“2005 -Current” (4401)
58. remove duplicates from 57 (4309)
59. 21 and 58 (129)
Costs filter: Centre for Reviews and Dissemination. NHS EED Economics Filter: EMBASE (Ovid) weekly
search. York: Centre for Reviews and Dissemination; 2010.
NHS Economic Evaluation Database (NHS EED) (Wiley) Issue 3/July:2013
Searched: 11 October 2013
1. (Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs):ti,ab,kw (5)
2. (Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or) accutni or
accu-tni):ti,ab,kw (5)
3. ((troponin t or tnt or ctnt or tropt or trop t) near/2 (sensitiv* or hs or early or initial or rapid or
present* or ultra or high performance or ultrasensitive)):ti,ab,kw (12)
4. ((troponin I or tni or ctni or tropI or trop I) near/2 (sensitiv* or hs or early or initial or rapid or present*
or ultra or high performance or ultrasensitive)):ti,ab,kw (10)
5. (troponin* near/2 (sensitiv* or hs or early or initial or rapid or present* or ultra or high performance or
ultrasensitive)):ti,ab,kw (27)
6. (troponin* near/5 (architect or elecsys or accutni or accu-tni or access or unicel)):ti,ab,kw (2)
7. #1 or #2 or #3 or #4 or #5 or #6 (42)
8. MeSH descriptor: [Troponin T] this term only (265)
9. MeSH descriptor: [Troponin I] this term only (309)
10. #8 or #9 (543)
11. (sensitiv* or hs or early or initial or rapid or present* or ultra or high performance or ultrasensitive):
ti,ab,kw (170,016)
12. #10 and #11 (236)
13. #7 or #12 (249)
14. MeSH descriptor: [Chest Pain] this term only (335)
15. ((chest or thorax or thoracic) near/2 (pain* or discomfort or tight* or pressure)):ti,ab,kw (1793)
16. (acute near/2 coronary near/2 syndrome*):ti,ab,kw (1678)
17. MeSH descriptor: [Myocardial Ischemia] explode all trees (20,427)
18. (preinfarc* Angina* or pre infarc* Angina*):ti,ab,kw (90
19. (Unstable angina*):ti,ab,kw (1818)
20. ((heart* or myocardi* or cardiac or coronary) near/2 (preinfarc* or infarc* or attack* or arrest* or
occlusion* or isch?emia*)):ti,ab,kw (16,156)
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21. (MI or ACS or STEMI or NSTE-ACS or NSTEACS or nonSTEMI or NSTEMI or AMI or UAP or OMI):ti,ab,
kw (4740)
22. #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 (28,923)
23. #13 and #22 from 2005 to 2013 (114)
NHS EED search retrieved three references.
Health Economic Evaluation Database (HEED) (Internet): up to 2013/10/18
(http://onlinelibrary.wiley.com/book/10.1002/9780470510933)
Searched: 18 October 2013
Compound search, (all data), unable to limit by date
Troponin*
AND
sensitiv* OR hs OR early OR initial OR rapid OR present OR ultra OR high performance OR ultrasensitive OR
elecsys OR architect OR accutni OR access OR unicel
N=20
Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs or Hstni or hs-tni or hsctni or
hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra
N=0
Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or accutni or accu-tni
N=0
EconLit (EBSCO) 1990–2013/09/01
Searched: 18 October 2013
Search modes – Boolean/Phrase
S1 TX Troponin* (0)
S2 TX Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs (0)
S3 TX Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or accutni or
accu-tni (0)
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Science Citation Index Expanded (SCI) (Web of Science): 1970–2013/10/21,
Conference Proceedings Citation Index (CPCI-S) (Web of Science):
1990–2013/10/21
Searched: 21 October 2013
1. 622,444 TS=(economic* or cost or costs or costly or costing or price or prices or pricing or
pharmacoeconomic* or budget*)
2. 10,144 TS=(expenditure* not energy)
3. 952 TS=(value NEAR money)
4. 626,873 #3 OR #2 OR #1
5. 22,383 TS=((energy or oxygen) NEAR cost)
6. 1804 TS=(metabolic NEAR cost)
7. 12,974 TS=((energy or oxygen) NEAR expenditure)
8. 35,684 #7 OR #6 OR #5
9. 602,398 #4 NOT #8
10. 230 TS=(Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs)
11. 91 TS=(Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or accutni
or accu-tni)
12. 1442 TS=((troponin* or tnt or ctnt or tropt or tni or ctni or tropI or “trop t” or “trop I”) NEAR/2
(sensitiv* or hs or early or initial or rapid or present* or ultra or “high performance” or ultrasensitive))
13. 1474 #12 OR #11 OR #10
14. 14,001 TS=((chest or thorax or thoracic) NEAR (pain* or discomfort or tight* or pressure))
15. 19,324 TS=(acute NEAR/2 coronary NEAR/2 syndrome*)
16. 393 TS=(preinfarc* angina* or pre infarc* angina)
17. 5486 TS=unstable angina*
18. 115,562 TS=((heart* or myocard* or cardiac or coronary) NEAR/2 (preinfarc* or infarc* or attack*
or arrest* or occlusion* or isch?emia*))
19. 40,195 TS=(MI or ACS or STEMI or NSTE-ACS or NSTEACS or nonSTEMI or NSTEMI or AMI or UAP
or OMI)
20. 155,582 #19 OR #18 OR #17 OR #16 OR #15 OR #14
21. 839 #20 AND #13
22. 32 #21 AND #9
Databases= SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC Timespan= 2005–2013.
Research Papers in Economics (REPEC) up to 2013/10/21 (http://econpapers.
repec.org/scripts/search/search.asp?pg=-1)
Searched: 21 October 2013
Advanced search
Free text search Results Total
Troponin 0/2 0
Troponins 0/1 0
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Appendix 2 Data extraction tables
Baseline study details
Study details Selection criteria Participant details
Test
manufacturer
Aldous (2012)41,46,50
Country: New Zealand
Funding: Funded by the
National Heart Foundation
of New Zealand and assay
reagents were provided by the
manufacturer (Roche). One
author declared personal
funding from Abbott
Recruitment: November 2007
to December 2010
Number of participants:
939,46 38541
Inclusion criteria:
Adults (≥18 years) with symptoms
suggestive of cardiac ischaemia
(acute chest, epigastric, neck, jaw
or arm pain or discomfort or
pressure without an apparent
non-cardiac source)
Exclusion criteria:
ST segment elevation on ECG;46
unable to provide informed
consent; would not be available
to follow-up
Patient category:
NSTEMI46
Mixed41
Median age (IQR), years: 65
(56–76)
Male (%): 60
White (%): 89
Previous CAD (%): 52
Previous family history (%): 60
Previous revascularisation
(%): 30
Diabetes (%): 17
Smoking (%): 61
Hypertension (%): 61
Dyslipidaemia (%): 58
Median BMI (IQR), kg/m2:
28 (25–31)
Median (IQR) time to
presentation (hours): 6.3
(3.3–13.3)
Roche
Aldous (2011)54,62,68
Country: New Zealand
Funding: Manufacturers
(Roche and Abbott) supplied
assays. The study was funded
by a New Zealand National
Heart Foundation grant
Recruitment: November 2006
to April 2007
Number of participants: 332
Inclusion criteria:
Consecutive patients presenting
to the ED with chest pain;
participants were eligible for
inclusion if the attending
clinician had sufficient suspicion
of ACS that serial Tns and ECGs
were considered necessary
Exclusion criteria:
< 18 years; samples not stored
for both time points (on
admission and at 6–24 hours)
Patient category:
Mixed
Median age (IQR), years: 64
(53–74)
Male (%): 60
White (%): 85
Previous CAD (%): 54
Previous family history (%): 40
Diabetes (%): 16
Smoking (%): 45
Hypertension (%): 46
Dyslipidaemia (%): 38
Median (IQR) time to
presentation (hours): 4.0
(2.0 to 8.6)
Roche
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Study details Selection criteria Participant details
Test
manufacturer
Body (2011)60,67,74
Country: UK
Funding: Central Manchester
NHS Trust
Recruitment: January 2006 to
February 2007
Number of participants
eligible (enrolled): 1004 (703)
Inclusion criteria:
Presenting to ED with chest pain;
age > 25 years and chest pain
within previous 24 hours that
initial treating physician
suspected may be cardiac in
nature
Exclusion criteria:
Renal failure requiring dialysis,
trauma with suspected
myocardial contusion, or another
medical condition mandating
hospital admission or if they did
not consent to and provide a
blood sample for use by the
research team
Patient category:
Mixed
Mean age (SD), years: 59 (14)
Male (%): 61
Kidney disease (%): 1
Previous AMI (%): 24
Previous family history (%): 48
Previous revascularisation
(%): 20
Diabetes (%): 18
Smoking (%): 31
Dyslipidaemia (%): 48
Median time to presentation
(hours): 3.5
Roche
Christ (2010)57
Country: Germany
Funding: hs-cTnT test kits
were provided by Roche
Recruitment: 7 September
2009 to 21 September 2009
Number of participants: 137
Inclusion criteria:
Consecutive patients with acute
chest pain of possible coronary
origin presenting to the
emergency department
Exclusion criteria: NR
Patient category:
Mixed
Mean age (SD), years: 66 (16)
Male (%): 64
Previous AMI (%): 32
Previous CAD (%): 34
Previous family history (%): 12
Previous revascularisation
(%): 24
Diabetes (%): 22
Smoking (%): 22
Hypertension (%): 66
Dyslipidaemia (%): 35
Mean BMI (SD), kg/m2: 28 (5)
Time to presentation (hours):
0–2, 36%; 2–6, 22%; 6–24,
33%; > 24, 20%
Roche
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Study details Selection criteria Participant details
Test
manufacturer
Collinson (2013)19,58,59
Country: UK
Funding: UK Health
Technology Assessment
programme
Study name: Point-of-care
arm of the RATPAC study
Recruitment: February 2007
to June 2008
Number of participants: 850
Inclusion criteria:
Patients presenting to the ED
with chest pain attributable to
suspected, but not proven, AMI
Exclusion criteria:
ECG changes diagnostic for AMI
or high-risk ACS (> 1mm ST
deviation, or > 3mm inverted
T waves); known CAD with
prolonged (> 1 hour) or
recurrent typical cardiac-type
pain; proven or suspected
serious non-cardiac pathology
(e.g. pulmonary embolism);
comorbidity or social problems
requiring hospital admission
even if AMI ruled out; obvious
non-cardiac cause of chest pain
(e.g. pneumothorax or muscular
pain); presentation > 12 hours
after most significant episode
of pain
Patient category: NSTEMI
Median age (IQR), years: 54
(44 to 64)
Male (%): 60
Previous AMI (%): 40
Previous family history (%):
Previous revascularisation
(%): 1
Diabetes (%): 8
Smoking (%): 28
Hypertension (%): 35
Dyslipidaemia (%): 24
Median (IQR) time to
presentation (hours): 8.25
(5.17 to 12.30)
Roche
Cullen (2013)63
Countries: New Zealand and
Australia
Funding: The manufacturers
(Abbott, Roche and Siemens)
provided partial funding
Study name: ADAPT study
(ACTRN12611001069943)
Recruitment: November 2007
to February 2011
Number of participants:
1635
Inclusion criteria:
Prospectively recruited adults
with at least 5 minutes of
possible cardiac symptoms in
accordance with the AHA case
definitions (acute chest,
epigastric, neck, jaw or arm
pain; or discomfort or pressure
without a clear non-cardiac
source)
Exclusion criteria:
Pregnancy; unable or unwilling
to consent; recruitment
inappropriate (e.g. terminal
illness); transfer from another
hospital; follow-up considered
impossible (e.g. homeless
patients)
Patient category:
Mixed
Mean age (SD), years: 59 (13)
Male (%): 60
Previous AMI (%): 24
Previous family history (%): 57
Previous revascularisation
(%): 8
Diabetes (%): 15
Smoking (%): 18
Hypertension (%): 52
Dyslipidaemia (%): 57
Mean (SD) time to
presentation (hours): 22.3
(60.5)
Abbott
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Test
manufacturer
Eggers (2012)44
Country: Sweden
Funding: Swedish Society of
Medicine and the Selander
Foundation
Study name: FASTER 1-study
and FAST II study
Recruitment: May 2000 (FAST
II), October 2002 (FASTER I) to
March 2001 (FAST II), August
2003 (FASTER I)
Number of participants
eligible (enrolled): 495 (360)
Inclusion criteria:
Chest pain with ≥ 15-minute
duration within the last 24 hours
(FAST II-study), or the last
8 hours (FASTER I-study).
Analysis restricted to patients
with symptom onset < 8 hours
Exclusion criteria:
ST segment elevation on the
admission 12-lead ECG, leading
to immediate reperfusion
therapy or its consideration was
used as exclusion criterion
Patient category:
NSTEMI
Median age (IQR), years:
67 (58–76)
Male (%): 66
Previous AMI (%): 38
Previous revascularisation
(%): 18
Diabetes (%): 18
Smoking (%): 18
Hypertension (%): 43
Dyslipidaemia (%): 38
Delay < 4 hours (%): 40
Roche
Freund (2011)49,71
Country: France
Funding: Assay kits for the
study were provided by the
manufacturers (Roche)
Recruitment: August 2005 to
January 2007
No. of participants: 317
Inclusion criteria:
Consecutive adults (>18 years)
presenting to the ED with chest
pain suggestive of ACS (onset or
peak within the previous 6 hours)
Exclusion criteria:
Patients with acute kidney failure
requiring dialysis were excluded
Patient category:
Mixed (13 were STEMI and
32 NSTEMI)
Mean (SD): 57 (17)
Male (%): 65
Previous CAD (%): 26
Previous family history (%): 32
Diabetes (%): 14
Smoking (%): 40
Hypertension (%):
Dyslipidaemia (%): 36
Roche
Hoeller (2011)39,43,45,47,52,53,56,63,
65,66,72
Countries: Switzerland, Spain,
USA and Germany
Funding: Swiss National
Science Foundation, Swiss
Heart Foundation, Department
of Internal Medicine of the
University Hospital Basel,
Roche, Siemens, Abbott,
Brahms, nanosphere, and
8sense
Study name: APACE trial
(NCT00470587)
Recruitment: April 2006 to
August 2011
Number of participants:
2245
Inclusion criteria:
Consecutive adults presenting to
the ED with symptoms
suggestive of AMI (e.g. acute
chest pain, angina pectoris at
rest, other thoracic sensations)
within an onset or peak within
the last 12 hours
Exclusion criteria:
Terminal kidney failure requiring
dialysis
Patient category:
Mixed
Median age (IQR), years:
62 (50–75)
Male (%): 69
Previous AMI (%): 24
Previous CAD (%): 34
Previous family history (%): 43
Previous revascularisation
(%): 24
Diabetes (%): 18
Smoking (%): 61
Hypertension (%): 64
Dyslipidaemia (%): 45
Median BMI (IQR), kg/m2:
27 (24–30)
Presenting < 3 hours from
symptom onset (%): 24
Roche, Abbott,
Beckman Coulter
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
124
Study details Selection criteria Participant details
Test
manufacturer
Keller (2011)48,69
Country: Germany
Funding: Abbott Diagnostics
provided study funding
Recruitment: January 2007 to
December 2008
Number of participants:
1818
Inclusion criteria:
Consecutive adults (18–85 years)
presenting to three chest pain
units with chest pain suggestive
of ACS
Exclusion criteria:
Major surgery or trauma within
the previous 4 weeks;
pregnancy; intravenous drug
abuse; anaemia (haemoglobin
< 10 g/dl)
Patient category:
Mixed
Mean age (SD), years: 61 (14)
Male (%): 66
Previous CAD (%): 36
Previous family history (%): 32
Diabetes (%): 16
Smoking (%): 24
Hypertension (%): 74
Dyslipidaemia (%): 73
Mean BMI (SD), kg/m2: 28 (5)
Abbott
Kurz (2011)55
Country: Germany
Funding: Investigators were
supported by Roche diagnostics
and assay kits were also
provided by the manufacturer
Recruitment: May 2008 to
December 2008
Number of participants: 94
Inclusion criteria:
Consecutive patients admitted to
a chest pain unit with symptoms
suggestive of ACS
Exclusion criteria:
ST segment elevation; severe
kidney dysfunction (glomerular
filtration rate
< 60ml/minute/1.73m2);
patients undergoing
percutaneous coronary
intervention during follow-up
sampling
Patient category:
NSTEMI
Mean age (SD), years: 66 (11)
Male (%): 71
Previous AMI (%): 37
Previous CAD (%): 50
Previous family history (%): 32
Previous revascularisation
(%): 17
Diabetes (%): 31
Smoking (%): 22
Hypertension (%): 78
Dyslipidaemia (%): 65
Median symptom onset
(IQR, minutes): 358 (152–929)
BMI (95% CI/range/IQR):
28 (4)
Roche
Lippi (2012)73
Country: Italy
Funding: NR
Recruitment: NR
Conference abstract only
Number of participants: 57
Inclusion criteria:
Consecutive patients presenting
to the ED with chest pain, within
3 hours of the onset of pain
Exclusion criteria:
None reported
Patient category:
Mixed
No participant details reported Beckman
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Test
manufacturer
Melki (2011)51,61
Country: Sweden
Funding: Partially supported by
a grant from Roche Diagnostics,
who also provided reagents.
Also supported by the Swedish
Heart and Lung Foundation and
National Board of Health and
Welfare
Recruitment: August 2006 to
January 2008
Number of participants: 233
Inclusion criteria:
Patients admitted to a coronary
care unit with chest pain or
other symptoms suggestive of
ACS within 12 hours of
admission
Exclusion criteria:
Patients with persistent
ST segment elevation
Patient category:
NSTEMI
Median age (IQR), years:
65 (55–76)
Male (%): 67
Previous AMI (%): 30
Previous revascularisation
(%): 21
Diabetes (%): 23
Smoking (%): 17
Hypertension (%): 50
Mean symptom onset (95%
CI/range/IQR, hours): 5 (3–8)
Roche
Parsonage (2013)58
Country: Australia
Funding: NR
Recruitment: NR
Conference abstract only
Number of participants: 737
Inclusion criteria:
Patients with symptoms of
possible ACS
Exclusion criteria:
None reported
Patient category:
Mixed
Mean age (IQR): 54 (44–65)
Male (%): 60
Abbott, Roche
Saenger (2010)70
Country: USA
Funding: Two authors
declared individual funding
from manufacturers (one from
Roche diagnostics and one
from Beckman Coulter and
Abbott)
Recruitment: NR
Conference abstract only
Number of participants: 288
Inclusion criteria:
Patients presenting to the ED
with symptoms suggestive of
AMI
Exclusion criteria:
None reported
Patient category:
Mixed
Details:
NSTEMI 19%, STEMI 15%
No further participant details
reported
Roche
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Test
manufacturer
Sanchis (2012)42
Country: Spain
Funding: Supported by a grant
from Roche Diagnostics
Study name: PITAGORAS
study
Recruitment: NR
Number of participants: 446
Inclusion criteria:
Patients presenting to the ED
with chest pain of possible
coronary origin and onset of
pain within the previous
24 hours
Exclusion criteria:
Exclusion criteria: persistent
ST segment elevation on ECG;
Tn elevation in any of two serial
determinations (at arrival and
6–8 hours later); prior diagnosis
of ischaemic heart disease by
either the finding of significant
stenosis in a prior coronary
angiogram or previously
documented AMI; left bundle
branch block or other
non-interpretable ECG or
inability to performance exercise
test; structural heart disease
different from ischaemic heart
disease; concomitant HF or
significant bradyarrhythmia
(< 55 beats/minute) or
tachyarrhythmia
(> 110 beats/minute) at
admission
Patient category:
NSTEMI
Mean age (SD), years: 60 (12)
Male (%): 59
Previous family history (%): 14
Diabetes (%): 20
Smoking (%): 25
Hypertension (%): 54
Dyslipidaemia (%): 46
Roche
Santaló (2013)40
Country: Spain
Funding: Reagents and
logistical support were
provided by Roche diagnostics
Study name: TUSCA study
Recruitment: NR
Number of participants: 358
Inclusion criteria:
Adult (> 18 years) described as
presenting with acute coronary
syndromes and symptom
duration ≥ 5 minutes; population
included 174 people with a final
diagnosis of non-acute coronary
syndromes
Exclusion criteria:
Exclusion criteria: ST segment
elevation; new left bundle
branch block; pre-admission
thrombolytic therapy;
defibrillation or cardioversion
before sampling; pregnancy;
renal failure requiring dialysis;
UA within 2 months; coronary
artery bypass graft within
3 months
Patient category:
NSTEMI
Mean age (range), years: 69
(27–93)
Male (%): 68
Previous CAD (%): 35
Diabetes (%): 26
Hypertension (%): 62
Presentation within 3 hours:
46.2%
Roche
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Study details Selection criteria Participant details
Test
manufacturer
Sebbane (2013)64
Country: France
Funding: Study funded by the
hospital, with assay reagents
supplied by the manufacturers
Recruitment: December 2009
to November 2011
Number of participants: 248
Inclusion criteria:
Adults presenting to the ED with
chest pain of recent (within
12 hours of presentation)
Exclusion criteria:
Traumatic causes of chest pain.
STEMI was defined by the
persistent elevation of the ST
segment of at least 1mm in two
contiguous ECG leads or by the
presence of a new left bundle
branch block with positive
cardiac enzyme results. Patients
with STEMI were excluded from
the analysis for our review
Patient category:
NSTEMI (data also reported for
mixed AMI but not extracted)
Median age (IQR), years: 61
(48–75)
Male (%): 63
Roche
NR, not reported; IQR, interquartile range; SD, standard deviation.
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Appendix 3 QUADAS-2 assessments
Study: Aldous (2011)54
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
Consecutive adults presenting to the ED with chest pain were eligible for inclusion
Was a consecutive or random sample of patients enrolled? Yes
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? RISK: Low
B. APPLICABILITY
Unselected chest pain population AMI diagnoses may have included both NSTEMI and STEMI
Do the included patients match the question? Concerns: High
DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
Roche Elecsys hs-TnT on admission and after 6 hours. Data reported for admission, for four thresholds
No details of interpretation reported. One threshold was derived from ROC analysis; primary analysis based on 99th centile
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? RISK: Low
B. APPLICABILITY
Are there concerns that the index test, its conduct, or interpretation differ from the review
question?
Concerns: Low
DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
Reference standard diagnosis of AMI based on joint ECS and ACC criteria and included serial conventional cTnI (10- to
12-hour time point not specified)
Determination of diagnosis was made blind to hs-TnT results
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Yes
Could the reference standard, its conduct, or its interpretation have introduced bias? RISK: Low
B. APPLICABILITY
Is there concern that the target condition as defined by the reference standard does not
match the review question?
Concerns: High
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DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
Participants for whom stored samples were not available at both time points were excluded
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? RISK: High
Study: Aldous (2012)46
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
Patients presenting to the ED between 05.30 and 20.00 hours, and with chest pain
Was a consecutive or random sample of patients enrolled? No
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? RISK: High
B. APPLICABILITY
Patients with ST segment elevation excluded
Do the included patients match the question? Concerns: Low
DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
Roche Elecsys hs-TnT
Data reported for multiple thresholds based on predetermined properties of the assay
Frozen samples used, unclear whether interpretation of index test was blind to reference standard
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? RISK: Low
B. APPLICABILITY
Are there concerns that the index test, its conduct, or interpretation differ from the review
question?
Concerns: Low
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DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
Reference standard final diagnosis of AMI, based on ACC criteria and including the results of serial conventional cTnI
(10- to 12-hour time point not specified), but blinded to hs-TnT results
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Yes
Could the reference standard, its conduct, or its interpretation have introduced bias? RISK: Low
B. APPLICABILITY
Is there concern that the target condition as defined by the reference standard does not
match the review question?
Concerns: High
DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
All participants appear to have been included in the analyses
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? RISK: Low
Study: Body (2011)67
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
Prospective enrolment of patients; unclear if consecutive
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? RISK: Unclear
B. APPLICABILITY
Mixed chest pain
Do the included patients match the question? Concerns: High
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DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
Roche Elecsys hs-TnT. Threshold 99th percentile cut point and LoD. Blinding not reported; objective test interpreted prior to
reference standard so unlikely to have been influenced by knowledge of reference standard
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? RISK: Low
B. APPLICABILITY
Are there concerns that the index test, its conduct, or interpretation differ from the review
question?
Concerns: Low
DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
Thorgeson criteria; time point not specified. Clinicians were blinded to hs-Tn
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Yes
Could the reference standard, its conduct, or its interpretation have introduced bias? RISK: Low
B. APPLICABILITY
Is there concern that the target condition as defined by the reference standard does not
match the review question?
Concerns: High
DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
301 patients were excluded prior to enrolment; all patients enrolled included in 2 × 2 table
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? RISK: Low
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Study: Christ (2010)57
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
Retrospective analysis of consecutive patients presenting to ED with chest pain
Was a consecutive or random sample of patients enrolled? Yes
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? RISK: Low
B. APPLICABILITY
Patients with general chest pain symptoms, includes participants with a final diagnosis of STEMI
Do the included patients match the question? Concerns: High
DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
Roche Elecsys hs-TnT. Threshold 99th percentile cut point. Blinding not reported; retrospective analysis and so disease
status may have been known when interpreting results. However, objective test and so unlikely to have been influenced by
knowledge of disease state
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? RISK: Low
B. APPLICABILITY
Are there concerns that the index test, its conduct, or interpretation differ from the review
question?
Concerns: Low
DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
Joint ESC and ACC criteria; time point not specified. Unclear whether clinicians were blinded to hs-Tn. A second consensus
diagnosis incorporating hs-Tn was also made and so clinicians may have been aware of the result for the first consensus
diagnosis based only on standard Tn
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? RISK: Unclear
B. APPLICABILITY
Is there concern that the target condition as defined by the reference standard does not
match the review question?
Concerns: High
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DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
No dropouts reported, all included patients accounted for in flow diagram and numbers suggest that Tn results were
available for all
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? RISK: Low
Study: Collinson (2013)19
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
Participants with chest pain and suspected AMI; study uses subgroup of one arm of an RCT. Patients at high risk of NSTEMI
excluded
Was a consecutive or random sample of patients enrolled? Yes
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? RISK: Low
B. APPLICABILITY
Chest pain patients excluding those with diagnostic ECG changes
Do the included patients match the question? Concerns: High
DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
Roche Elecsys hs-TnT on admission and at 90 minutes
Reference standard (final diagnosis) determined after hs-TnT
Threshold based on assay characteristics including 99th centile
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? RISK: Low
B. APPLICABILITY
Are there concerns that the index test, its conduct, or interpretation differ from the review
question?
Concerns: Low
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DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
Reference standard diagnosis of AMI based on joint ESC and ACC criteria and included serial conventional cTnT or cTnI
(10- to 12-hour time point specified)
Determination of diagnosis was made blind to hs-TnT results
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Yes
Could the reference standard, its conduct, or its interpretation have introduced bias? RISK: Low
B. APPLICABILITY
Is there concern that the target condition as defined by the reference standard does not
match the review question?
Concerns: Low
DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
1125 enrolled, 25 no samples collected, 250 samples taken but study samples not collected
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? RISK: High
Study: Cullen (2013)63
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
Consecutively recruited adults presenting to the ED with cardiac symptoms
Was a consecutive or random sample of patients enrolled? Yes
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? RISK: Low
B. APPLICABILITY
Unselected chest pain population AMI diagnoses may have included both NSTEMI and STEMI
Do the included patients match the question? Concerns: High
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DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
Abbott ARCHITECT hs-STAT TnI; threshold was 99th centile
Frozen samples were used, but laboratory technicians were blinded to patient data
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? RISK: Low
B. APPLICABILITY
Are there concerns that the index test, its conduct, or interpretation differ from the review
question?
Concerns: Low
DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
30-day MACE, adjudicated blind to index tests, but with access to clinical records, ECG and conventional Tn results
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Yes
Could the reference standard, its conduct, or its interpretation have introduced bias? RISK: Low
B. APPLICABILITY
Is there concern that the target condition as defined by the reference standard does not
match the review question?
Concerns: Low
DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
No patients were lost to 30-day follow-up. Procedure for adjudication of 30-day MACE was the same in all cases, but
investigations undergone by individual patients varied
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? No
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? RISK: Low
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Study: Eggers (2012)44
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
Unclear whether consecutive or random patients were enrolled.
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? RISK: Unclear
B. APPLICABILITY
Non-STEMI patients with chest pain presenting to coronary care/chest pain unit
Do the included patients match the question? Concerns: High
DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
Roche Elecsys hs-TnT. Threshold 99th percentile cut point and 95% specificity value. Blinding not reported; objective test
interpreted prior to reference standard so unlikely to have been influenced by knowledge of reference standard
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? RISK: Low
B. APPLICABILITY
Are there concerns that the index test, its conduct, or interpretation differ from the review
question?
Concerns: Low
DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
Joint ESC and ACC criteria; time point not specified. Unclear whether clinicians were blinded to high-sensitivity troponin.
A second consensus diagnosis
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? RISK: Unclear
B. APPLICABILITY
Is there concern that the target condition as defined by the reference standard does not
match the review question?
Concerns: High
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DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
Only 360 patients out of 495 who fulfilled inclusion criteria had all biochemical tests performed and were included in the
analysis; reasons for not performing tests were not reported
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? RISK: High
Study: Freund (2011)49
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
Consecutive adults presenting to the ED with chest pain (onset or peak within previous 6 hours). Patients with acute kidney
failure requiring dialysis were excluded
Was a consecutive or random sample of patients enrolled? Yes
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? RISK: Low
B. APPLICABILITY
Unselected ED chest pain population, includes participants with a final diagnosis of STEMI; data also presented for
subgroups with low-moderate and with high pre-test probability
Do the included patients match the question? Concerns: High
DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
Roche Elecsys hs-TnT on admission and at 3–9 hours if available. Reference standard (final diagnosis) adjudicated by two
independent physicians after acute episode. Threshold was 99th centile
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? RISK: Low
B. APPLICABILITY
Are there concerns that the index test, its conduct, or interpretation differ from the review
question?
Concerns: Low
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DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
Reference standard final diagnosis, based on joint ESC and ACC criteria and included conventional cTnI on admission and
at 3–9 hours if needed (10- to 12-hour time point not specified). Clinicians adjudicating final diagnosis were blind to hs-TnT
results
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Yes
Could the reference standard, its conduct, or its interpretation have introduced bias? RISK: Low
B. APPLICABILITY
Is there concern that the target condition as defined by the reference standard does not
match the review question?
Concerns: High
DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
All participants appear to have been included in the analyses
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? RISK: Low
Study: Hoeller (2013)39
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
Patients presenting to the ED with symptoms suggestive of AMI. Consecutive patients with hs-TnT measurements available
were included
Was a consecutive or random sample of patients enrolled? Yes
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? RISK: Low
B. APPLICABILITY
Unselected chest pain population AMI diagnoses may have included both NSTEMI and STEMI
Do the included patients match the question? Concerns: High
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DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
Roche hs-TnT, Beckman Coulter Hs-AccuTnI and Abbott ARCHITECT hs-TnI on admission
Reference standard probably made later than admission; 99th centiles for assays used as diagnostic thresholds (some
publications also reported data for ROC-derived thresholds)
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? RISK: Low
B. APPLICABILITY
Are there concerns that the index test, its conduct, or interpretation differ from the review
question?
Concerns: Low
DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
Reference standard final diagnosis of AMI, ESC criteria and included cTn assays (0 and 6 hours). Unclear whether those
adjudicating final diagnosis were blind to hs-TnI/hs-TnT results in all cases, some publications reported blinding
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Yes/no
Could the reference standard, its conduct, or its interpretation have introduced bias? RISK: Low
B. APPLICABILITY
Is there concern that the target condition as defined by the reference standard does not
match the review question?
Concerns: Low
DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
2245 participants were included in the trial, 2072 were included in the hs-TnT analysis, 1151 were included in the hs-TnI
(Beckman) analysis, and 1567 were included in the hs-TnI (Abbott) analysis
Most exclusions were because hsTn measurements were not available
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? RISK: High
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Study: Keller (2011)48
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
Consecutive patients presenting to chest pain units
Was a consecutive or random sample of patients enrolled? Yes
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? RISK: Low
B. APPLICABILITY
General chest pain populations, some participants had a final diagnosis of STEMI
Do the included patients match the question? Concerns: High
DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
Abbott Architect STAT hs-TnI, on admission and at 3 hours. Reference standard (final diagnosis) was adjudicated after
hs-TnI testing. Thresholds based on test properties, appeared to be prespecified
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? RISK: Low
B. APPLICABILITY
Are there concerns that the index test, its conduct, or interpretation differ from the review
question?
Concerns: Low
DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
Reference standard diagnosis of AMI based on joint ESC and ACC criteria and included serial conventional cTnT (10- to
12-hour time point not specified)
Determination of diagnosis was made blind to hs-TnT results
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Yes
Could the reference standard, its conduct, or its interpretation have introduced bias? RISK: Low
B. APPLICABILITY
Is there concern that the target condition as defined by the reference standard does not
match the review question?
Concerns: High
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DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
None of the analyses included all study participants (558 or 867 participants missing)
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? RISK: High
Study: Kurz (2011)55
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
Consecutive patients admitted to a chest pain unit. 206 Patients not included owing to ‘technical reasons’ (not fully
defined, e.g. venepuncture not possible)
Was a consecutive or random sample of patients enrolled? Yes
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? RISK: Unclear
B. APPLICABILITY
Appears to be an unselected chest pain population, STEMI excluded. Second publication110 is for a retrospectively selected
subgroup of participants with a diagnosis of NSTEMI or UA. Patients were admitted to chest pain units
Do the included patients match the question? Concerns: High
DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
Roche Elecsys hs-TnT, data reported for admission, 3- and 6-hour samples (6-hour data not extracted)
Reference standard Tn testing occurred after hs-TnT. Threshold was prespecified for data extracted from Giannitsis et al.,110
but not from Kurz et al.55 (low risk of bias for Giannitsis et al.110 data)
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? RISK: Low
B. APPLICABILITY
Are there concerns that the index test, its conduct, or interpretation differ from the review
question?
Concerns: Low
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DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
Reference standard diagnosis of AMI based on joint ESC and ACC criteria and included serial conventional cTnT (10- to
12-hour time point not specified)
Unclear whether determination of diagnosis was made blind to hs-TnT results
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? RISK: Unclear
B. APPLICABILITY
Is there concern that the target condition as defined by the reference standard does not
match the review question?
Concerns: High
DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
All participants appear to have been included in the analyses
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? RISK: Low
Study: Lippi (2012)73
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
Consecutive patients presenting to the ED with chest pain of recent onset (< 3 hours)
No exclusion criteria reported
Was a consecutive or random sample of patients enrolled? Yes
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? RISK: Low
B. APPLICABILITY
Unselected chest pain population AMI diagnoses may have included both NSTEMI and STEMI
Do the included patients match the question? Concerns: High
DOI: 10.3310/hta19440 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 44
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
157
DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
Beckman Coulter HS-AccuTnI on admission. Reference standard final diagnosis (AMI); probably made later than admission
hs-TnI. Threshold derived from ROC analysis
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it prespecified? No
Could the conduct or interpretation of the index test have introduced bias? RISK: High
B. APPLICABILITY
Are there concerns that the index test, its conduct, or interpretation differ from the review
question?
Concerns: Low
DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
Reference standard final diagnosis of AMI, criteria for diagnosis not reported
Unclear whether those adjudicating final diagnosis were blind to hs-TnI
Is the reference standard likely to correctly classify the target condition? Unclear
Were the reference standard results interpreted without knowledge of the results of the index test? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? RISK: Unclear
B. APPLICABILITY
Is there concern that the target condition as defined by the reference standard does not
match the review question?
Concerns: High
DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
No withdrawals reported
Did all patients receive a reference standard? Unclear
Did patients receive the same reference standard? Unclear
Were all patients included in the analysis? Unclear
Could the patient flow have introduced bias? RISK: Unclear
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Study: Melki (2011)51
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
Recruitment described as ‘consecutive except for temporary interruptions of the study due to high work load in the
coronary care unit’
Was a consecutive or random sample of patients enrolled? No
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? RISK: High
B. APPLICABILITY
Chest pain patients admitted to chest pain unit, excluding ST segment elevation
Do the included patients match the question? Concerns: High
DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
Roche Elecsys hs-TnT on admission and at 2 hours. Reference standard (final diagnosis) determined after hs-TnT testing.
Threshold based on assay characteristics, appears predetermined
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? RISK: Low
B. APPLICABILITY
Are there concerns that the index test, its conduct, or interpretation differ from the review
question?
Concerns: Low
DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
Reference standard diagnosis of AMI based on joint ESC and ACC criteria and included serial conventional cTnT or cTnI
(9- to 12-hour time point specified)
Determination of diagnosis was made blind to hs-TnT results
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Yes
Could the reference standard, its conduct, or its interpretation have introduced bias? RISK: Low
B. APPLICABILITY
Is there concern that the target condition as defined by the reference standard does not
match the review question?
Concerns: Low
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DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
All participants appear to have been included in the analyses
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? RISK: Low
Study: Parsonage (2013)58
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
Prospective studies; no further details on recruitment
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? RISK: Unclear
B. APPLICABILITY
Unselected chest pain population AMI diagnoses may have included both NSTEMI and STEMI
Do the included patients match the question? Concerns: High
DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
Roche Elecsys hs-TnT and Abbott ARCHITECT hs-STAT TnI. Threshold was 99th centile
Index test occurred before adjudication of final diagnosis
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? RISK: Low
B. APPLICABILITY
Are there concerns that the index test, its conduct, or interpretation differ from the review
question?
Concerns: Low
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
160
DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
Reference standard diagnosis of AMI (criteria unclear) and included serial conventional cTnI (10- to 12-hour time point not
specified). Determination of diagnosis was made blind to hs-TnT and hs-TnI results
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Yes
Could the reference standard, its conduct, or its interpretation have introduced bias? RISK: Low
B. APPLICABILITY
Is there concern that the target condition as defined by the reference standard does not
match the review question?
Concerns: High
DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
Patients appear to be missing from the analyses, as 2 × 2 data (derived from reported sensitivity and specificity estimates
and total number of AMI) do not match reported number of test positives
Did all patients receive a reference standard? Unclear
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Unclear
Could the patient flow have introduced bias? RISK: Unclear
Study: Saenger (2010)70
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
No details on how patients were selected. No exclusion criteria reported
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? RISK: Unclear
B. APPLICABILITY
No exclusion criteria reported, reference standard was AMI (diagnosis method not specified),diagnoses included STEMI
Do the included patients match the question? Concerns: High
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DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
Roche Elecsys hs-TnT on admission and after 3 hours. Data reported for admission and 0–3 hours. No details of
interpretation reported. Threshold for Δ value derived from ROC analysis; 99th centile also used
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? RISK: Low
B. APPLICABILITY
Are there concerns that the index test, its conduct, or interpretation differ from the review
question?
Concerns: Low
DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
Reference standard diagnosis of AMI (no details reported)
Is the reference standard likely to correctly classify the target condition? Unclear
Were the reference standard results interpreted without knowledge of the results of the index test? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? RISK: Unclear
B. APPLICABILITY
Is there concern that the target condition as defined by the reference standard does not
match the review question?
Concerns: High
DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
No withdrawals reported
Did all patients receive a reference standard? Unclear
Did patients receive the same reference standard? Unclear
Were all patients included in the analysis? Unclear
Could the patient flow have introduced bias? RISK: Unclear
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Study: Sanchis (2012)42
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
Patients excluded owing to Tn elevation in any of two serial determinations (at arrival and 6–8 hours later) and prior
diagnosis of ischaemic heart disease. No details on how patients were selected for the study
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? RISK: High
B. APPLICABILITY
Selected low-risk population
Do the included patients match the question? Concerns: High
DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
Roche Elecsys hs-TnT on admission and at 6–8 hours (data reported for admission and peak values). Reference standard
(30-day composite) occurred after testing. Thresholds were reported as prespecified
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? RISK: Low
B. APPLICABILITY
Are there concerns that the index test, its conduct, or interpretation differ from the review
question?
Concerns: Low
DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
Composite 30-day end point of AMI, death and revascularisation
Not clear whether those adjudicating AMI were aware of hs-TnT results
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? RISK: Unclear
B. APPLICABILITY
Is there concern that the target condition as defined by the reference standard does not
match the review question?
Concerns: Low
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DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
All participants appeared to have been included in the analyses
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? RISK: Low
Study: Santalo (2013)40
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
Consecutive adult patients presenting to the ED
Was a consecutive or random sample of patients enrolled? Yes
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? RISK: Low
B. APPLICABILITY
Appears to be an unselected ED chest pain population
Do the included patients match the question? Concerns: Low
DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
Roche Elecsys hs-TnT on admission and at 2, 4 and 6–8 hours or until discharge (data reported for admission and Δ values).
Unclear whether hs-TnT interpreted blind to cTnT
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? RISK: Low
B. APPLICABILITY
Are there concerns that the index test, its conduct, or interpretation differ from the review
question?
Concerns: Low
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DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
Final diagnosis adjudicated by committee, based on Roche cTnT at admission and 2, 4 and 6–8 hours or until discharge
(10- to 12-hour time point not specified). NSTEMI defined as cTnT > 10 ng/l and ΔcTnT > 20%; also 99th centile. Unclear
whether adjudicators were blinded to hs-TnT
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? RISK: Unclear
B. APPLICABILITY
Is there concern that the target condition as defined by the reference standard does not
match the review question?
Concerns:
Unclear
DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
All participants appear to have been included in the analyses
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? RISK: Low
Study: Sebbane (2013)62
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
No details on how patients were selected for inclusion
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? RISK: Unclear
B. APPLICABILITY
Unselected cohort of adult patients presenting with chest pain of recent onset (within 12 hours)
Do the included patients match the question? Concerns: Low
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DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
Roche Elecsys hs-TnT on admission or from sample taken during pre-hospital management. Final diagnosis adjudicated
1 month after acute episode. Optimal diagnostic thresholds were determined using within-study ROC analyses; 99th centile
also reported
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? RISK: Low
B. APPLICABILITY
Are there concerns that the index test, its conduct, or interpretation differ from the review
question?
Concerns: Low
DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
Diagnosis determined by two independent ED physicians, based on joint ESC and ACC criteria. Reference standard included
cTnI taken on admission, at 6 hours and beyond, as needed (10- to 12-hour time point not specified). Physicians had access
to serial cTnI results, but were blinded to hs-TnT results
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Yes
Could the reference standard, its conduct, or its interpretation have introduced bias? RISK: Low
B. APPLICABILITY
Is there concern that the target condition as defined by the reference standard does not
match the review question?
Concerns: High
DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
54 patients were excluded from the analyses because of missing data, including lack of copeptin, hs-cTnT, and cTnI
measurements
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? RISK: High
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Appendix 4 Table of excluded studies with
rationale
To be included in the review, studies had to fulfil the following criteria:
Population Adults (≥ 18 years) presenting with acute ‘pain, discomfort or pressure in the chest, epigastrium,
neck, jaw, or upper limb without an apparent non-cardiac source’ attributable to a suspected, but not
proven, AMI or ACS.
Setting Secondary or tertiary care.
Index test Abbott ARCHITECT (STAT hs-cTnI); Beckman Coulter Access and Unicel DxI (accuTnI+ 3); Roche
Elecsys (cTnT-hs or cTnT-hs STAT); results available within 3 hours.
Reference standard Universal definition of AMI, including measurement of Tn T or I (using any method not
defined as a hs-cTn test) on presentation and 10–12 hours after the onset of symptoms in ≥ 80% of the
population or occurrence of MACE (any definition used in identified studies) during 30-day follow-up.
Outcome Sufficient data to construct 2 × 2 table of test performance.
The table below summarises studies that were screened for inclusion, based on full-text publication, but
which did not fulfil one or more of the above criteria. Studies were assessed sequentially against criteria; as
soon as a study had failed, based on one of the criteria, it was not assessed against subsequent criteria.
The table shows which of the criteria each study fulfilled (‘Yes’) and on which item it failed (‘No’).
Study details
Primary
study Population Setting Index test
Reference
standard Outcome
Ahmed (2013)111 Yes Yes Yes Yes No
Aldous (2010)112 Yes Yes Yes Yes Unclear No
Aldous (2010)113 Yes Yes Yes Yes Unclear No
Aldous (2012)114 No
Aldous (2010)115 Yes Yes Yes Unclear No
Aldous (2012)116 Yes Yes Yes Unclear Yes No
Aldous (2012)117 Yes Yes Yes No
Aldous (2012)118 No
Aldous (2012)54 No
Alexandra (2013)119 Yes Yes Yes No
Arenja (2010)120 Yes Yes Yes Yes No
Bahrmann (2012)121 Yes No
Bahrmann (2013)122 Yes No
Bahrmann (2013)123 Yes No
Bahrmann (2012)124 Yes Yes Yes Yes No
Balmelli (2013)125 Yes Yes Yes Yes Unclear No
Balmelli (2011)126 Yes Yes Yes Yes Unclear No
Beyrau (2009)127 Yes No
DOI: 10.3310/hta19440 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 44
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
167
Study details
Primary
study Population Setting Index test
Reference
standard Outcome
Bhardwaj (2011)128 Yes Yes Yes No
Bhardwaj (2011)129 Yes Yes Yes No
Biasillo (2010)130 Yes Yes Yes Unclear No
Biasucci (2010)131 Yes Yes Yes Yes No
Biasucci (2010)132 Yes Yes Yes Yes No
Biasucci (2010)133 Yes Yes Yes Yes No
Biasucci (2010)134 Yes Yes Yes Yes No
Biasucci (2011)135 Yes Yes Yes Yes No
Biener (2013)136 Yes Unclear Yes Unclear Unclear No
Biener (2012)137 Yes Yes Yes Unclear Unclear No
Biener (2013)138 Yes Yes Yes No
Biosite (2006)139 Yes Yes Yes No
Body (2012)140 Yes Yes Yes Unclear Unclear No
Body (2012)141 Yes Yes Yes Yes Yes No
Body (2012)142 No
Braga (2011)143 Yes Yes Yes Yes Yes No
Braga (2011)144 Yes Yes Yes Yes Yes No
Bronze (2012)145 Yes Yes Yes Yes No
Brown (2007)146 Yes Yes Yes No
Buccelletti (2012)147 Yes Yes Yes Yes No
Buhl (2011)148 Yes No
Cardillo (2012)149 Yes Yes Yes Yes Yes No
Carmo (2013)150 No
Ceriani (2012)151 No
Charpentier (2011)152 Yes Yes Yes No
Chenevier-Gobeaux (2013)153 No
Collinson (2012)154 Yes Yes Yes No
Collinson (2012)155 Yes Yes Yes No
Collinson (2012)156 Yes Yes Yes No
Collinson (2006)157 Yes Yes Yes No
Collinson (2010)158 Yes Yes Yes No
Costabel (2013)159 No
Cullen (2011)160 Yes Yes Yes No
Dawson (2013)161 Yes No
Diercks (2012)162 Yes Yes Yes No
Drexler (2011)163 Yes Yes Yes Unclear Unclear No
Engel (2007)164 Yes Yes Yes No
Escabi-Mendoza (2010)165 Yes Yes Yes No
Figiel (2008)166 Yes No
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Study details
Primary
study Population Setting Index test
Reference
standard Outcome
Fitzgerald (2011)79 Yes Yes Yes No
Freund (2011)167 Yes Yes Yes Unclear Unclear No
Freund (2011)168 Yes Yes Yes Unclear Unclear No
Giannitsis (2010)110 Yes No
Giannitsis (2011)169 Yes Yes Yes Unclear Unclear No
Giavarina (2012)170 No
Giavarina (2011)171 Yes Yes Yes No
Gimenez (2012)172 Yes Yes Yes No
Gimenez (2012)173 Yes Yes Yes No
Goodacre (2011)80 Yes Yes Yes No
Goodacre (2013)7 No
Goodacre (2011)87 Yes Yes Yes No
Gustapane (2012)174 Yes Yes Yes Unclear No
Gustapane (2012)175 Yes Yes Yes Unclear No
Haaf (2011)176 Yes Yes Yes Unclear Unclear No
Haaf (2011)177 Yes Yes Yes Unclear Unclear No
Haaf (2013)178 No
Haaf (2012)179 Yes Yes Yes Yes No
Haaf (2012)180 Yes Yes Yes Yes No
Haltern (2010)181 Yes Yes Yes No
Heinisch (2010)182 Yes Yes Yes Unclear Unclear No
Hochholzer (2011)183 Yes Yes Yes Yes No
Hochholzer (2010)184 Yes Yes Yes Yes No
Hoeller (2012)185 Yes Yes Yes Yes No
Hoeller (2012)186 Yes Yes Yes Yes No
Ilva (2009)187 Yes Yes No
Inoue (2011)188 Yes Yes Yes Yes No
Irfan (2011)189 Yes Yes Yes Unclear Unclear No
Irfan (2011)190 Yes Yes Yes Unclear No
Irfan (2013)191 Yes Yes Yes Yes Unclear No
Irfan (2013)192 Yes Yes Yes Yes Unclear No
Jairam (2011)193 Yes No
Januzzi (2010)194 Yes Yes Yes No
Januzzi (2009)195 Yes Yes Yes Yes No
Januzzi (2013)196 Yes Yes Yes No
Jia (2009)197 Yes Yes Yes No
Kagawa (2013)198 Yes Yes Yes No
Karakas (2011)199 Yes Yes Yes Yes No
Kavsak (2012)200 Yes Yes Yes Unclear Unclear No
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Study details
Primary
study Population Setting Index test
Reference
standard Outcome
Kavsak (2007)201 Yes Yes Yes No
Kavsak (2013)202 Yes Yes Yes Unclear No
Kavsak (2005)203 Yes Yes Yes No
Kavsak (2012)204 Yes Yes Yes Yes Unclear No
Kavsak (2008)205 Yes No
Kavsak (2011)206 Yes Yes Yes Yes No
Kavsak (2010)207 Yes Yes Yes Yes Yes No
Keene (2012)208 Yes Yes Yes Yes No
Keller (2011)209 Yes Yes Yes Yes Unclear No
Keller (2011)210 Yes Yes Yes Yes Unclear No
Keller (2009)211 Yes Yes Yes No
Keller (2010)212 Yes Yes Yes No
Keller (2009)213 Yes Yes Yes No
Kelly (2011)214 Yes Yes Yes No
Khan (2011)215 Yes Yes Yes Yes No
Khoo (2008)216 Yes Unclear Yes No
Kitamura (2012)217 Yes Yes Yes No
Kobayashi (2011)218 Yes Yes Yes Unclear No
Kobayashi (2011)219 Yes Yes Yes Yes No
Koenig (2008)220 Yes Yes Yes Yes No
Lacnak (2007)221 Yes Yes Yes Unclear No
Lee (2011)222 Yes Yes Yes Unclear No
Lindahl (2009)223 Yes No
Lippi (2013)224 No
Lippi (2012)225 No
Lippi (2013)226 No
Lotze (2011)227 Yes Yes Yes No
Lotze (2011)228 Yes Yes Yes Yes No
Macrae (2006)229 Yes Yes Yes No
Mair (2011)230 Yes No
Mair (2011)231 Yes No
Matsui (2011)232 Yes Yes Yes Unclear Unclear No
Mazhar (2011)233 Yes Yes Yes Unclear No
Melanson (2008)234 Yes Yes Yes No
Melki (2011)235 Yes Yes Yes Yes No
Melki (2011)236 Yes Yes Yes No
Menhofer (2013)237 Yes No
Meune (2011)238 Yes Yes Yes Yes Yes No
Meune (2011)108 Yes Yes Yes Yes Yes No
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Study details
Primary
study Population Setting Index test
Reference
standard Outcome
Meune (2013)239 Yes Yes Yes Yes No
Meune (2011)240 Yes Yes Yes Yes No
Mikkel (2013)241 Yes Yes Yes Yes Unclear No
Mikkel (2013)242 Yes Yes Yes No
Mikkel (2013)243 Yes Yes Yes No
Mills (2010)244 Yes Yes Yes Unclear No
Mills (2010)245 Yes Yes Yes Unclear No
Mills (2012)246 Yes Yes Yes Yes No
Mingels (2012)247 Yes No
Moehring (2012)248 Yes Yes Yes Yes No
Moehring (2012)249 Yes Yes Yes Yes Unclear No
Montagnana (2012)250 Yes Yes Yes Yes Yes No
Morrow (2009)251 No
Nagurney (2005)252 Yes Yes Yes No
Nanosphere (2010)253 Yes Yes Yes Unclear Yes No
Naroo (2009)254 Yes Yes Yes No
Ngan (2010)255 Yes Yes Yes Yes Yes No
Noad (2010)256 Yes Yes Yes Unclear Unclear No
Normann (2012)257 Yes Yes Yes Yes No
Nusier (2006)258 Yes Yes Yes No
Olivieri (2012)259 Yes Yes Yes No
Orsborne (2012)260 No
Paoloni (2010)261 Yes Yes Yes Unclear No
Perego (2011)262 Yes
Plebani (2009)263 Yes Yes Yes No
Ploner (2011)264 Yes No No
Popp (2010)265 Yes Yes Yes Yes No
Potocki (2011)266 Yes Yes Yes No
Pracon (2012)267 Yes Yes Yes No
Rajdl (2011)268 Yes Yes Yes Yes Unclear No
Ray (2011)269 Yes Yes Yes Unclear Unclear No
Reichlin (2012)270 No
Reichlin (2011)271 Yes Yes Yes Unclear Unclear No
Reichlin (2012)272 Yes Yes Yes Yes No
Reichlin (2010)273 Yes Yes Yes Unclear No
Reichlin (2010)274 Yes Yes Yes Unclear No
Reichlin (2012)275 Yes Yes Yes Yes No
Rubini Gimenez (2012)276 Yes Yes Yes Yes Unclear No
Rudolph (2011)277 Yes Yes Yes Unclear Unclear No
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Study details
Primary
study Population Setting Index test
Reference
standard Outcome
Rudolph (2011)278 Yes Yes Yes Unclear Unclear No
Rudolph (2012)279 Yes Yes Yes No
Samaraie (2010)280 Yes Yes Yes Unclear No
Scharnhorst (2011)281 Yes Yes Yes No
Schaub (2012)282 Yes Yes Yes Yes Yes No
Schoos (2013)283 Yes Yes Yes Yes Unclear No
Schoos (2013)284 Yes Yes Yes Yes Unclear No
Schreiber (2012)285 Yes Yes Yes No
Sethi (2013)286 No
Shand (2012)287 Yes Yes Unclear Unclear No
Shortt (2013)288 No
Spanuth (2011)289 Yes Yes Yes Unclear Unclear No
Spasic-Obradovic (2011)290 Yes Yes Yes Yes No
Stengaard (2012)291 Yes Yes Yes Unclear Unclear No
Tajsic (2013)292 Yes Yes Yes Unclear Unclear No
Tajsic (2013)293 Yes Yes Yes Unclear Unclear No
Tajsic (2012)294 Yes Yes Yes Unclear No
Tajsic (2013)295 Yes Yes Yes Unclear Unclear No
Tamimi (2010)296 Yes Yes Yes No
Tanaka (2006)297 Yes Yes Yes No
Than (2012)298 Yes Yes Yes No
Thelin (2013)299 Yes Yes Yes Yes No
Thomas (2007)300 Yes No
Thomas (2007)301 Yes No
Truong (2012)302 Yes Yes Yes No
Truong (2011)303 Yes Yes No Unclear Unclear No
Twerenbold (2010)304 Yes Yes Yes Yes Unclear No
Twerenbold (2010)305 Yes Yes Yes Yes Unclear No
Twerenbold (2010)306 Yes Yes Yes Yes Unclear No
Twerenbold (2011)307 Yes Yes Yes No
Twerenbold (2012)308 Yes Yes Yes Yes No
University of Edinburgh (2013)309 Yes Yes Yes Unclear No
University of Erlangen (2013)310 Yes Yes Yes Unclear Unclear
Van Wijk (2012)311 Yes Yes Yes Yes No
Vasikaran (2012)312 No
Veljkovic (2012)313 Yes Yes Yes Yes Unclear No
Venge (2008)314 Yes No
Venge (2009)315 Yes No
Venge (2010)316 Yes No
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Study details
Primary
study Population Setting Index test
Reference
standard Outcome
Weber (2011)317 Yes No
Weber (2009)318 Yes No
Wildi (2012)319 Yes Yes Yes No
Wong (2010)320 Yes No Yes No
Worster (2013)321 Yes No Yes Yes No No
Zahid (2009)322 Yes Yes Yes Unclear Unclear No
Zahid (2008)323 Yes Yes Yes No
Zellweger (2012)324 Yes Yes Yes Yes No
Zuily (2011)325 Yes Yes Yes Yes No
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Appendix 5 Sensitivity analyses (base case)
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Appendix 6 Sensitivity analyses
(secondary analysis)
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Appendix 8 Subgroup analyses
(secondary analysis)
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Appendix 9 Subgroup analyses based on
accuracy and acute myocardial infarction prevalence
(available for only the Roche 99th centile test)
Base case
MI
prevalencea
Roche 99th
centile Standard Tn Increments
Costs QALYs Costs QALYs ΔCosts ΔQALYs ΔCosts/ΔQALYs
Base case 17% £2301 11.740 £2697 11.749 –£396 –0.010 £41,233
Age ≤ 70 years 28% £3411 10.946 £3853 10.961 –£442 –0.015 £28,633
Age > 70 years 10% £1550 6.274 £1880 6.275 –£330 –0.001 £355,571
With pre-existing CAD 20% £2641 11.528 £3012 11.534 –£371 –0.006 £58,509
Without pre-existing CAD 16% £2236 11.816 £2592 11.821 –£356 –0.004 £80,454
Symptom onset < 3 hours 22% £2726 11.369 £3222 11.391 –£496 –0.022 £22,111
Symptom onset > 3 hours 13% £1929 12.032 £2277 12.036 –£348 –0.003 £103,107
Symptom onset < 3 hours 17% £2241 11.732 £2697 11.749 –£456 –0.017 £26,327
Symptom onset > 3 hours 17% £2341 11.745 £2697 11.749 –£356 –0.004 £80,677
Base case 17% £2832 11.532 £3064 11.493 –£232 0.039 Dominant
Age ≤ 70 yearsb 28% £3839 10.780 £4148 10.756 –£310 0.024 Dominant
Age > 70 yearsc 10% £2111 6.245 £2259 6.222 –£148 0.023 Dominant
With pre-existing CAD 20% £3142 11.325 £3359 11.293 –£217 0.031 Dominant
Without pre-existing CAD 16% £2778 11.604 £2967 11.560 –£189 0.044 Dominant
Symptom onset < 3 hours 22% £3209 11.180 £3556 11.159 –£347 0.021 Dominant
Symptom onset > 3 hours 13% £2503 11.806 £2673 11.760 –£171 0.046 Dominant
Symptom onset < 3 hours 17% £2772 11.524 £3064 11.493 –£292 0.031 Dominant
Symptom onset > 3 hours 17% £2873 11.535 £3064 11.493 –£192 0.042 Dominant
a The two studies presenting data on subgroups39,67 were both conducted in patients in whom NSTEMI had not been
excluded. They were not at specifically high or low risk of AMI. We calibrated the prevalence (obtained from these
studies) in the subgroup to be adapted to a population with a prevalence of 17% (see below).
b Average age= 53 (base case value) years.
c Average age= 75 years.
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Acute myocardial infarction prevalence in subgroups
Subgroup
Prevalence
of AMI (x)
Prevalence of AMI in
whole population
from subgroups
were derived (y)
Prevalence assuming
population prevalence
of 17% (multiple x*y/17) Source
Age ≤ 70 years 24% 15% 28% APACE39,52
Age > 70 years 9% 15% 10% APACE39,52
Patients with CAD 18% 16% 20% APACE39,52
Patients without CAD 14% 16% 16% APACE39,52
< 3 hours from symptoms67 24% 18% 22% APACE,39
Body (2011)67
> 3 hours from symptoms67 14% 18% 13% APACE,39
Body (2011)67
< 3 hours from symptoms39 21% 21% 17% APACE,39
Body (2011)67
> 3 hours from symptoms39 21% 21% 17% APACE,39
Body (2011)67
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Appendix 10 National Institute for Health and
Care Excellence guidance relevant to the
management of suspected acute coronary syndrome
l MI – secondary prevention: secondary prevention in primary and secondary care for patients following
a myocardial infarction. NICE clinical guideline CG172 (2013). URL: http://guidance.nice.org.uk/CG172.
Date for review: not stated.
l Chest pain of recent onset: assessment and diagnosis of recent onset chest pain or discomfort of
suspected cardiac origin. NICE clinical guideline CG95 (2010). URL: www.nice.org.uk/guidance/CG95.
Reviewed March 2013, review recommended.
l Unstable angina and NSTEMI: the early management of unstable angina and non-ST segment elevation
myocardial infarction. NICE clinical guideline CG94 (2010). URL: www.nice.org.uk/guidance/CG94.
Last modified November 2013.
l BRAHMS copeptin assay to rule out myocardial infarction in patients with acute chest pain. NICE
medical technology guidance MTG4 (2011). URL: http://guidance.nice.org.uk/MTG4. Date for review:
not stated.
l Myocardial infarction with ST segment elevation: the acute management of myocardial infarction with
ST segment elevation. NICE clinical guideline CG167 (2013). URL: http://guidance.nice.org.uk/CG167.
Date for review: not stated.
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